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ABSTRACT 
 
Lymphatic vessels exist in nearly all tissues, yet, despite their omnipresence, there remains a 
large knowledge gap between the described fundamental roles of lymphatic capillaries and 
our understanding of their functional biology, adaptive ability, and pathological response. 
This thesis addressed these shortcomings by utilizing an integrative biomedical engineering 
approach to examine molecular and mechanical regulators of lymphatic capillaries using in 
vivo models of lymphatic capillary biology, function, and adaptation.  
 
Using a model of skin regeneration in the mouse tail, we demonstrated that slow interstitial 
flow created by lymphatic drainage was necessary for lymphatic capillary organization. This 
novel model permitted the identification of spatial, temporal and chemical factors governing 
lymphangiogenesis. In contrast to the sprouting mechanism of blood angiogenesis, lymphatic 
endothelial cells (LECs) were demonstrated to organize in a vasculogenesis-like manner, 
migrating in the direction of interstitial flow and then organizing into functional lymphatic 
capillaries. Lymphangiogenesis was inhibited by blocking vascular endothelial growth factor 
(VEGF)-C signaling from day 0, but initiation of receptor blockade once LECs had already 
migrated did not prevent vessel organization. This uniquely demonstrated the need for a 
biochemical mediator (VEGF-C) to initiate lymphangiogenesis, but that an important 
biomechanical force, interstitial flow, was necessary for functional capillary organization.  
 
Further insight into the necessity of interstitial flow in LEC biology was found in the response 
of lymphatic capillary to induced lymphedema, wherein lymphatic drainage is significantly 
reduced. In a mouse tail model of secondary lymphedema, we demonstrated that the 
edematous environment – characterized by extracellular matrix breakdown, lipid 
accumulation, and reduced interstitial flow – resulted in hyperplasia of LECs but concurrent 
poor function due to the lack of interstitial flow as an organizational guiding cue. Similar 
dermal matrix adaptations to dysfunctional lymphatic drainage were also noted in two mouse 
models of congenital lymphedema, the Chy and VEGFR-3-Ig mice, further demonstrating the 
intimate connection of lymphatic capillary function with tissue maintenance and remodeling.  
 
To quantitatively demonstrate the changes in lymphatic capillary uptake and tissue hydraulic 
conductivity found in these and other transgenic mouse models, we developed a poroelastic 
model of interstitial transport. Tissue hydraulic conductivity was also calculated in tissues 
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lacking lymphatics using an unsteady-state solution, demonstrating that lymphedema causes a 
significant increase in tissue conductivity. This model was then utilized to assess the effects of 
a high fat diet, metabolic disorders, and lymphatic dysfunction on the tissue and on lymphatic 
capillary function. We discovered that lymphatic capillary uptake function was significantly 
reduced with dyslipidemia, suggesting a novel interplay between lymphatic function and lipid 
metabolism.  
 
Additionally, we uncovered a new and critical role for lymphangiogenesis and lymphatic 
transport in reproduction. We demonstrated that lymphangiogenesis is a regular, non-
pathological event during folliculogenesis in the ovary. These new lymphatic capillaries are 
seemingly necessary for hormone transport from the ovary – an essential feedback mechanism 
during pregnancy. Blockade of lymphangiogenesis resulted in decreased systemic 
progesterone and estradiol levels and resulted in failed fetal development.  
 
In conclusion, this work highlights the critical roles of the lymphatic circulation and 
demonstrates the interplay between lymphatic biology and the biochemical and biophysical 
environment in which lymphatic capillaries reside. Interstitial flow and the interstitium 
modulate lymphatic behavior, and lymphatic function, in turn, controls the tissue 
microenvironment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: lymphatic, interstitial flow, extracellular matrix, VEGF-C, VEGFR-3, 
lymphangiogenesis, lymphedema, folliculogenesis 
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RÉSUMÉ 
 
Les vaisseaux lymphatiques se trouvent dans pratiquement tous les tissus. Pourtant, malgré 
leur présence importante, il y a encore une grande différence de connaissance entre les rôles 
fondamentaux des capillaires lymphatiques déjà décrits et les connaissances que nous avons 
de leur fonction biologique, leur capacité adaptative et la réponse pathologique. Cette thèse 
vise à combler ces lacunes en utilisant l’ingénierie biomédicale pour examiner les régulateurs 
mécaniques et moléculaires des capillaires lymphatiques grâce à des modèles in vivo de la 
biologie, des fonctions et de l’adaptation des capillaires lymphatiques. 
 
En utilisant un modèle de régénération de la peau sur la queue des souris, nous avons 
démontré que le flux interstitiel lent créé par le drainage lymphatique était nécessaire pour 
l’organisation des capillaires lymphatiques. Ce nouveau modèle a permis l’identification de 
facteurs spatiaux, temporaux et chimiques gérant la lymphangiogénèse. Contrairement au 
mécanisme de croissance  pour l’angiogénèse du sang, les cellules endothéliales lymphatiques 
(LECs) ont démontré une organisation semblable à la vasculogénèse, migrant en direction du 
flux interstitiel, puis en s’organisant en capillaires lymphatiques fonctionnels. La 
lymphangiogénèse est inhibée en bloquant la signalisation des facteurs de croissance 
endothéliale vasculaire (VEGF-C) à partir du jour 0, mais l’initiation du blocus de récepteur 
une fois que les LECs ont déjà migré, n’empêche pas l’organisation des vaisseaux. Cette 
nouvelle approche a démontré le besoin de médiateur biochimique (VEGF-C) pour initier la 
lymphangiogénèse, mais qu’une force biomécanique importante, un flux interstitiel, était 
nécessaire pour l’organisation des capillaires fonctionnels.  
 
De plus, la nécessité du flux interstitiel dans la biologie des LECs a été démontrée dans la 
réponse des capillaires lymphatiques à un lymphœdème induit, où le drainage lymphatique est 
significativement réduit. Dans le modèle de lymphœdème secondaire dans la queue de souris, 
nous avons démontré que l’environnement œdémateux – caractérisé par une défaillance de la 
matrice extracellulaire, une accumulation des lipides et une réduction du flux interstitiel – a 
pour conséquence une hyperplasie des LECs, mais conduit à une fonction diminuée due au 
manque de flux interstitiel comme signal organisationnel. Des adaptations similaires de la 
matrice dermale au dysfonctionnement du drainage lymphatique ont aussi été remarquées 
dans deux modèles de souris de lymphœdème congénital, les souris Chy et VEGFR-3-Ig, de 
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plus elles démontrent la connexion intime de la fonction des capillaires lymphatiques avec la 
maintenance du tissu et son remodelage. 
 
Pour démontrer quantitativement les changements dans l’absorption des capillaires 
lymphatiques et la conductivité hydraulique du tissu trouvé dans ces modèles de souris 
transgéniques, nous avons développé un modèle poro-élastique de transport interstitiel. La 
conductivité hydraulique du tissu a aussi été calculée dans les tissus manquants de 
lymphatiques en utilisant une solution non-stationnaire, démontrant que le lymphœdème 
provoque une augmentation significative de la conductivité du tissu. Ce modèle a été utilisé 
ensuite pour tester les effets d’un régime enrichi en graisses, des troubles métaboliques et des 
dysfonctions des lymphatiques sur le tissu et la fonction des capillaires lymphatiques. Nous 
avons découvert que l’absorption des capillaires lymphatiques a été fortement réduite avec 
une dyslipidémie, mettant en évidence une nouvelle interaction entre la fonction lymphatique 
et le métabolisme des lipides. 
 
De plus, nous avons découvert un nouveau rôle critique pour la lymphangiogénèse et le 
transport lymphatique dans la reproduction. Nous avons démontré que la lymphangiogénèse 
est un événement régulier et non pathologique lors de la folliculogénèse dans l’ovaire. Ces 
nouveaux capillaires lymphatiques sont apparemment nécessaires pour le transport des 
hormones à partir de l’ovaire – un mécanisme essentiel durant la grossesse. Bloquer la 
lymphangiogénèse résulte en une diminution importante du niveau de progestérone et 
d’oestrdiol et conduit à un défaut du développement du fœtus.  
 
En conclusion, ce travail met en évidence les rôles critiques de la circulation lymphatique et 
démontre les interactions entre la biologie lymphatique et l’environnement biochimique et 
biophysique dans lequel se trouvent les capillaires lymphatiques. Le flux interstitiel et 
l’interstitium modulent le comportement et la fonction des lymphatiques, qui eux-mêmes,  
contrôlent le microenvironnement du tissu adjacent. 
 
 
 
Mots-clés : lymphatiques, flux interstitiel, matrice extracellulaire, VEGF-C, VEGFR-3, 
lymphangiogénèse, lymphœdème, folliculogénèse. 
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CHAPTER 1:  
OVERVIEW OF THE THESIS 
 
 
1.1: Aims 
 
The overall goals of this thesis are to identify and explore interactions between 
molecular and mechanical regulators of lymphatic capillary biology with respect to both 
quiescent tissue homeostasis and the pathological tissue states of skin regeneration 
(lymphangiogenesis) and lymphedema, and to quantitatively demonstrate alterations in 
lymphatic capillary function.  
The specific aims addressed in this thesis are to: 
(1) Identify the relative importance and interplay of contributing factors – molecular, 
mechanical, and cellular – to lymphangiogenesis in adult skin regeneration. 
(2) Determine the tissue pathology of both primary (congenital) and secondary (induced) 
lymphedema and how lymphatic capillary biology and function are affected. 
(3) Quantify changes in lymphatic capillary drainage function in response to potential 
molecular effectors. 
(4) Define a role for lymphatic capillaries and ovarian lymphangiogenesis in female 
reproduction. 
 
1.2: Motivation & Approach 
 
Lymphatic vessels and lymphatic circulation is found throughout the body and forms 
an integral part of the body’s circulatory system. Despite the critical roles that lymphatic 
capillaries plays in modulating interstitial fluid balance, maintaining immune surveillance, 
and transporting lipids, knowledge of the lymphatic system and the biology of lymphatic 
endothelial cells (LECs), particularly with regard to their function, remains lacking. To date, 
the bulk of research focused on lymphatic capillaries has been aimed at (a) developmental 
biology and (b) lymphangiogenesis in tumor progression. This research has elucidated an 
array of LEC-specific molecular markers, growth factors, and signaling molecules, and by 
comparing and contrasting lymphangiogenesis – both developmental and pathological – with 
the more widely studied blood angiogenesis, has lent a great deal of understanding and 
brought attention to the importance of lymphatic biology in the scientific community. By 
taking this approach, however, it leaves a significant opportunity to explore what we still do 
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not know about lymphatic capillary biology: How do adult lymphatic capillaries in the skin 
actually function and what factors may modulate this? Do LECs adapt to their environment 
and consequently modulate lymphatic capillary function? And what is the pathobiology of 
lymphatic capillaries in lymphedema and inflammatory conditions? 
 To approach these questions, an integrative biomedical engineering approach was 
taken. The complex biochemical and biomechanical environment in which dermal lymphatic 
capillaries reside would normally lead to the simplified, in vitro methods to directly determine 
outcomes of various experimental questions. For example: adding growth factors to LECs 
growing on 2-D plastic surfaces may help to identify the molecular response to the growth 
factor, but tells us little of the actual mechanism of lymphangiogenesis in a 3-D tissue 
environment. Well-designed engineered systems and experiments can, however, be applied in 
vivo so as to more relevantly tackle the problem of lymphatic capillary function. In this way, 
the environment remains wholly coupled to the biology, and vice versa. One of the principle 
examples in this work is in models utilizing the mouse tail. All lymphatic flow in the tail must 
move from the tip of the tail back towards the body. Because of the simple, cylindrical 
geometry of the tail, this flow is macroscopically unidirectional. This allowed not only the 
application of a quantitative model of lymphatic uptake and interstitial transport (Chapter 6), 
but also permits the mouse-tail model of lymphangiogenesis (Chapter 3) to have a well-
understood direction of interstitial transport. Thus, by approaching and developing models 
integrating the anatomy, biology, physiology, and mechanics of the adult lymphatic 
environment, we can confidently address the adaptive responses of the lymphatic endothelium 
in vivo and gain keen insight into controlling factors of lymphatic capillary biology. 
 
1.3: Thesis Overview 
 
The contents of the subsequent chapters of this thesis, and the studies that they 
represent, are summarized here so as to frame them directly within the overall objective and 
specific aims. Chapter 2 provides a general overview of background information on lymphatic 
capillaries and the environment in which they reside so that the subsequent research 
manuscripts may be held in better context.  
The first manuscript chapter, Chapter 3, defines the mechanism of lymphangiogenesis 
in regenerating mouse skin and characterizes – spatially and temporally – lymphatic 
organization and potentially contributing factors. The mode of vessel regrowth was not 
sprouting from existing capillaries, but rather a process akin to embryonic vasculogenesis. 
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Single LECs, or groups of LECs, first migrate in to the regenerating tissue, in the direction of 
interstitial fluid flow, and then coalesce to form organized, functional vessels.  
As the mechanism of lymphangiogenesis detailed in Chapter 3 was very step-wise and 
pseudo-independent of VEGF-C signaling (the paramount lymphatic growth factor), Chapter 
4 then discusses work on cooperative and redundant signaling of the receptors to VEGF-C, 
VEGFR-2 and VEGFR-3, in proliferation, migration, and organization of LECs during 
lymphangiogenesis. As the prevalent pathway of lymphangiogenesis, we found that VEGFR-
3 signaling was, indeed, important to initiate lymphangiogenesis – through LEC proliferation 
and migration – but was not required for the later LEC organization into new vessels. Rather, 
VEGFR-3 signaling initiates lymphangiogenesis, but functional capillary organization is 
VEGF-C-independent: interstitial flow is the organizing guidance cue. Chapters 3 and 4, 
completing Specific Aim 1, thus present the balance and interplay between molecular 
signaling and the mechanical, organizational force of fluid flow.  
Chapter 5 then presents what happens to lymphatic capillaries and their environment 
when interstitial flow stops in secondary lymphedema induced in the mouse tail. The chapter 
describes the model and the temporal characterization with respect to matrix degradation, 
lipid accumulation, and lymphatic vessel hyperplasia. What is truly interesting is that despite 
LEC proliferation, the lack of flow as an organizational guidance cue results in grossly 
hyperplastic, poorly functioning lymphatic capillaries. The model also successfully 
recapitulated the initial breakdown of the extracellular matrix and the subsequent dermal 
remodeling and subcutaneous lipid accumulation observed in the human condition. Lack of a 
normal matrix further hinders the ability of lymphatic capillaries to function normally.  
In Chapter 7, two models of congenital primary lymphedema, the Chy and K14-
VEGFR-3-Ig mice, are described and used to further demonstrate the adaptive tissue response 
to lymphedema and serve as an excellent basis of studying fluid transport in the interstitium. 
Chapter 6 presents the development of methods to quantify lymphatic capillary uptake and 
tissue hydraulic conductivity. The mouse models of primary lymphedema present the 
unsteady-state solution to the developed equations, as there is insignificant fluid flux to the 
lymphatic capillaries (because there are no lymphatics to take up interstitial fluid). Further 
discussion on quantifying lymphatic function in normal and edematous mice, a necessary step 
in determining the actual success of potential treatments for pathologies resulting from 
lymphatic dysfunction, is also presented in Chapter 6. For example, we found that 
dyslipidemia in the tissue reduced lymphatic function and that targeting lipids may improve 
functional drainage. Specific Aims 2 and 3 were therefore accomplished in Chapters 5, 6, and 
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7. More specifically: Chapters 5 and 6 explore both induced and congenital lymphedema with 
respect to their tissue morphology and changes to lymphatic capillary morphology and 
function; Chapter 6 quantifies lymphatic capillary functional uptake of interstitial fluid in 
these models; and Chapter 6 also identifies dyslipidemia in the tissue as a negative effector of 
lymphatic capillary function. 
Lymphatic vessels are known to modulate fluid balance, immune cell transport, and 
lipid metabolism, but in Chapter 8, a novel role for lymphatics and lymphangiogenesis in 
reproduction is presented. Blood angiogenesis has been established as an essential process in 
the ovaries both during folliculogenesis and sustained pregnancy, but lymphatics, 
lymphangiogenesis, and their potential roles have been sorely ignored. We found that 
lymphatic vessels function in the murine ovary for hormone transport during pregnancy, and 
that a lack of lymphatic capillaries during reproduction resulted in significantly reduced 
systemic progesterone and estrogen levels. Without these new lymphatic capillaries, fetal 
development was impaired and pregnancies failed. By discovering this novel role for 
lymphatics in reproduction, Specific Aim 4 was completed.  
The findings of the thesis study are then summarized in the concluding chapter, 
Chapter 9. Key results are placed within the context of the field and a brief discussion of the 
current and future directions that these results might lead are also included. 
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CHAPTER 2: 
BACKGROUND ON THE LYMPHATICS AND INTERSTITIAL FLOW 
 
2.1: The Lymphatic System 
 
Fluid transport through the lymphatic vasculature forms an integral part of the body’s 
circulation. Throughout nearly all tissues of the body, lymphatic capillaries drain interstitial 
fluid, macromolecules, and cells and transport them, through larger conducting lymphatic 
vessels and the lymph nodes (Figure 2.1), back to systemic blood circulation. As interstitial 
fluid is sourced from fluid extravasted from the blood vasculature, the lymphatics maintain 
tissue homeostasis and complete the body’s circulatory loop (1). 
 
 
Figure 2.1: Schematic of the lymphatic vessels encompassing lymphatic circulation. The focus of this thesis is 
the initial lymphatic capillaries, here shown in respect to the greater downstream lymphatics and lymph nodes. 
Artwork courtesy Carolyn Yong.  
 
While often neglected as nothing more than a passive tissue drainage system, in reality 
the roles of the lymphatic circulation are more active, diverse, and important. By serving as 
the low pressure reservoir in vascularized tissues, the lymphatic vessels promote interstitial 
flow – the subtle fluid flow through the extracellular matrix from blood capillaries and into 
initial lymphatic vessels (2). Interstitial flow has been demonstrated to be a key 
morphoregulator of cells in the interstitium (2, 3), so the lymphatic vessels actually have the 
potential to control the morphogenesis and migration of other cell types such as tumor and 
immune cells (4). Lymphatic vessels, by connecting the periphery to the lymph nodes, allow 
not only active immune cell trafficking for antigen presentation within the lymph node, but 
may also permit the nodes to sample incoming fluid for inflammatory mediators or antigens 
(5). Dietary lipid uptake from the intestinal lumen is, surprisingly, first through the lymphatic 
capillaries located within the villi of the intestinal wall (6). The lymphatic circulation is thus 
potentially important in regulating lipid metabolism as well.  
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2.1.1: Lymphatic Endothelial Cells (LECs) 
  
While in standard in vitro culture conditions blood endothelial cells and LECs are 
phenotypically quite similar, LECs in vivo form vessels that function very differently from the 
blood vasculature. Research on the embryonic development of the lymphatic vasculature has 
identified several genes and molecules specific to LECs that drive their differentiation, may 
modulate their function, and permit their identification both in culture and in tissues (Table 
2.1)(7). In total, LECs differ from blood endothelial cells not only in molecular expression, 
but also in their molecular responses and adaptive morphoregulation, likely due to their 
different roles in vivo. Once formed into capillaries, the differences between the blood and 
lymphatic endothelium, and how these differences impact their respective functions, becomes 
more striking.  
 
Table 2.1: Genes attributed to the lymphatic endothelium and the transgenic consequence in mouse models 
(table taken from Tammela, 2005 (7)) 
 
 
2.1.2: Lymphatic capillaries 
  
Initial lymphatic vessel morphology varies strikingly from that of their blood 
counterparts (Table 2.2) due to their functional differences (7). Lymphatic vessels exist in the 
tissue as a collapsed network of overlapping LECs, are not surrounded by pericytes, possess 
minimal interrupted basement membrane, and are directly anchored to the extracellular matrix 
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(ECM) by anchoring filaments (8, 9) where basement membrane is lacking. These physical 
vessel characteristics permit open fluid flow into the vessel from the interstitial space. While 
it may be contrary to initial intuition, because of the anchoring filaments that tightly tie LECs 
to the extracellular matrix, when interstitial fluid pressure (IFP) increases – and therefore, a 
demand for lymphatic drainage – the vessels are not crushed, but, rather are pulled open as the 
ECM expands (Figure 2.2) to increase flux into the capillary (10). In tissues with low 
compliance, (i.e., a stiffer matrix) the capillaries are thereby more sensitive to changes in IFP 
and fluid uptake is readily increased, as in the healthy lung (11).  
Lymphatic capillary uptake of fluid proceeds between the overlapping LECs through 
unique cell-cell junctions (9, 12). These junctions – recently described to be analogous in 
appearance to overlapping oak leaves (13) – are incredibly dynamic, with LECs actively 
responding to changes in interstitial flows, inflammatory molecules, and migrating cells by 
altering their molecular expression to open or close these cell-cell connections (13, 14), 
resulting in accordingly increased or decreased drainage. Fluid entry into lymphatic 
capillaries is further described in section 2.2.1 and quantified in vivo in Chapter 6. 
 
 
Table 2.2: Morphological differences between blood capillaries, lymphatic capillaries and collecting lymphatic 
vessels (table taken from Tammela, 2005 (7)) 
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Figure 2.2: Flow enters lymphatic capillaries between cells; increased interstitial pressure (IFP) expands the 
matrix, pulling on the LECs and their anchoring filaments, opening the cell-cell junctions; pulling the cell-cell 
junctions open permits increased drainage into the capillary (original artwork). 
 
 
2.1.3: Greater Lymphatics 
  
Initial lymphatics lead to larger collecting lymphatic vessels that further connect 
lymph nodes and downstream collecting vessels before returning lymph flow to the blood 
circulation (Figure 2.2). Unlike the initial lymphatic capillaries, collecting vessels possess 
bileaflet valves to limit backflow and smooth muscle that intrinsically pumps to maintain 
lymph flow (10). Indeed, this pumping is necessary for the low pressure lymphatic network to 
actually propel lymph throughout the body. This thesis does not focus on transport within 
these vessels, but they play a vital role in maintaining lymphatic drainage from upstream 
tissues. 
 Lymph nodes are lymphoid organs located throughout the lymphatic network that 
provide the primary specific immune sampling from peripheral tissues and permit the 
development of an antigen specific lymphocyte response (5). Lymph node anatomy and 
physiology is a detailed field in of itself, primarily focused on the organs’ roles in immunity 
and as cancer metastasis sites. This thesis does not focus on transport within collecting 
lymphatic vessels, nor lymph node function, but acknowledges the vital role they play in 
maintaining lymphatic drainage from upstream tissues. 
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2.2: Roles of Lymphatic Capillaries 
 
2.2.1: Interstitial Flow Driven by Lymphatic Capillary Function 
  
From a physical perspective, the primary role of the lymphatic capillaries is to drain 
interstitial fluid, thus maintaining tissue homeostasis and driving interstitial flow. Fluid entry 
into lymphatic capillaries is quite different, however, than fluid extravasation from the blood 
vasculature. Extravasation is governed by Starling’s law of capillary filtration: 
( ) ( )( )erstitiumcapillaryerstitiumcapillaryv PPLpJ intint ππσ −+−= , 
which demonstrates the balance between hydrostatic pressure, ∆P, and osmotic pressure, ∆π, 
across the capillary wall governed by the reflection coefficient, σ, and the overall vessel 
filtration coefficient, Lp. The equation can be applied to lymphatic drainage – reversing the 
pressure differences, of course – when adapted properly taking into account the unique 
morphology of the lymphatic capillary. As interstitial fluid flow directly into the lymphatic 
capillary, and not through the vessel wall, the osmotic pressure driving force, ∆π, is zero. 
Similarly, because σ (which ranges from 0.0-1.0 for zero to complete reflection) refers to the 
vessel’s ability to prevent the extravasation/intravasation of molecules (e.g., proteins), in 
lymphatics capillaries this term is also zero (15). What remains is merely the hydrostatic 
pressure driving force and the filtration coefficient, Lp, which is governed by the overall 
vessel permeability and vessel wall area (both of which increase when the vessel is opened by 
interstitial pressure increases). Further use of Starling’s law of capillary filtration and in 
calculating fluid flux into lymphatic capillaries is given in Chapter 6. 
Fluid entry into lymphatic capillaries thus provides for interstitial flow as fluid is 
transported across the interstitium from blood to lymphatic capillary. While these flow rates 
are very small (0.1-10 μm/s) (3), a new appreciation for subtle flow effects on cell behavior is 
increasingly emerging. The morphogenetic potential of interstitial flow, along with further 
explanations of its sources and importance are found in the original review manuscript 
entitled, “A Driving Force for Change: Interstitial Flow as a Morphoregulator”, included as an 
Appendix to this chapter. 
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2.2.2: Lymphatic Capillaries in Immunity 
 
Antigen-presenting immune cells (APCs), dendritic cells and macrophages, after 
encountering antigens in the periphery, migrate to a lymphatic capillary and traffic to the 
sentinel lymph node. Lymphatic vessels secrete the cytokine CCL21, which serves as a 
chemoattractant for APCs via binding to the APC receptor CCR7 (5). How interstitial flow 
affects this process and whether or not LECs can actively regulate APC attraction and entry is 
the topic of current research in the laboratory; it is believed that these cells behave similarly to 
metastatic tumor cells (4). According to the theory of autologous chemotaxis, proper 
lymphatic capillary drainage function may be necessary for APC trafficking and entry into 
lymphatic circulation. More comprehensive reading on the role of the lymphatic system in 
immunity can be found in the excellent reviews: (5, 16, 17). 
 
 
2.2.3: Lymphatic Capillaries in Lipid Transport 
 
Lymphatic vessels are the primary route of lipid absorption from the small intestine. 
Enterocytes, specialized cells of the intestinal epithelium, package lipids into chylomicrons, 
which then enter the lymphatic capillaries (also called lacteals) found within the intestinal villi 
(6). In this way, lipids first pass through the lymphatic circulation before entering the blood 
circulation and subsequent metabolism in the liver (18). As this thesis is focused on lymphatic 
capillaries in the dermis, intestinal lymphatics and their potential role in lipid metabolism are 
not directly discussed. However, dermal lymphatic capillaries, by taking up extravasated 
molecules from the interstitium, provide the route of reverse lipid transport from the skin. 
Indeed, when capillary function is compromised, lipid accumulates in the dermal tissue space 
(19). Thus, dermal lipid accumulation and adipogenesis can be utilized as a marker of 
lymphatic dysfunction and a potential exists for further cross-talk between lymphatic function 
and adiposity – an area currently under intense exploration. The impact of dyslipidemia on 
dermal lymphatic capillary uptake is quantified in Chapter 6. 
 
2.3: Lymphangiogenesis 
  
Lymphangiogenesis, the growth of new lymphatic vessels, is modulated by many of 
the lymphatic molecules ascribed above (Table 2.1). The molecules important in 
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developmental lymphangiogenesis, however, are different from those considered to be 
paramount in the adult during lymphangiogenesis associated with wound healing or tumor 
growth and metastasis (20). The principal, and most widely studied, growth factors driving 
lymphangiogenesis are members of the vascular endothelial growth factor (VEGF) family.  
VEGF-C and -D were identified and characterized following much work on the role of 
lymphatics in tumor progression and the search for potential lymphangiogenic therapies in 
lymphedema (21) as the growth factors essential for the proliferation and migration of LECs 
(22). Blocking the primary receptor to these ligands, VEGFR-3, inhibits lymphangiogenesis 
in healing wounds (22, 23), inflammation (24, 25), and prevents tumor metastasis (26). In this 
thesis, the mechanism of lymphangiogenesis in adult skin regeneration is explored more in 
depth in Chapter 3 and the role of VEGFR-3 signaling in this process is more clearly defined 
in Chapter 4. The role of lymphangiogenesis during reproductive cycles in the ovary is newly 
described in Chapter 9. 
 
2.4: Lymphedema 
  
Lymphedema is the most common pathology directly linked to lymphatic fluid 
transport. Lymphedema is classified generally into two forms: primary (congenital) and 
secondary (induced). Primary lymphedema has been linked to mutations in LEC genes 
essential for proper lymphatic vessel development; improper development of lymphatic valve 
structures or insufficient organization of dermal lymphatic capillaries leads to failed 
interstitial fluid and lymph clearance (27-30). Secondary lymphedema is caused when pre-
existing, normal lymphatic vessels are ligated by surgery (e.g., lymph node removal as a 
treatment to prevent breast cancer metastasis), inflammation, or radiation, among others (31). 
As a chronic pathology, dysfunctional lymphatic transport leads to remodeling of the skin and 
subcutaneous extracellular matrix, accumulation of lipids, and failures in immune response in 
the tissue or limb upstream from the ligation (19). These morphological adaptations can 
worsen the condition and prevent successful resolution – indeed while compression cuffs, 
massage, and surgical removal of tissue have demonstrated success in minimizing the 
condition, unfortunately, there is no complete “cure” for lymphedema (31). The pathology of 
secondary lymphedema is characterized in Chapter 4, while the tissue adaptation to primary 
lymphedema, and the resultant fluid transport implications, are demonstrated in Chapters 5 
and 6. 
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ABSTRACT 
 
Dynamic stresses that are present in all living tissues drive small fluid flows, called interstitial 
flows, through the extracellular matrix. Interstitial flow not only helps to transport nutrients 
throughout the tissue, but also has important roles in tissue maintenance and pathobiology that 
have been, until recently, largely overlooked. Here, we present evidence for the various 
effects of interstitial flow on cell biology, including its roles in embryonic development, tissue 
morphogenesis and remodeling, inflammation and lymphedema, tumor biology and immune 
cell trafficking. We also discuss possible mechanisms by which interstitial flow can induce 
morphoregulation, including direct shear stress, matrix–cell transduction (as has been 
proposed in the endothelial glycocalyx) and the newly emerging concept of autologous 
gradient formation. 
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INTRODUCTION 
The importance of dynamic mechanical stress (see Glossary) in tissue development, 
maintenance, function and pathogenesis has been well established for several decades. The 
field of biomechanics originated to characterize the mechanical behavior of tissues that serve 
obvious mechanical functions (e.g. bone, muscle, arteries and lung tissue) and how these 
mechanical properties change in pathological states. This research evolved and branched into 
the field of mechanobiology, which focuses on understanding the cell biology that controls 
tissue mechanics, in other words, the response of cells to mechanical stress and the way they 
adapt to and control their mechanical environment [1 and 2]. Mechanobiology research today 
remains largely devoted to understanding the control of mechanically important tissues for 
tissue engineering applications and other areas of therapeutic design. 
However, even in tissues that do not serve primarily mechanical functions or undergo 
obvious strains, mechanical stress is an important regulator of tissue development, health and 
pathology. Dynamic stresses and pressure gradients exist in all living tissues. These tissue 
stresses can impart forces on the cell, including fluid shear stress, pressure forces and forces 
on integrins, and they can also affect cell behavior by transporting solutes and shaping the 
extracellular distribution of key signaling proteins. For example, small fluid flows within the 
interstitial space are needed to drive protein transport from the blood to interstitial cells, 
because proteins are too large to readily diffuse the distances between blood capillaries, 
distances optimized for the transport of oxygen and other small molecules to cells. Dynamic 
stresses are therefore not only present in all living tissues, but are also required for 
physiological functions and tissue homeostasis. A clear example of the necessity of activity is 
seen in the atrophy of muscle and bone when movement is limited.  
Here, we focus on the importance of a subtle but essential dynamic force: interstitial 
fluid flow. We argue not only that interstitial flow is an important morphoregulator in tissue 
development, maintenance and remodeling, but also that it is used by interstitial cells to signal 
the state of their surroundings, help establish extracellular microenvironments, and guide 
lymphocytes and tumor cells towards draining lymphatic vessels (also referred to generally 
herein as lymphatics). 
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What is interstitial flow? 
Interstitial flow is fluid flow through a 3D matrix, around interstitial cells such as 
fibroblasts, tumor cells, tissue immune cells and adipocytes. It differs from open-channel 
flow, such as blood flow within vessels, in several ways (Figure 1): for example, it generally 
flows with a much slower velocity because of the high flow resistance of the extracellular 
matrix, it moves around the cell–matrix interface in all directions rather than only on the 
apical side, and it can have important effects on pericellular protein gradients, particularly 
those that are matrix binding. Interstitial flow also occurs across the blood vessel wall (called 
transvascular flow) (e.g. in arteries, this flow is two orders of magnitude slower than that of 
the blood) and the glycocalyx on the luminal surface of blood endothelium can impart some 
features of interstitial flow on the endothelium.  
Interstitial flow is driven primarily by plasma leaving a blood capillary through its 
wall and draining into the initial lymphatics (Figure 2). Even when lymphatics are not 
functional or are blocked, some interstitial flow can occur by plasma reabsorption in post-
capillary venules (although not all can be removed this way). In healthy adult tissues, the 
pressure difference between the two capillary networks maintains fluid pressure gradients that 
are altered by skeletal motion and also by subtle movements, such as those arising from 
arterial pulsation, respiration and organ movement. One noted exception to the intervascular 
pressure driving force is in cartilage and bone, where dynamic compression drives flow 
through the matrix. 
There are only a few direct measurements of interstitial flow velocities in vivo in the 
literature; these velocities are difficult to measure and interpret because they are so slow and 
heterogeneous, they depend on the tracer moving with the same velocity as the fluid (which is 
difficult to confirm in the dense interstitial space, and the tracer can also cause artifacts when 
introduced into the tissue), and they have only been measured close to the surface by 
fluorescence recovery after photobleaching (FRAP) or nuclear magnetic resonance (NMR). 
Furthermore, these measurements are typically performed in anesthetized animals, in which 
interstitial fluid velocities are likely to be substantially different from those in awake animals 
because of changes in blood pressure and lymphatic pumping [3 and 4]. Reported measured 
velocities vary between 0.1 and 4.0 μm s−1 [5 and 6]. Interstitial flow velocity can also be 
estimated using Darcy's law, which relates velocity to the pressure gradient and the hydraulic 
conductivity, K (Box 1). This is sometimes more convenient, because interstitial pressures can 
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be measured more reliably using micropipettes or wick-in-needle techniques [7] and K can be 
measured in tissues ex vivo using confined compression tests [8 and 9].  
Even though it can be extremely slow, interstitial flow can have important effects on 
tissue morphogenesis and function, cell migration and differentiation and matrix remodeling, 
among other processes. The mechanisms by which such flows can drive cell response might 
be purely mechanical, such as shear stress on the cell surface, pressure force ‘pushing’ on the 
cell or tethering forces on cell–matrix connections (Figure 3). Importantly, it can also have 
non-mechanical affects on the cells, such as shifting the pericellular distribution of secreted 
proteins (e.g. morphogens, proteases and chemokines). These transport effects are likely to be 
more important than mechanical stress in tissues that do not serve primarily mechanical 
functions, because of the small magnitudes of stresses and flows found there. In these tissues, 
interstitial flow-induced protein redistribution might help to direct cell migration and guide 
the cell–cell interactions that lead to pattern formation during morphogenesis. Thus, 
interstitial flow affects both the mechanical microenvironment of the cell and the biochemical 
environment to which it is so acutely tuned. 
Biological flows in development 
In embryos that have not yet developed a vascular system or heart, flow that is driven 
through the differentiating cell mass is necessary for proper development. In the embryonic 
node (an embryonic structure located at the anterior tip of the primitive centerline) ciliary 
movement generates the leftward movement of fluid that leads to the left–right asymmetry of 
the organs (in which the heart is on the left, the liver on the right, etc.) [10], and when this 
cilia-driven flow within the node is reversed experimentally, the left–right asymmetry 
becomes reversed [11]. It has been suggested through mathematical modeling that nodal flow 
directs morphogen transport and mixing, thus driving asymmetric development [12]. This is 
indeed likely, because the actions of morphogens (to give cells directional and positional 
information) are achieved through their transcellular concentration gradients rather than their 
absolute amounts. In developing embryos, such spatial information guides cell differentiation 
[13]. Morphogen transport and gradient patterning are also believed to regulate the branching 
of developing lungs in the embryo [14], and it is expected that interstitial flows, caused by 
embryonic lung movements that simulate breathing, would influence morphogen 
distributions. Interstitial flow can also impart shear stress on the cell surface, which, as a 
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mechanical stimulus, can itself drive embryonic cell differentiation and determine lineage fate 
[15 and 16] and could be responsible for shaping organs [17 and 18]. 
Interstitial flow has also been implicated in lymphatic development. Using a skin 
regeneration model in which interstitial fluid flow could be traced and correlated with 
lymphatic proliferation, migration and reorganization over time, it has been shown that 
lymphatic cells migrate in the direction of interstitial flow and organize around fluid channels, 
and that they cannot organize into functional capillaries when interstitial flow is severely 
reduced [19 and 20]. Thus, interstitial flow can act as an important morphogenic cue, by 
mechanisms we discuss later. 
Interstitial flow in tissue function and pathology 
Much evidence has emerged to indicate that interstitial flow has an important 
regulatory role in tissue function. Transvascular flow across the arterial wall provides nutrient 
transport to the metabolically active cells there, and seemingly has a crucial role in 
maintaining arterial smooth muscle tone [21, 22 and 23]. In cartilage, where lymphatics are 
absent and intercellular distances are large, interstitial fluid flow is driven by mechanical 
loading and is necessary for nutrient transport and cell–cell communication when diffusion is 
inadequate [24, 25 and 26]. Also, interstitial flow rather than solid stress is responsible for at 
least some of the mechanical stress-induced matrix production in cartilage [27], because 
dynamic rather than static compression was found to promote proteoglycan and collagen 
synthesis [28] and increase chondrocyte metabolism [29] (interstitial flow is always present in 
tissues undergoing dynamic compression). Dynamic compression stimulates directional 
deposition of proteoglycans and matrix fiber compaction in the direction of flow [26] and 
directs remodeling by enhancing the transport of tissue inhibitor of metalloproteinase-1 
(TIMP-1) [30]. In bone, physical activity causes oscillatory compression that has been 
estimated to increase the convective transport of macromolecules up to 100 times more than 
what is possible with diffusion [31]. Finally, in tissue repair, the migration of endothelial and 
epithelial cells is crucial for wound healing, which (at least on 2D surfaces) can be activated 
by shear stress [32 and 33], suggesting that interstitial flow also promotes wound healing in 
3D tissues by shear stress. In vitro, interstitial flow enhances blood and lymphatic capillary 
formation [34] and acts synergistically with matrix-bound VEGF to induce capillarogenesis, 
probably by enhancing and directing the liberation of VEGF from the matrix to guide 
organization in the direction of flow [35, 36 and 37]. 
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Physiological evidence that interstitial flow is crucial in normal tissue function can be 
seen in pathologies in which interstitial flow is reduced or enhanced. Lymphedema is a 
condition in which interstitial fluid flow is severely reduced due to either malformations in the 
lymphatic system (primary lymphedema) or blockage downstream, such as that which occurs 
after lymph node resection (secondary lymphedema). The accumulation, rather than 
clearance, of fluid from the interstitial space results in inflammation and extensive tissue 
remodeling, lymphatic hyperplasia, and adipocyte growth and lipid accumulation [38 and 39]. 
Fluid stagnation in lymphedema also prevents normal immune cell trafficking in the affected 
tissue, which can exacerbate the pathology. These resultant chronic pathological conditions in 
lymphedema highlight the importance of interstitial fluid convection in maintaining healthy 
tissue. 
Abnormally increased interstitial flow rates can occur during inflammation (when 
blood capillaries become leaky) and can also trigger fibroblasts to differentiate or remodel the 
extracellular matrix. Although this can be due to increased transport of differentiation factors 
from inflammatory cells to fibroblasts, increased interstitial flow itself could be an important 
contributing factor to the development of tissue fibrosis: in vitro studies have shown that 4–
10 μm s−1 interstitial flow through a 3D collagen matrix seeded with human lung or dermal 
fibroblasts causes autocrine upregulation of transforming growth factor (TGF)-β1, 
differentiation into myofibroblasts (Figure 4a), increased collagen production and collagen 
alignment [40, 41 and 42]. In this way, high interstitial flow could be an early signaling cue of 
inflammation that triggers fibroblasts to begin rapid matrix repair. It could also help explain 
why tissue fibrosis often follows inflammation in many tissues, including the lung, skin and 
surrounding tumors, and why fibrosis can occur in the apparent absence of inflammatory 
cells, such as in idiopathic pulmonary fibrosis [43 and 44].  
Interstitial flow in cancer 
Interstitial flow in and around tumor tissue has particular importance in delivering 
anticancer agents to tumor tissue. Given that growing tumors induce angiogenesis and 
angiogenic tumor vessels are more permeable to proteins and large molecules than mature 
vessels [45], there has been substantial interest in exploiting tumor vessel permeability to 
selectively accumulate drug carriers by size in tumor tissue. However, interstitial transport is 
driven by pressure differences between the blood and interstitium, and in tumors interstitial 
fluid pressure is higher, ranging from 10 mmHg to 20 mmHg (with measurements as high as 
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90 mmHg), than in normal tissues, which have pressures that are typically <10 mmHg (Table 
1) [46]. Thus, the driving force for fluid movement from the blood into the tumor stroma is 
lower than that in normal tissues. These high interstitial pressures are due in part to the lack of 
functional lymphatics within the tumor [47] and result in a net convective flow out from the 
tumor mass into the surrounding tissue as a result of the lower interstitial pressure found 
there. (The conclusion that tumors lack functional lymphatics is controversial, however; 
several reports have suggested that metastatic tumors can induce lymphatic growth into the 
tumor mass [48].)  
Although the challenges to therapeutic delivery to solid tumors have been researched 
extensively, the impact of the extratumoral interstitial flow environment on tumor biology has 
not been much explored. Slow interstitial flow from the tumor mass into the surrounding 
tissue and draining lymphatics might, for example, help the tumor invade tissue and 
lymphatics by directing proteolytic enzymes and autocrine chemokines away from the tumor 
and towards the draining lymphatics. Alternatively, it might promote the formation of a 
fibrotic capsule around the tumor (as flow itself can drive fibroblast differentiation, as 
mentioned earlier [41]), which might inhibit tumor spread. Also, it is likely to affect the 
recruitment and function of tumor-associated macrophages that are found around highly 
invasive tumors [49] by further distributing chemotactic factors. 
New insights into how interstitial flow can affect tumor biology and invasion are just 
beginning to emerge. For example, it was recently shown that tumor cell proliferation can be 
influenced by intratumoral pressure [50]. In tumors overexpressing lymphangiogenic growth 
factors, peritumoral lymphatics (those surrounding and draining the tumor) were found to 
drain fluid at an increased rate, and tumor cells were directly observed homing to those 
lymphatics [51]. Finally, recent in vitro studies suggest that interstitial flow from tumor cells 
directed towards lymphatic endothelial cells greatly enhances the migration of tumor cells 
towards the lymphatics, through a combination of autocrine and paracrine signaling 
mechanisms [Shields, J.D, unpublished data]. We explore this possibility further when 
discussing autologous chemotaxis. 
Mechanisms of flow-induced cell response 
Evidence that interstitial flow can direct mechanotransduction events on the cell 
surface comes from recent studies on the endothelial glycocalyx. Originally, the shear stress 
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effects seen on endothelial cells were presumed to be due directly to fluid shear stress acting 
on the cell surface, but there is increasing appreciation for the role of the glycocalyx in 
moderating or amplifying fluid stresses to the cell surface. The primary constituents of the 
glycocalyx are heparan sulfate, chondroitin sulfate and hyaluronan [52], anchored to the cell 
by proteoglycan core proteins. The role of the glycocalyx in transducing shear stress to the 
cell has been demonstrated by selectively degrading these components and exposing the cells 
to shear: for example, when either heparinase or hyaluronidase were applied to an endothelial 
cell monolayer, well established responses to shear stress, such as the release of nitric oxide, 
were eliminated [53 and 54]. Although such stresses are not identical to those in true 
interstitial flow, as mentioned earlier, the fact that cells might sense flow only when the 
glycocalyx is intact gives strong support to the importance of cell–ECM connections in 
transducing mechanical stress by slow interstitial flow. In 3D in vitro matrices, cell surface 
shear stresses for flow rates of 1 μm s−1 were estimated to average 5 × 10−3 to 
7 × 10−3 dyne cm−2 and peak at 1.5 × 10−2 dyne cm−2, although the precise architecture of 
matrix fibers strongly affected these stresses [55]. It is unknown to what limit cells might 
sense shear stress, but with such low levels, it is likely that the glycocalyx and/or surrounding 
ECM helps amplify the signals to transduce mechanical stress to the cell. 
Another mechanism by which interstitial flow can affect cellular responses is by 
changing pericellular diffusion gradients of morphogens that are redistributed by the flow 
according to how they are transported: by diffusive and/or convective transport (see 
Glossary). Given that morphogens act by directing cellular responses spatially according to 
transcellular gradients, subtle changes in their pericellular distributions (e.g. the introduction 
of asymmetry) can have important effects on directed cell processes. In addition, many 
chemokines and growth factors that are both secreted by and act upon the same cell bind 
strongly to the matrix (usually to sulfated proteoglycan components of the matrix), including 
members of the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), 
Wnt and TGF families and many immunoresponsive chemokines, such as CCL21, that direct 
leukocyte migration [56]. The binding of these factors to the matrix gives the cell more 
control of its microenvironment and enables solid-phase gradients to form. In addition, some 
of these proteins can signal to cells in both their liberated and their matrix-bound forms. 
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Interstitial flow in cell homing: the concept of autologous chemotaxis 
Chemokine gradients act as directional signals for cell chemotaxis or morphogenesis. 
Because migrating cells move up a chemokine concentration gradient, it is generally assumed 
that the chemokine is secreted by an upstream cell or tissue. An alternative mechanism, 
however, has recently been described whereby a cell can receive directional cues while 
simultaneously being the source of such cues, using interstitial flow. In this mechanism, even 
extremely subtle flows can affect the pericellular distribution of self-secreted proteins that 
interact with the matrix and thus cause autologous transcellular gradients, increasing in the 
direction of flow, to form (Figure 4c) [57]. Flow only slightly biases the distributions of a 
secreted matrix-binding morphogen and proteases that can liberate the morphogen, but those 
effects multiply and combine with the fact that, once the morphogen is liberated, it is further 
biased by flow. In this way, the ability of the secreted morphogen to bind the matrix serves as 
an amplification mechanism for autocrine gradient formation only in the presence of subtle 
interstitial flow. This has been demonstrated experimentally using a 3D culture of endothelial 
cells suspended in a VEGF-containing matrix, in which VEGF was covalently bound and 
liberated only upon proteolytic release by the cells [35]; capillary organization occurred only 
in the presence of both VEGF and interstitial flow (Figure 4b). This was presumably due to 
directed liberation of VEGF. 
This putative phenomenon of autocrine morphogen gradient formation by interstitial 
flow and matrix binding of morphogens suggests that leukocytes and tumor cells might use 
interstitial flow to home to draining lymphatics. This is possible when the cell expresses the 
homing chemokine receptor and also secretes the chemokine ligand. These cells include 
tumor cells [expressing the chemokine receptor CCR7 and the ligand CCL21 (Shields, J.D., 
unpublished data)], dendritic cells (expressing the chemokine receptor CCR7 and the ligand 
CCL19 [58]) and macrophages (expressing VEGF receptor-3 and its ligand VEGF-C [49]). 
As all of these ligands can bind to the matrix, and as all are important cues for migration, 
there is potential for each to direct migration by this mechanism. Mathematical modeling 
shows that even the smallest flows can create autologous gradients in such systems [57]. Not 
only might this help to explain why certain cell types have receptors for ligands that they 
themselves secrete, but this mechanism of self-directed cell migration might also be 
fundamental to the movement of tumor and immune cells in the direction of interstitial 
transport, that is, towards functional lymphatic vessels and on to the nearest lymph node. 
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Flow-induced autologous chemotaxis has recently been demonstrated in vitro, using human 
invasive and noninvasive breast cancer cells, to take place through the chemokine CCR7 and 
its receptor CCL21: whereas flow strongly enhanced the migration of tumor cells through 3D 
matrices in the direction of flow, blocking CCR7 signaling eliminated this effect (Shields, 
J.D., unpublished data). Thus, it is possible that autologous chemotaxis is a powerful 
mechanism that cells use to find and home to functional draining lymphatics. 
CONCLUDING REMARKS 
In summary, interstitial flow is an important component of normal tissue function and 
homeostasis and of many pathologies, from development through to adulthood. It might also 
be a key morphoregulator, acting by giving directional cues to cells. As prime examples, 
dendritic cell trafficking to lymph nodes and tumor invasion and dissemination through 
lymphatics can use interstitial flow to home towards lymphatic capillaries. Future research 
that incorporates and examines interstitial flow as a key microenvironmental component will 
be necessary to elucidate such mechanisms fully and exploit its potential in therapy and tissue 
engineering.  
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GLOSSARY 
Autologous chemotaxis 
a migratory mechanism whereby a cell can respond to a chemotactic gradient while at 
the same time being the source of the chemokine, when interstitial flow is present, to 
create the transcellular gradient. 
Convection 
transport driven by fluid movement. 
Diffusion 
transport driven by random thermal molecular motion (from high to low 
concentration). 
Fluid shear stress 
the tangential stress exerted on a surface (e.g. of a cell) due to fluid viscosity and flow. 
Glycocalyx 
a layer of heparan sulfate proteoglycans and hyaluronan secreted by and coating 
endothelial cells. 
Matrix binding 
the ability of a morphogen to be chemically bound to the matrix, typically through 
interactions with sulfated proteoglycans. 
Pressure gradient 
the difference in pressure divided by a unit length. 
Stress 
force per unit area. 
 
Box 1: Darcy's law  
 
 
where v is the bulk fluid velocity, K is the hydraulic conductivity, and ΔP is the pressure 
difference over length l of the tissue. 
Darcy's law provides the fundamental equation for low Reynolds number flows through 
porous media. Originally developed in 1856 to describe flow through a gravel bed, Darcy's 
law (here in simplified form) can be applied to biological tissues to calculate interstitial flow 
velocities because the physical parameters of pressure and K can be measured more readily. 
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FIGURE LEGENDS 
Figure 1. Interstitial and intravascular flows and their corresponding microenvironments. A 
blood vessel is shown, with insets showing the transvascular and glycocalyx regions. Black 
arrows represent luminal flow, and green arrows represent intra-glycocalyx, transvascular, 
and interstitial flows. By definition, interstitial flow refers to fluid flow around an interstitial 
cell: a cell attached to extracellular matrix in three dimensions. For endothelial cells, flow 
within vessels occurs only on the apical surface. Where there is a glycocalyx, flow might 
percolate through that network of proteoglycans and cause complex stresses on the cell 
surface, but fluid flow is still two-dimensional with respect to the cell surface. However, the 
intimate cell–matrix–flow interactions at the glycocalyx–cell interface might lead to effects 
similar to those in three dimensions. Intravascular pressure can drive flow through the 
vascular wall, but endothelial cells and smooth muscle cells will experience flow stresses 
through cell–cell connections and through cell–matrix connections as in true interstitial flow. 
Figure 2. Determinants of interstitial flow velocity. Darcy's law describes fluid flow through 
a 3D matrix as being driven by a fluid pressure gradient and controlled by a flow resistance. It 
is analogous to water flow through a mat of hair in a bathtub drain: the more dense the hair 
mat, the slower the fluid drains. One important source of interstitial convection is fluid 
movement driven by the pressure gradient between blood and lymphatic capillaries (red and 
green, respectively), determined by the pressure difference (Pblood – Plymphatic) divided by the 
intercapillary distance. The pressure gradient yields a resultant velocity, v (green arrows), 
controlled by the interstitial hydraulic conductivity, K, which varies depending on the density 
and composition of each tissue (Box 1, Table 1). 
Figure 3. The direct effects that interstitial flow has on cells. Interstitial flow can induce (a) 
fluid shear stress, σ, on the cell surface; (b) forces normal to the cell surface (F); (c) shear and 
normal forces to the pericellular matrix that is mechanically coupled to the cytoskeleton; and 
(d) redistribution of pericellular proteins (autocrine and paracrine signals) that bind cell 
receptors. 
Figure 4. Examples of cellular responses to interstitial flow. (a) Interstitial flow at 4 μm/s 
levels (right) cause human dermal fibroblasts seeded in type I collagen to differentiate into 
myofibroblasts by upregulation of TGF-β and align themselves and the matrix fibers 
perpendicular to the flow. Reproduced with permission from Ref. [41]; the scale bar 
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represents 20 μm. (b) Human blood endothelial cells form branched structures with lumens 
when cultured under interstitial flow (right). Here, low levels (4 μm/s) of interstitial flow 
greatly enhanced the effects of matrix-bound VEGF on capillary morphogenesis. Reproduced 
with permission from Ref. [35]; the scale bar represents 40 μm. (c) Computational modeling 
demonstrates that when morphogens or chemokines are autologously secreted by a cell in 
matrix-binding form and under low levels of interstitial flow, autologous morphogen 
gradients develop to guide cell processes in the direction of flow. The concentration profiles 
of liberated VEGF released by cell-secreted proteases,under the conditions in (b) are shown. 
Reproduced with permission from Ref. [35]. 
 40 
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 41
Figure 1 
 
 42 
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 43
Figure 2 
 
 44 
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 45
Figure 3 
 
 
 46 
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 47
Figure 4 
 
 
 48 
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 49
CHAPTER 3: 
ORIGINAL MANUSCRIPT 2 
 
 
Characterization of Lymphangiogenesis in a Model of 
Adult Skin Regeneration 
 
Joseph M. Rutkowski1, Kendrick C. Boardman2, and Melody A. Swartz1,2 
 
 
1Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, 
Switzerland 
2Department of Biomedical Engineering, Northwestern University, Evanston, IL USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted 9 January 2006; accepted in final form 25 April 2006 
American Journal of Physiology – Heart and Circulatory Physiology 
291: H1402-H1410, 2006. First published April 28, 2006.
 50 
ABSTRACT 
 
To date, adult lymphangiogenesis is not well understood. In this study we describe the 
evolution of lymphatic capillaries in regenerating skin and correlate lymphatic migration and 
organization with the expression of matrix metalloproteinases (MMPs), immune cells, the 
growth factors VEGF-A and VEGF-C, and the heparan sulfate proteogylcan perlecan, a key 
component of basement membrane. We show that while lymphatic endothelial cells (LECs) 
migrate and organize unidirectionally, in the direction of interstitial fluid flow, they do not 
sprout into the region but rather migrate as single cells that later join together into vessels. 
Furthermore, in a modified “shunted flow” version of the model, infiltrated LECs fail to 
organize into functional vessels, indicating that interstitial fluid flow is necessary for 
lymphatic organization. Perlecan expression on new lymphatic vessels was only observed 
after vessel organization was complete, and also appeared first in the distal region, consistent 
with the directionality of lymphatic migration and organization. VEGF-C expression peaked 
at the initiation of lymphangiogenesis but was reduced to lower levels throughout 
organization and maturation. In mice lacking MMP-9, lymphatics regenerated normally, 
suggesting that MMP-9 is not required for lymphangiogenesis, at least in mouse skin. This 
study thus characterizes the process of adult lymphangiogenesis and differentiates it from 
sprouting blood angiogenesis, verifies its dependence on interstitial fluid flow for vessel 
organization, and correlates its temporal evolution with those of relevant environmental 
factors.  
 
 
 
 
 
 
 
 
 
 
Key words: lymphatic, vasculogenesis, interstitial fluid flow, MMP-9, perlecan 
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INTRODUCTION 
 
Adult lymphangiogenesis is an important process that occurs in wound healing and 
may play a role in lymphedema and cancer metastasis. Increasingly, the importance of 
lymphatic biology is being realized and many key advances in the field have recently 
emerged, particularly in the identification and characterization of key molecular regulators of 
lymphangiogenesis (1, 2). Through the analysis of gene expression in embryonic 
development, for example, the control of the lymphatic endothelial cell (LEC) phenotype by 
Prox1 (3) and the requirement of neuropilin-2 (4) and podoplanin (5) expression by LECs in 
embryonic lymphatic vessel formation have been established. Vascular endothelial growth 
factor (VEGF) receptor-3 (VEGFR-3) (6) and its ligands VEGF-C (7-9) and VEGF-D (10) 
have been well-established as critical for both embryonic and adult lymphangiogenesis, 
although VEGFR-3 ligation may not be required for lymphatic vessel maintenance (11). 
Developmental and mechanistic studies of these factors and others, including angiopoietin-1 
(12) and -2 (13), are continuing to elucidate the molecular underpinnings of 
lymphangiogenesis. 
Despite this emerging knowledge, lymphangiogenesis in adult tissues is not 
adequately understood. Regulators of developmental lymphangiogenesis may not necessarily 
have the same relevance in adult lymphangiogenesis or lymphatic regeneration, particularly 
considering that many of these factors play multiple roles in early development of both blood 
and lymphatic vessels before becoming specific to one type of endothelial cell in adulthood 
(2). Furthermore, many studies of adult lymphangiogenesis utilize models in which lymphatic 
growth is induced by orthotopic human tumor xenografts in mice (1) or by exogenous 
stimulation in alymphatic tissues (14, 15), which may not accurately reflect physiologically 
relevant situations. 
We recently developed a mouse model of adult lymphangiogenesis in regenerating 
skin and used it to demonstrate the role of interstitial flow in lymphangiogenesis (16, 17). In 
this model, a small circumferential band of skin is removed from the middle of the tail, fitted 
with a gas-permeable silicone sleeve, and filled with collagen. The collagen provides a 
scaffold for tissue regeneration that is initially cell-free, allowing the infiltration of immune 
cells and ingrowth of blood and lymphatic vessels to be tracked both spatially and temporally 
as the tissue regenerates. Furthermore, the silicone sleeve keeps the wound moist and intact 
and prevents granulation; indeed, the regenerated skin is virtually identical to native skin 
except for the absence of hair follicles that do not regenerate. Importantly, the collagen 
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scaffold serves as a fluid bridge for the one-way interstitial convection of lymph fluid 
between the distal and proximal halves of the tail. In other words, since lymph always flows 
from the tip of the mouse tail towards the body, interstitial fluid flow through the regenerating 
region will always be unidirectional.  
We previously used this model to demonstrate that interstitial flow plays an 
organizational role in lymphangiogenesis, specifically showing that lymphatic capillaries 
develop in the direction of lymph flow. We had hypothesized that flow was necessary to 
create fluid channels in the regenerating region into which LECs migrate and organize into 
lymphatic vessels. This model was also used to demonstrate that although complete inhibition 
of lymphangiogenesis in regenerating skin could be achieved by systemic delivery of 
mF431C1, a VEGFR-3 blocking antibody (11), excess VEGF-C in the regenerating region 
could not enhance physiological lymphangiogenesis (18). This model has thus proven useful 
for studying the effects of established biochemical cues on lymphatic regeneration.  
Here we characterize the process of lymphangiogenesis in the regenerating skin model 
to assess relative timing, distribution, and importance of some potential key regulating factors 
relative to lymphatic growth. Specifically, we examine lymphatic growth and morphology at 
early (1, 3, 5, 7, and 10 days) and later (17, 25, and 60 days) timepoints in the regeneration 
process and correlate temporally the presence of VEGF-C, VEGF-A, the heparan sulfate 
proteoglycan (HSPG) perlecan (a key component of basement membrane), MMPs, and 
immune cells to lymphatic growth and morphology. We demonstrate that lymphatic 
regeneration occurs via single LECs migrating with interstitial fluid flow and later, after 
populating the region, coalescing into vessels. We also provide further evidence that 
interstitial fluid flow is necessary for LEC organization using a shunted flow modification of 
our model. We show that VEGF-C expression is decreased as the lymphatic vessels become 
connected and functional, at which time a discontinuous perlecan expression pattern begins to 
become present on the lymphatics. Also, our data suggests that MMP-9 may not be important 
in adult dermal lymphangiogenesis, and support previous observations that macrophages may 
play a critical role (15).  
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MATERIALS & METHODS 
 
Animal and sample preparation 
All studies utilized 6–8 week old female BALB/c mice (Charles River Laboratories, 
France); 3-5 mice were used at each timepoint. Mice were anesthetized with an intraperitoneal 
injection of ketamine (65 mg/kg), xylazine (13 mg/kg), and acepromazine (2mg/kg). An 
analgesic, butorphanol (0.05 mg/kg), was administered subcutaneously twice daily for three 
days following the procedure. All protocols were approved by the Veterinary Authorities of 
the Canton Vaud according to Swiss law (protocol number # 1687). 
Mice were prepared as described previously (17). Briefly, a 2 mm wide 
circumferential band of dermal tissue was excised midway up the tail. The area was then 
covered with a gas-permeable silicone sleeve and filled with type I rat tail collagen (BD 
Pharmingen, San Jose, CA). The sleeve was secured with Nexaband adhesive (Abbott Labs, 
Abbott Park, IL) at the proximal edge. Mice were sacrificed at specified times from 1-60 days 
post-procedure. Additionally, to test the hypothesis that interstitial fluid flow is necessary for 
lymphatic organization, a modified “shunted flow” model was prepared in three mice. In this 
modified model, a 2 mm square excision was made instead of a circumferential excision, 
allowing for lymph to circumvent around the regenerating region through existing lymphatics 
in the intact tissue (Fig. 1).  
After sacrificing the animals, a section of tail 8 mm long (containing the regenerating 
region along with some native distal and proximal tissue) was removed and flash frozen in 
liquid N2. Tissue samples were transversely cryosectioned into 12 and 60 μm-thick sections 
and stored at -80˚C until immunostaining. 
To further examine the role of MMP-9 in this model, MMP-9 deficient on an FVB/NJ 
background, along with wild-type controls, were obtained (FVB.Cg-Mmp9tm1Tvu/J; The 
Jackson Laboratory, Bar Harbor, ME). Nine female mice at 6 weeks of age from the MMP-9 
deficient strain and 9 female FVB/NJ controls were prepared as described.  Three mice from 
each group were sacrificed at 17, 25, and 60 days. 
 
Microlymphangiography 
Mice were anesthetized as above and the regeneration of the lymphatic vasculature 
was examined by fluorescence microlymphangiography (17, 19). A fluorescently labeled 
macromolecule (2000 kDa fluorescein-conjugated dextran, 2 mg/ml; Molecular Probes, 
Carlsbad, CA) was injected intradermally at a constant pressure of 45 cm of water into the tip 
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of the tail. As the fluorescent tracer was picked up and transported by the lymphatic vessels, it 
was clearly visible within dermal lymphatic capillaries, thus providing a clear visualization of 
lymphatic functionality. The lymphatic vasculature was monitored with a Zeiss Axiovert 
200M fluorescence microscope and Zeiss MRm camera. 
 
Immunofluorescence and immunohistochemistry  
To visualize blood endothelial cells (BECs) and LECs, both thin (12 μm) and thick (60 
μm) sections were co-stained with primary antibodies to the lymphatic-specific marker 
LYVE-1 (1:500; rabbit polyclonal; Upstate, Charlottesville, VA), and endothelial cell marker 
CD31 (1:200; rat polyclonal; BD Pharmingen). Although CD31 has an affinity for 
lymphatics, co-staining eliminated any discrepancy in identifying BECs from LECs. For 
immune cells and MMPs, thin (12 μm) sections were labeled using the following anti-mouse 
antibodies: the leukocyte-common CD45 (1:100; rat monoclonal; BD Pharmingen), the 
macrophage-specific surface marker F4/80 (1:50; rat monoclonal; Serotec, Raleigh, NC), the 
Langerhans dendritic cell protein langerin (1:50; goat polyclonal; Santa Cruz Biotechnology, 
Santa Cruz, CA), MMP-2 (1:25; goat polyclonal; R&D Systems, Minneapolis, MN), MMP-8 
(1:100; goat polyclonal; Santa Cruz Biotechnology), MMP-9 (1:400; rabbit polyclonal; 
Chemicon, Temecula, CA) or MMP-13 (1:500; goat polyclonal; Chemicon). The heparan 
sulfate proteoglycan perlecan was also stained (1:500; rat monoclonal; U.S. Biological, 
Swampscott, MA) together with LYVE-1. These antibodies were detected with Alexafluor 
488 or 594-conjugated donkey, rabbit, and goat IgG secondary antibodies (1:200, Molecular 
Probes, Carlsbad, CA), counterstained with DAPI (Vector Labs, Burlingame, CA). Thin 
sections were observed and imaged under a Zeiss Axiovert 200M fluorescence microscope 
with an Axiocam MRm camera. Confocal stacks of thick (60 μm) sections were scanned 
using a Zeiss LSM 510 Meta confocal microscope and maximum projections were generated 
for presentation. 
VEGF-A and VEGF-C were labeled immunohistochemically. Sections were first fixed 
in 4% PFA, blocked against endogenous biotin and avidin (Biotin Blocking System, Dako, 
Carpenteria, CA), then labeled with VEGF-A (1:50; rabbit polyclonal; Santa Cruz) or VEGF-
C (1:50; goat polyclonal; Santa Cruz) and biotinylated secondary antibodies (1:200; 
AffiniPure donkey and rabbit, respectively; Jackson ImmunoResearch, West Grove, PA). 
These were then visualized using the ABC-AP kit and VectaRed (Vector Labs). Sections were 
counterstained with hematoxylin, dehydrated, and mounted with Eukitt (Fluka Chemie AG, 
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Buchs, Switzerland). Images were captured with an Olympus AX70 Microscope and DP70 
Camera. 
 
Image analysis 
Images of the regenerating region were assembled into complete montages in 
Photoshop (Adobe Systems, San Jose, CA). LECs were defined as cells with a blue (DAPI-
stained) nuclei surrounded by green (LYVE-1 with AlexaFluor 488) labeling. After defining 
the borders of the region, the number of LECs within each half of the regenerating region 
were counted and summed across three random 12 μm sections from each animal. Similarly, 
Langerhans dendritic cells were counted by identifying nuclei of langerin-labeled cells in the 
regenerating regions of three 12 μm sections at each time point.  
Metamorph 6.3 image analysis software (Molecular Devices Corp., Sunnyvale, CA) 
was used for quantifying MMPs, growth factors, and other immune cells. For immune cells 
and MMPs, three regenerating region montages from like groups of images were analyzed to 
identify positive fluorescent labeling using intensity thresholding. The region was then clearly 
identified with a freehand tool (with care taken to exclude pockets or defects in the tissue 
sections) and the percentage of stained area within each regenerating region was obtained. 
Values for three regions were averaged. For growth factor quantification, the color range of 
Vector Red (Vector Labs) staining, indicating positive labeling of either VEGF-A or VEGF-
C, was identified and the percent coverage of each regenerating region was similarly 
measured. The data was normalized for each factor to the maximum expression.  
 
Statistics 
ANOVA and two-tailed t-tests were performed to determine statistical significance. 
Data are reported as average ± standard deviation. For MMPs, immune cells, and growth 
factors, the total expression during regeneration was compared to that of normal (control) 
tissue to determine significance in upregulation during regeneration. Additionally, single-
factor ANOVA was performed on expression during regeneration to determine if there were 
significant differences among all of the time points.  
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RESULTS AND DISCUSSION 
 
Unidirectional regeneration with interstitial fluid flow 
First, we confirmed our earlier findings (17) that in regenerating mouse tail skin, 
lymphangiogenesis occurred in the direction of lymphatic flow – distal to proximal – which 
was also the direction of interstitial flow in the regenerating skin where lymph flow was 
interrupted. We further quantified this directionality in migration to demonstrate statistical 
significance (Fig. 2F). This was in contrast to blood angiogenesis, which occurred from all 
directions in the regenerating skin. Quantification of LECs in 12 μm sections revealed that the 
regenerating region was initially free of LECs and remained so through day 10 (Fig. 2E). 
While very few LECs were seen in the region at day 10 (Fig. 2B), those present were confined 
to the distal half (P=0.007) (Fig 2F). At day 17 (Fig. 2C), some LECs were present in the 
proximal half, but the distal population was much greater (P<0.001). Even at later timepoints 
of 25 and 40 days, LECs populated the upstream (distal) region significantly more than the 
downstream region (P=0.04 and P=0.006 for 25 and 40 days, respectively), indicating that 
proliferation and migration were occurring primarily from the distal region. Even though the 
total number of LECs in the region did not significantly change after day 17 (Fig. 2E), it was 
not until day 60 (Fig. 2D), when functional and continuous lymphatic capillaries appeared 
normal, that the distribution of LECs equalized between both halves of the regenerating 
region (P=0.4).  
To further explore whether interstitial flow is necessary for lymphatic organization, 
mice were prepared with a square regenerating region (as opposed to the circumferential 
model), which allows lymph flow to be circumvented around the implanted collagen gel in the 
intact lymphatic vessels. Unlike the circumferential collagen implant, where distal lymph 
must flow interstitially through the regenerating region to be picked up by functional 
lymphatics on the proximal side, lymph need not flow through the high resistance 
regeneration zone in the square model since the intact surrounding lymphatic vessels provide 
a lower resistance to flow. While this relative lack of directional interstitial flow did not 
inhibit re-epithelialization or blood angiogenesis, we found that LECs failed to organize into a 
connected, functional lymphatic network in this shunted flow region (Fig. 1), demonstrating 
that interstitial fluid flow is necessary for functional lymphatic capillary organization.  
Conversely, blood vessel regeneration was independent of the interstitial flow 
direction. Blood vessels initially appeared to sprout from the deeper, larger blood vessels 
underneath the regenerating region (near the bone) at day 7, and at day 10, sprouts were seen 
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equally from distal and proximal edges as well (Fig. 2B). By day 17, blood vessels were 
present throughout the region. In the square shunted flow model, blood vessel regeneration 
was indistinguishable from that seen in the circumferential model (data not shown), as was re-
epithelialization of the collagen gel. 
 
Lymphatic morphogenesis: coalescing rather than sprouting 
Confocal microscopy of 60 μm sections revealed that in contrast to sprouting, LECs 
migrated as single cells (sometimes coalescing into small groups of cells) in the direction of 
interstitial flow, and, after sufficiently populating the region, later organized into vessels. 
LECs were generally absent from the regenerating region until day 10 when individual LECs 
or small groups were seen migrating into the distal half of the region (Fig. 3A). By day 17, 
multicellular groups or ducts were present (Fig. 3B), but were not connected to other groups. 
LECs predominantly began to organize in a fashion reminiscent of vasculogenesis by day 25. 
At this time, LECs in both the distal and proximal halves were already organized into vessel 
structures (Fig. 3C). At day 60, the regenerated region had a complete lymphatic vasculature 
whose morphology appeared similar to that of native vessels. In contrast, during concurrent 
blood angiogenesis, new blood vessels sprout directly from the existing native vasculature. 
Thus, by migrating as single cells in the direction of interstitial flow and then later coalescing 
into individual short vessel fragments and eventually into an interconnected capillary 
network, LEC organization into vessels was more reminiscent of vasculogenesis than of 
sprouting angiogenesis.  
 
Development of basement membrane following lymphatic organization 
Past analysis of endothelial cell basement membrane composition has shown that the 
predominant HSPG in the basement membrane of mature blood vessels is perlecan (20). This 
HSPG, produced in varying degrees by all endothelial cells (21), is essential for 
developmental vasculogenesis in mice (22), and is expressed during angiogenesis (23) and 
following vessel injury (24). Although lymphatic capillaries have a discontinuous basement 
membrane (25), it is not known at what stage during lymphangiogenesis it appears. Using 
confocal microscopy on 60 μm sections, we observed perlecan co-localization with lymphatic 
vessels in regenerating skin only after organization had occurred, at day 25 and day 60 (Fig. 
3). Furthermore, its expression followed the spatial pattern of vessel formation and 
organization. At early times, before vessel organization was seen (day 10 and day 17), 
perlecan expression was limited to new blood vessels. At day 25 (Fig. 3C), when significant 
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organization of LECs into vessels was underway, some lymphatic structures in the distal half 
were perlecan positive while those in the proximal half were not. By day 60 (Fig. 3D), nearly 
all lymphatic vessels in the distal half were co-localized with perlecan, but in the proximal 
half where some vessels were still forming, perlecan expression appeared more sporadically. 
In normal intact skin, the lymphatic capillaries strongly expressed perlecan (Fig. 3E). Thus, 
since the HSPG perlecan identifies basement membrane on regenerating lymphatic vessels 
and appears only after vessel organization has occurred, it may be indicative of lymphatic 
vessel maturation. Additionally, its initial appearance only on distal vessels further 
demonstrates the directionality of both LEC migration and lymphatic organization in this 
model.   
 
Early VEGF-A and -C upregulation 
Expression of VEGF-A and VEGF-C were highest during the initiation of both blood 
and lymph angiogenesis. VEGF-A expression (Fig. 4) appeared to be highest at day 5, slightly 
preceding observable blood angiogenesis. These differences in expression, however, were not 
statistically significant. VEGF-C expression (Fig. 4) was highest prior to, and during the 
initiation of, lymphangiogenesis (days 3-10). This expression was significantly higher at days 
3-10 than at days 17 and 25 (P=0.033). These expression profiles suggest that heightened 
expression of both VEGF-A and VEGF-C signaling might be most important in early (i.e. 
initiation) rather than later (i.e. organization and maturation) stages of vasculogenesis and 
lymphangiogenesis, consistent with their known functional roles (2, 26). 
 
MMP expression 
MMPs known to be upregulated in murine wound healing, specifically MMP-2, -8, -9, 
and -13 (27-29), were examined to determine their transient relationship to lymphatic 
regeneration. Our results suggest that only MMP-9 and MMP-13 were significantly elevated 
in the regenerating region compared to normal control skin (P=0.006 and 0.001, respectively), 
although the expression of MMP-2 was almost significantly higher during regeneration than 
in control tissue (P=0.056) and appeared to peak at day 17 (Fig. 4). MMP-2 and -9 play 
important roles in extracellular matrix remodeling (30, 31), endothelial cell migration (32-34), 
and vasculogenesis (34, 35); we found that MMP-2 expression (Fig. 4) increased after day 10, 
concurrent with blood angiogenesis and at the initiation of lymphangiogenesis. Surprisingly, 
MMP-9 expression was very low after day 7, so its link to endothelial cell migration might be 
more important for blood angiogenesis but not critical to lymphangiogenesis. MMP-13 has 
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been demonstrated to play a critical role in blood neovascularization (36) in conjunction with 
macrophages, which help induce angiogenic sprouting by using MMPs to extravasate from 
blood vessels (37). MMP-13 expression appeared to peak early, by day 7, thus preceding 
elevated macrophage numbers in the regenerating region (below). Although a role in blood 
neovascularization has been established (36), it is therefore possible that MMP-13 activity is 
only critical for revascularization by mechanisms dependent on sprouting from the existing 
vasculature. MMP-8 expression was very low at all times in the regenerating tissue, despite 
other observations that it is upregulated in dermal wounds by neutrophils (38). 
To examine the hypothesis that MMP-9 is not necessary for adult dermal 
lymphangiogenesis, we examined lymphatic regeneration in transgenic mice lacking MMP-9. 
The regenerating regions of these MMP-9 deficient mice were stained for LECs and BECs at 
day 17 and day 60. There were no observable differences in the extent or morphology of 
either lymphatic or blood vessels in the regenerating region of these mice compared to 
matched wild-type control mice (Fig. 5A). Additionally, the number of LECs identified in the 
regenerating region at day 17, a critical timepoint in regeneration, was the same between the 
MMP-deficient mice and matched wild type controls (P=0.48) (Fig. 5B). This is not 
inconsistent with other reports that showed minimal differences in blood angiogenesis in 
MMP-9 deficient mice (39, 40). It has been suggested that MMP-2 might have a more crucial 
role than MMP-9 in retinal angiogenesis (40) and that synergy between MMP-2 and -9 is 
essential for tumor vascularization (39); our data suggests that MMP-2 might be more 
important in lymphangiogenesis, at least in regenerating mouse skin, than MMP-9.  
The temporal expression patterns of each of the MMPs surveyed correlated with the 
results other wound healing studies (27, 28, 38, 41). While it was not possible to define the 
exact role of each MMP due to their release by many cell types, including infiltrating immune 
cells, keratinocytes, and endothelial cells, as well as potentially overlapping and/or redundant 
roles in many different components of the skin regeneration process, our data demonstrate 
that in terms of timing, MMP-2 was the most closely correlated to the onset of 
lymphangiogenesis, and that lymphangiogenesis appeared normal in MMP-9 null mice.  
 
Immune cell infiltration 
Macrophages and dendritic cells, as antigen-presenting immune cells, utilize 
lymphatic vessels in adaptive immunity and may be involved in lymphangiogenesis (15); 
furthermore, macrophages both secrete VEGF-C (42) and chemotact up a VEGF-C gradient 
(43) and may thus help direct LEC migration as well. We found that macrophage numbers 
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were much higher during regeneration (P=0.001) and peaked during LEC migration and 
organization at days 17-25 (P=0.058), hinting that macrophages may contribute to pre-
lymphatic fluid channeling, a role already demonstrated in blood angiogenesis (44) and 
consistent with recent findings that macrophages are necessary in inflammation-induced 
corneal lymphangiogenesis (15). Total immune cell numbers peaked at day 3 (P<0.001)(Fig. 
4). These early infiltrating immune cells at day 3 were typically neutrophils, as evidenced by 
polymorphonuclear Giemsa staining (data not shown). Very few Langerhans dendritic cells, 
normally present in the epidermis, were seen in the regenerating region until day 17 or 25, 
presumably when the regenerated epidermis is sufficiently integrated (P=0.028). Due to 
intense immune cell infiltration during inflammation and in the wound healing response, exact 
roles for immune cells were difficult to discern, however, the correlation of macrophage 
infiltration with lymphangiogenesis at later times supports the prospective role of 
macrophages in pre-lymphatic tunneling.  
 
CONCLUSIONS 
 
This study of lymphangiogenesis in regenerating skin provides new insight into adult 
lymphatic regeneration in a physiologically relevant environment and correlates potential 
contributing factors, such as MMPs and immune cells, to this process. We showed that 
migrating LECs populate the regenerating region in the direction of interstitial fluid flow, and 
then grow together in a vasculogenesis-like fashion to form a new interconnected network of 
lymphatic vessels. Also, we demonstrated that interstitial flow is necessary for the 
organization of LECs into a functional network while MMP-9 was not. Among the factors 
examined, the timing of MMP-2 and macrophages were more closely correlated to the late 
infiltration of LECs in the regenerating region, while basement membrane begins to develop 
only after the lymphatic structures have organized into functional vessels.  
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FIGURE LEGENDS 
Fig. 1. Interstitial flow and the mouse tail model of skin regeneration. (A) In the 
circumferential model, lymph flow from distal lymphatics (that is traveling in the proximal 
direction) must move interstitially through the collagen implant in order to continue its flow 
in the proximal lymphatic capillaries. Functional and organized lymphatic capillaries are seen 
by microlymphangiography at day 60. (B) In the square model, lymph flow is circumvented 
around the implant in pre-existing lymphatic capillaries, and the entire lymphatic circuit is 
uninterrupted. Lymph does not become interstitial fluid in the implant as in the 
circumferential model, and thus interstitial flow through this square implant is much less than 
that through the circumferential implant. In this shunted flow model, LECs do not organize 
into a functional network (as evidenced by microlymphangiography), despite the otherwise 
normal skin regeneration. In all microlymphangiography images, green indicates the lymph 
fluid tracer (fluorescein-dextran) and thus identifies functional lymphatics and interstitial flow 
of post-lymph through the regenerating regions. Bar = 1 mm. 
 
Fig. 2. Lymphatic regeneration occurs in the direction of interstitial flow as shown by 
maximum projections of confocal scans. (A) At 7 days, the regenerating region (marked by 
yellow dashes) is free of LECs, but blood vessels (red) appear to sprout from deeper vessels 
(open arrows). (B) At day 10, very few LECs (arrowheads) are seen, while blood vessel 
sprouting is present in all directions. (C) At day 17, LECs (green) are seen in higher numbers 
in the distal end of the regenerating region, and more organization (arrows) is also seen in the 
distal end. LECs in the proximal half mostly remain as single cells. Blood vessels are present 
throughout the regenerating region. (D) At day 60, LECs are present throughout the 
regenerating region and organized into an interconnected network, similar to that seen in 
native skin (white arrow). Note the overall contraction of the regenerating region over time. 
Bar = 300 μm. (E) Quantification of total LECs in the regenerating region confirms that LEC 
infiltration begins around day 10, is drastically increased at day 17, and is mostly complete by 
day 25. (F) Relative distribution of LECs in the distal vs. proximal halves of the regenerating 
region verifies qualitative observations that migration is primarily occurring from the distal 
end. Through day 40, the relative number of LECs in the distal half is consistently and 
significantly greater than that in the proximal half. By day 60, LEC distribution is normalized. 
(* P<0.05) 
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Fig. 3. Lymphangiogenesis as a process of cell migration and subsequent organization, rather 
than sprouting, with basement membrane developing after vessels become functional. Shown 
are maximum projections of confocal scans. (A) At day 10, the regenerating region is mostly 
free of LECs (green) with only a few LECs (arrows heads) present near the distal end. The 
basement membrane proteoglycan perlecan (red) is readily detected on blood vessels. (B) At 
day 17, LECs are present throughout the entire regenerating region and organized into 
discrete and separate multi-cellular structures. Perlecan expression is not seen to be co-
localized with any of these structures, indicating that basement membrane is absent in these 
primitive structures. (C) At day 25, lymphatic organization is extensive and nearly complete. 
Perlecan is detected only on lymphatic vessels in the distal half of the regenerating region 
(arrows). (D) By day 60, a discontinuous perlecan staining pattern is present on nearly all 
lymphatic vessels (arrows), although staining is visibly stronger in the distal half. (E) 
Lymphatic capillaries in native skin show strong perlecan staining. Bar=50 μm. 
 
Fig. 4. Comparison of the relative temporal expression patterns of VEGF-A and VEGF-C, 
MMPs, and immune cells during regeneration. VEGF-A expression was highest at the 
initiation of angiogenesis (days 5). VEGF-C expression was highest during the initiation of 
lymphangiogenesis (days 5-10) and was reduced during the organization phase (days 17+). 
Expression of MMP-2 peaked during lymphangiogenesis. MMP-8 expression was very low 
throughout regeneration. MMP-9 was high at early times, but decreased after day 7, while 
MMP-13 expression was highest before day 10, just preceding macrophage infiltration. Early 
infiltration of CD45+ immune cells at day 3 primarily reflects neutrophils. Macrophages 
(F4/80+) were highest after day 10, correlating with the onset of LEC infiltration. Langerhans 
dendritic cells (langerin+) did not repopulate the region until day 17 and later, when LECs 
were present and undergoing vessel organization. (* P<0.05; over control indicates significant 
change in regeneration, over bracket indicates temporal significance during regeneration) 
 
Fig. 5. No differences were seen in lymphatic regeneration in MMP-9 null mice vs. matched 
wild type controls. (A) The regenerated blood (red) and lymphatic (green) vessels in MMP-9 
null mice were morphologically indistinguishable to those in control mice at day 17 and day 
60. Bar=150 μm. (B) The number of LECs counted in the regenerating region at day 17 was 
not significantly different between the mouse strains (P=0.48). 
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ABSTRACT 
 
Activation of vascular endothelial growth factor receptor -3 (VEGFR-3) by VEGF-C initiates 
lymphangiogenesis by promoting lymphatic proliferation and migration. However, it is 
unclear whether VEGFR-3 signaling is required beyond these initial stages, namely during the 
organization of new lymphatic endothelial cells (LECs) into functional capillaries. 
Furthermore, the role of VEGFR-2, which is also expressed on LECs and binds VEGF-C, is 
unclear. We addressed these questions by selectively neutralizing VEGFR-3 and/or VEGFR-2 
for various time periods in an adult model of lymphangiogenesis in regenerating skin. While 
blocking either VEGFR-2 or VEGFR-3 with specific antagonist mAbs (DC101 and mF4-
31C1, respectively) prior to lymphatic migration prevented lymphangiogenesis, blocking 
VEGFR-3 subsequent to migration did not affect organization into functional capillaries, and 
VEGFR-2 blocking had only a small hindrance on organization. These findings were 
confirmed in vitro using human LECs and anti-human antagonist mAbs (IMC-1121a and hF4-
3C5): both VEGFR-2 and -3 signaling were required for migration and proliferation, but 
tubulogenesis in 3D cultures was unaffected by VEGFR-3 blocking and partially hindered by 
VEGFR-2 blocking. Furthermore, both in vitro and in vivo, while VEGFR-3 blocking had no 
effect on LEC organization, co-neutralization of VEGFR-2 and VEGFR-3 completely 
prevented lymphatic organization. Our findings demonstrate that cooperative signaling of 
VEGFR-2 and -3 is necessary for lymphatic migration and proliferation, but VEGFR-3 is 
redundant with VEGFR-2 for LEC organization into functional capillaries.  
 
 
 
 
 
 
 
 
 
Key words: VEGF-C, mouse, in vitro, wound healing, vasculogenesis
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INTRODUCTION 
 
Vascular endothelial growth factor (VEGF) receptor -3 (VEGFR-3) activation by its 
ligands VEGF-C and VEGF-D is necessary for developmental and adult lymphangiogenesis 
(1-4). In tumor models, neutralization of VEGF-C with soluble VEGFR-3 reduced 
lymphangiogenesis and lymphatic function at the periphery of VEGF-C–overexpressing 
tumors (5). Signaling through VEGFR-3 has therefore been implicated in tumor lymph node 
metastases (6-8). Indeed, this importance has been demonstrated through the inhibition of 
VEGFR-3 that prevented prostate and melanoma (9) and breast cancer metastases (10) by 
suppressing tumor-associated lymphangiogenesis. 
However, lymphangiogenesis is a complex process comprised of multiple events 
including lymphatic endothelial cell (LEC) proliferation, migration, organization, and vessel 
maturation. Although VEGFR-3 signaling has been shown to be unnecessary for lymphatic 
maintenance and function of existing lymphatic vessels (5), its roles in each of the various 
steps of lymphatic development remain unclear. Proteolytically processed (mature) VEGF-C 
and -D can also bind to VEGFR-2 (11-13), and the activation of VEGFR-2 can also induce or 
guide lymphangiogenesis (14, 15). Furthermore, it has been reported that VEGFR-2 can form 
heterodimers with VEGFR-3 (16, 17), but it is unclear whether heterodimer phosphorylation 
signals different functional responses than homodimer phosphorylation. It is also not known 
how these receptors interact from a functional perspective and how their different signaling 
patterns may affect different stages of lymphatic development.  
Here we explore the individual and combined roles of VEGFR-2 and VEGFR-3 signaling 
in three distinct components of adult lymphangiogenesis – LEC proliferation, migration, and 
vessel organization – using complementary in vivo and in vitro models. We use a model of 
adult skin regeneration in the mouse tail that we developed previously to investigate the role 
of interstitial flow in the organization of lymphangiogenesis during dermal wound healing. In 
that study, we showed that lymphangiogenesis proceeds by unidirectional migration of LECs 
in the direction of interstitial fluid flow along fluid channels, followed by subsequent 
organization into a functional network of lymphatic vessels in a manner reminiscent of 
vasculogenesis (18, 19). Thus, in this model, adult lymphangiogenesis can be clearly divided 
temporally into three discrete phases – migration (determined by the distal-to-proximal 
distribution of cells in the regenerating region), proliferation (determined by total LEC 
number), and capillary organization (determined by immunostaining thick sections and via 
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microlymphangiography) - allowing us to investigate the importance of VEGFR-2 and 
VEGFR-3 signaling at each phase.  
Using this model, we previously demonstrated that endogenous VEGF-C expression is 
increased during lymphatic migration and proliferation but decreased during later stages of 
lymphatic organization (18, 19), and that delivery of exogenous VEGF-C induced lymphatic 
hyperplasia without improving lymphatic organization or function beyond control levels (20). 
Additionally, in this same model, blockage of VEGFR-3 with the mAb mF4-31C1 prevented 
regeneration of functional lymphatic vessels in the mouse skin without affecting pre-existing 
vessels (21). These findings suggest that while VEGF-C/VEGFR-3 signaling is necessary for 
lymphangiogenesis, it may not serve an important role in the functional or organizational 
evolution of lymphangiogenesis. Based on these results, we hypothesized that VEGFR-2 and 
VEGFR-3 signaling are important primarily during the early stages of lymphangiogenesis, 
which require LEC migration and proliferation, but are less important during the subsequent 
organization of LECs into functional lymphatic capillaries. To this end, antagonist mAbs 
against mouse VEGFR-2 and -3 were delivered at different stages of physiological lymphatic 
regeneration in adult mouse skin to determine the specific roles of these receptors in 
lymphangiogenesis. To support our in vivo results we also examined the importance of these 
receptors using in vitro models of human LEC migration, proliferation, and 3-D tubulogenesis 
in the presence or absence of antagonist mAbs to human VEGFR-2 and VEGFR-3.  
 
MATERIALS AND METHODS 
 
Neutralizing Antibodies 
All antagonist antibodies were provided by ImClone Systems, NY, NY. For in vivo 
studies, 0.625 mg of anti-mouse VEGFR-2 (DC101) (22) and/or anti-mouse VEGFR-3 (mF4-
31C1) (21) were injected intraperitoneally every two days. For in vitro studies, anti-human 
VEGFR-2 (IMC-1121a, 20 μg/mL) and anti-human VEGFR-3 (hF4-3C5, 10 μg/mL) (23) 
were used.  
 
In vivo studies 
Lymphangiogenesis model 
For all studies 6–8 week old, female BALB/c mice (Charles River Laboratories, France) 
were used; at least three mice were used for each condition at each time point examined. Mice 
were anesthetized with an intraperitoneal injection of ketamine (65 mg/kg), xylazine (13 
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mg/kg), and acepromazine (2 mg/kg). An analgesic, butorphanol (0.05 mg/kg), was 
administered subcutaneously twice daily for three days following the procedure. All protocols 
were approved by the Veterinary Authorities of the Canton Vaud according to Swiss law 
(protocol number #1687). 
The regenerating region of skin was created as previously described (18). Briefly, a 2-
mm wide circumferential band of dermal tissue (in which the lymphatic network in the tail 
skin is contained) was excised midway up the tail, leaving the underlying bone, muscle, major 
blood vessels, and tendons intact. The area was then covered with a close–fitting, gas 
permeable silicone sleeve and filled with type I rat tail collagen (BD Pharmingen, San Diego, 
CA). The collagen scaffold provides a pre-existing matrix in which epithelial and 
subepithelial tissues readily regenerate. LECs later observed within this region were thus the 
result of de novo cell migration, proliferation, and organization. 
The neutralizing antibodies were then administered as described above for durations that 
varied by experimental group (Table 1). 
 
Detection of functional lymphatics via microlymphangiography 
To visualize lymph flow patterns in situ, a 2 mg/mL solution of fluorescein-conjugated 
dextran of 70kDa (Molecular Probes, Carlsbad, CA) was injected intradermally into the tail 
tip at a constant pressure where it was taken up and transported by the lymphatics in the 
proximal direction, revealing functional lymphatic vessels and fluid channels. Fluorescence 
images were captured with a Zeiss MRm camera on a Zeiss Axiovert 200M fluorescence 
microscope. 
 
Immunofluorescence and immunohistochemistry 
Tail specimens were cut into either 12 or 60 μm-thick longitudinal cryosections and 
immunostained. To detect LECs, a rabbit polyclonal antibody against the lymphatic-specific 
hyaluronan receptor LYVE-1 (Upstate, Charlottesville, VA) was used along with an Alexa 
Fluor 488 conjugated goat anti-rabbit secondary antibody (Molecular Probes). To detect blood 
endothelial cells, a rat polyclonal CD31 antibody (BD Pharmingen) was used along with an 
Alexa Fluor 546 conjugated goat anti-rat secondary antibody (Molecular Probes). Cell nuclei 
were labeled with DAPI (Vector Labs, Burlingame, CA). Thin-section images of the 
regenerating region were imaged (as above) and assembled into complete montages in 
Photoshop (Adobe Systems, San Jose, CA). Thick sections were imaged with confocal 
microscopy on a Zeiss LSM 510 META confocal microscope; maximum projections are 
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presented. LECs were defined as cells with a nucleus completely surrounded by LYVE-1 
labeling. After defining the borders of the regenerating region, the number of LECs within 
each half were counted and summed across three random 12 μm sections from each animal. 
 
In vitro studies 
Lymphatic endothelial cell (LEC) culture  
Human dermal LECs were isolated from neonatal foreskins as previously described 
(24) and maintained in EBM basal media (Cambrex, Walkersville, MD) supplemented with 
20% FBS, 1% penicillin-streptomycin-amphotericin B (both GIBCO, Carlsbad, California), 1 
μg/mL hydrocortisone, and 50 μmol/l DBcAMP (both Sigma, St. Louis, MO) in collagen type 
I coated flasks (50 μg/mL). They were utilized until passage 8. 
 
In vitro proliferation assay 
The effects of VEGFR-2 and VEGFR-3 signaling on LEC proliferation were evaluated 
using a colorimetric BrdU Kit (Calbiochem, San Diego, CA). LECs were serum-starved for 2 
h, seeded into a collagen-coated 96 well plate (3x104 cells/well), and allowed to adhere for an 
additional 2 h. 100 μl full medium supplemented with 100 ng/mL recombinant human 
wildtype VEGF-C (rhVEGF-C, 2179-VC-025 , R & D Systems, Minneapolis, MN) along 
with either (i) 10 µg/mL Hf4-3C5, (ii) 20 µg/mL IMC-1121a, (iii) a combination of both 
antibodies, or (iv) no antibodies. Proliferation (proportional to BrdU incorporation) was 
measured after 24, 48 and 72 hours of receptor blockage. Samples were fixed and 
permeabilized, then BrdU incorporation was detected according to the manufacturer’s 
instructions.  
 
 
In vitro migration assay 
Polycarbonate transwell inserts (8 μm pore, Millipore, Billerica, MA) were coated with 
50 μg/mL type I collagen (BD Bioscience). LECs were seeded at a density of 105 cells per 
insert in basal growth medium. The lower chamber consisted of either basal media alone or 
full growth media supplemented with 100 ng/mL rhVEGF-C and either (i) 10 µg/mL Hf4-
3C5, (ii) 20 µg/mL IMC-1121a, (iii) a combination of both antibodies, or (iv) no antibodies. 
Appropriate neutralizing antibodies were also added to the top chamber for the duration of the 
experiment. Chambers were incubated at 37ºC for 24 hours before the samples were washed 
with PBS and fixed in methanol at 4 ºC. Non-migrated cells were removed with a cotton 
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swab. The membranes were then removed and mounted with Vectashield containing DAPI 
(Vector). Samples were visualized with a 40x objective and the numbers of migrated cells 
within 8 random fields of view were counted. Migration per insert was then calculated and 
expressed as fold increase over control. 
 
In vitro tubulogenesis assay 
A gel suspension assay was used to assess LEC organization, independent of 
proliferation and migration, into capillary tubules within a 3D environment. LECs were 
seeded within Growth Factor Reduced Matrigel (BD Biosciences) at densities of either 
0.5x106 (low density) or 1.5x106 cells per mL (high density). The solution was plated into 8-
well coverslip chamberslides (Lab-TEK Nalge Nunc, Naperville,) and the gel was allowed to 
polymerize for 2 h before treatment. Gels were subsequently maintained at 37ºC/5% CO2 in 
either basal media or full media supplemented with 100 ng/mL rhVEGF-C and either (i) 10 
µg/mL hF4-3C5, (ii) 20 µg/mL IMC-1121a, (iii) a combination of both antibodies, or (iv) no 
antibodies. After 6 days, gels were fixed in 2% PFA and cell structures were visualized with 
Alexafluor 488-conjugated phalloidin (Molecular Probes) and counterstained with DAPI. 
Samples were visualized using confocal microscopy (as above). Tube length per unit area was 
calculated using Image J software (NIH, Bethesda, MD) 
 
Immunoprecipitation and immunoblot for receptor phosphorylation 
LECs were grown to 95% confluence in 10 cm culture dishes. Cells were washed in 
PBS and serum starved for 48 hours and then incubated in the presence of either 10 µg/mL 
hf4-3C5, 10 µg/mL IMC-1121a, a combination of both, or neither for 30 minutes. Samples 
were then treated with 100 ng/mL wildtype rhVEGF-C for 20 minutes, lysed with modified 
RIPA buffer supplemented with a protease inhibitor cocktail (Pierce, Rockford, IL; and 1% 
PMSF) and phosphatase inhibitor cocktails (Sigma). Cleared lysate supernatants were then 
incubated with either 2 μg/ml anti-human VEGFR-3 (sc-321, Santa Cruz) or 2 μg/ml anti-
human VEGFR-2 (AF357, R & D Systems) and 30 μl Protein A/G agarose beads (Pierce) 
overnight at 4ºC. The pellets were then washed three times in inhibitor-supplemented lysis 
buffer, washed once in PBS, and boiled in laemmli sample buffer. Protein samples were then 
separated by SDS polyacrylamide gel electrophoresis, transferred onto nitrocellulose 
membrane, and phosphorylated VEGFR-2 or VEGFR-3 was detected with mouse anti-human 
PY20 (1.0 µg/mL, Upstate) and an HRP-conjugated secondary antibody (Amersham 
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Biosciences, Uppsala, Sweden). Total receptor was detected with either anti-VEGFR-3 (sc-
321) or anti-VEGFR-2 (sc-6251, Santa Cruz). 
 
Statistical methods 
For determination of LEC numbers in the regenerating region, at least three sections 
were counted per specimen. Data is presented as mean ± one standard deviation. All P values 
were calculated using a two-sided Student’s t-test.  
 
RESULTS 
 
Adult lymphatic regeneration without receptor neutralization  
Immunostaining of control mouse 60 μm-thick cryosections from the mouse tail skin 
regeneration model (Fig. 1A) demonstrated that unorganized LECs began to migrate into and 
proliferate within the distal half of the regenerating region 10 days post surgery (Fig. 1B). At 
day 17, LECs were present in both distal and proximal halves but were largely unorganized. 
At day 60, LECs in the control mice were highly organized into lymphatic vessels, indicating 
a regenerated lymphatic capillary network. All LYVE-1 positive cells (and structures) were 
confirmed to be LECs in this model (Supplemental Fig. 1). 
Microlymphangiography, in which a fluorescent tracer is injected intradermally into 
the tip of the tail and taken up by the functional distal lymphatics, confirmed that the newly 
formed functional lymphatic vessels in the regenerating region did not sprout from pre-
existing vessels but instead organized after migration (Fig. 1C). At both days 10 and 17, prior 
to organization of LECs into regenerating lymphatic capillaries, upstream lymph collected at 
the distal boundary and slowly diffused across the regenerating region. At day 60, when LECs 
were organized into vessels, upstream lymph was transported through the region inside 
regenerated hexagonal lymphatic vessels. 
 
Effects of VEGFR-3 neutralization on lymphatic regeneration in vivo 
To determine the involvement of VEGFR-3 in different stages of lymphangiogenesis, 
VEGFR-3 was inhibited during different stages of lymphatic regeneration. Consistent with 
our previous observations (21), we found that inhibition of VEGFR-3 from day 0 to day 60 
completely prevented lymphangiogenesis as demonstrated by both immunohistochemical and 
functional analyses (Fig. 1D-E). When VEGFR-3 blockade was removed subsequent to the 
initiation of lymphangiogenesis but prior to substantial lymphatic migration (days 10-60 of 
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regeneration), LECs failed to migrate into the regenerating region and no functional vessels 
were formed. This finding confirmed that VEGFR-3 signaling is necessary for LEC migration 
into regenerating tissue.  
At day 17 of normal regeneration, we found large numbers of unorganized LEC clusters, 
but no tubular capillary-like structures (Fig. 1F); thus, we also inhibited VEGFR-3 from day 
17 to day 60. Surprisingly, LEC clusters efficiently organized into functional vessels despite 
the absence of VEGFR-3 signaling and were indistinguishable from regenerated lymphatics in 
control mice (Fig. 1D-E). Thus, VEGFR-3 is crucial for the migration and colonization of the 
wound during regenerative lymphangiogenesis, but not for their organization into functional 
vessels.  
LECs appear inside the regenerating region as a result of their proliferation, migration or 
both since the regenerating region is initially acellular. Furthermore, it has been established 
that LECs migrate and organize from the distal end to the proximal end in this model, 
consistent with the direction of fluid flow (18, 19). Thus, LECs found in the regenerating 
region result primarily from cell migration from the distal host dermis. The total number of 
LECs and their distal-to-proximal distribution in the regenerating region are indicative of the 
degree of LEC migration and proliferation, respectively, over a given period of time. In 
untreated mice, quantitative measurements of LECs (LYVE-1 labeled cells in thin 
cryosections) in the distal vs. proximal halves of the regenerating region confirmed their 
unidirectional migration, with cells initially entering the distal region at day 10 and gradually 
migrating until, by day 60, the LECs are uniformly distributed throughout the entire region 
(Fig. 1F, 1G). Blocking VEGFR-3 activation from day 10 to 60 or from day 17 to 60 
significantly decreased the total number of LECs as compared to untreated controls (Fig. 1F). 
Blocking of VEGFR-3 also prevented LEC migration into the proximal portion of the 
regenerating region (Fig. 1G), resulting in the skewing of the LEC distribution towards the 
distal region. Specifically, we observed a significant difference between the percentage of 
LECs in the distal vs. proximal portions of the regenerating regions in mice treated with 
blocking mAbs to VEGFR-3 during days 10-60 and days 17-60. These distributions were 
remarkably similar to the distributions seen at days 10 and 17 in the wounds of control 
animals (Fig. 1G), lending further credence to arrested migration. Their overall numbers were 
similar to those when blocking was begun as well, attesting to arrested proliferation. 
Blocking VEGFR-3 from day 17 to 60 prevented further LEC migration and 
proliferation in regenerating tissue, but did not hinder the organization of LECs into 
functional capillaries within the regenerating region. Therefore, these findings strongly 
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suggest that VEGFR-3 activation is critical for LEC migration and proliferation but not their 
functional organization into lymphatic vessels. 
 
Effects of VEGFR-2 neutralization on adult lymphangiogenesis 
The effects of blocking VEGFR-2 activation on lymphangiogenesis were similar to 
those resulting from blocking VEGFR-3 (Fig. 2A). First, VEGFR-2 blocking from day 0-60 
completely blocked any lymphangiogenic response, consistent with other reports that 
VEGFR-2 is essential to lymphangiogenesis (14, 25, 26). VEGFR-2 blocking from day 10-60 
also resulted in the prevention of lymphatic migration, while blocking from day 17-60 
allowed existing LECs in the regenerating region to organize into lymphatic vessels. This data 
suggest that the activation of VEGFR-2 is also necessary for LEC proliferation and migration 
but not for LEC organization into functional vessels. However, while analysis of total LEC 
numbers in the regenerating region (Fig. 2C) when VEGFR-3 was blocked between days 17-
60 demonstrated that the number of LECs remained constant at the level present at the 
initiation of treatment (day 17), LEC numbers following VEGFR-2 blocking for the same 
period were reduced. This may reflect a small role of VEGFR-2 in LEC survival during later 
stages of lymphangiogenesis. 
 
Effects of combined VEGFR-2 and VEGFR-3 neutralization on adult 
lymphangiogenesis 
Since the neutralization of either VEGFR-2 or VEGFR-3 signaling alone inhibited LEC 
migration and proliferation but did not prevent their subsequent organization into lymphatic 
capillaries, we hypothesized that VEGFR-3 may be redundant with VEGFR-2 for lymphatic 
organization. To explore this possibility, mice were treated with both antagonist antibodies to 
VEGFR-2 and VEGFR-3 during various periods of skin regeneration (blocking between day 
0-60, 10-60, and 17-60). Lymphatic regeneration was completely arrested in all cases (Fig. 
2B-D), confirming the hypothesis and demonstrating the necessity for signaling of at least one 
of these receptors for all stages of lymphangiogenesis.  
 
Roles of VEGFR-2 and VEGFR-3 signaling in LEC proliferation in vitro 
The processes necessary for lymphatic regeneration, LEC proliferation, migration, and 
capillary organization, can be more readily assessed using in vitro studies that allow the roles of 
VEGFR-2 and VEGFR-3 signaling on each of these processes to be investigated in greater detail. 
Unlike the multitude of potentially contributing factors in the regeneration region that may cloud the 
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in vivo assesments, these LEC-only in vitro studies permit a transparent examination of the specific 
impacts receptor blocking has on LEC behavior. To be able assess the roles of VEGFR-2 and 
VEGFR-3 on proliferation, migration and organization in vitro, we first confirmed that our cultured 
LECs possessed functional receptors by immunoprecipitation (Fig. 3A). Stimulation with 
recombinant human wild type VEGF-C induced receptor signaling via tyrosine phosphorylation of 
both VEGFR-2 (top two panels) and VEGFR-3 (lower two panels). Furthermore, the efficiency of 
both human blocking antibodies was clarified. Neutralization of VEGFR-3 specifically prevented 
VEGFR-3 phosphorylation but showed little to no effect on VEGFR-2 signaling. Likewise, 
neutralization of VEGFR-2 blocked its phosphorylation down to baseline levels (seen when no 
VEGF-C was added to the medium), but allowed VEGFR-3 to phosphorylate. We also saw the 
presence of VEGFR-2/-3 heterodimers, as seen in each of the immunoprecipitation experiments (i.e., 
a lower MW band (corresponding to VEGFR-3) was phosphorylated along with the 200 kDa band 
(corresponding to VEGFR-2) that was co-immunoprecipitated, as seen in the top panel. 
Complete medium supplemented with 100 ng/mL VEGF-C promoted LEC 
proliferation (7.2 ± 0.3 fold increase over matching control after 72 h). Blocking the 
activation of either VEGFR-2 or VEGFR-3 significantly (but not completely) inhibited LEC 
proliferation (to 5.0 ± 0.3 fold and 3.7 ± 0.4 fold, respectively; Fig. 3B). Combined inhibition 
of both receptors further reduced proliferation (to 2.2 ± 0.3 fold).  
 
Role of VEGFR-2 and VEGFR-3 signaling in LEC migration in vitro 
  The relative importance of VEGFR-2 and VEGFR-3 signaling in LEC migratory responses in 
vitro mirrored those seen in vivo (Fig. 3C). Full media supplemented with 100 ng/mL recombinant 
human wild type VEGF-C (untreated) induced a 14 ± 3 fold increase in migration over basal levels. 
Inhibition of either VEGFR-2 or VEGFR-3 significantly decreased migration by 58% and 75%, 
respectively. Furthermore, combined inhibition of both receptors completely abolished LEC 
migration stimulated by VEGF-C. Thus, the activation of both receptors in vitro was necessary for 
LEC migration in an apparently additive manner. 
 
Role of VEGFR-2 and VEGFR-3 signaling in LEC organization in vitro 
 Finally, we examined the roles of VEGFR-2 and VEGFR-3 in capillary organization using in 
vitro tubulogenesis experiments under conditions that do not require LEC proliferation. When seeded 
at 1.5 x 106 cells/mL, LECs readily formed tubular networks with numerous filopodia between cells 
of neighboring structures (Fig. 4A). Similar multicellular structures were also seen in cultures with 
VEGFR-3 blocking. Organization was also seen when VEGFR-2 was blocked although this was 
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hindered in comparison to control and VEGFR-3 blockage. When the receptors were blocked 
together, almost no tubular structures were observed. To quantify these observations, the 
organizational capacity of LECs within a 3D matrix for each culture condition was measured as total 
tube length per unit area (Fig. 4B). Although capillary structures were clearly visible, VEGFR-2 
blockage resulted in reduced tube length compared with full media supplemented with VEGF-C 
alone. In contrast, blocking VEGFR-3 had no effect on the ability of LECs to form tube-like 
networks. Low density (0.5 x 106 cells/mL) seeded LECs failed to organize with or without blocking 
(data not shown), suggesting that LEC organization in 3D gels requires a minimum seeding density 
or maximum LEC-LEC distance for cell signaling.  
These observations corroborate our in vivo data and demonstrate that while lymphatic 
capillary organization does not require VEGFR-3 signaling when VEGFR-2 signaling is functional, 
one or the other is needed, and VEGFR-2 appears to be more important than VEGFR-3 in LEC 
organization. 
 
DISCUSSION 
 
Using complimentary in vivo and in vitro studies designed to clearly delineate the 
contributing processes of lymphatic regeneration, we demonstrate that VEGFR-3 plays both 
cooperative and redundant functions with VEGFR-2 in lymphangiogenesis. Signaling through 
both receptors concurrently is required for LEC migration and proliferation. However, once 
LECs are present in sufficient numbers, VEGFR-3 signaling is redundant with VEGFR-2 for 
organization, since blocking VEGFR-3 had no effect on organization. Likewise, VEGFR-2 
signaling is partially redundant with VEGFR-3, since organization was hindered but not 
blocked when VEGFR-2 was blocked. We use the term ‘redundant’ rather than ‘unnecessary’ 
because at least one receptor is necessary – when both receptors are blocked simultaneously, 
vessel organization is blocked. These findings support the hypothesis that VEGFR-3 signaling 
is critical for lymphatic proliferation and migration, but not for functional organization of 
lymphatic vessels, and represent, to our knowledge, the first demonstration of the individual 
roles of VEGFR-2 and VEGFR-3 in these three distinct components of lymphangiogenesis.  
Although less physiologically relevant, the in vitro studies allowed further 
confirmation of receptor roles specifically in LEC proliferation, migration, and organization 
in the absence of other cells or confounding cellular events that might also be affected by 
VEGFR-2 and VEGFR-3. Consistent with our in vivo data, VEGFR-3 was completely 
redundant with VEGFR-2 signaling for LEC tubulogenesis. In order for tube formation to 
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show receptor redundancy, high seeding density was necessary to minimize the amount of 
migration required for vessel formation, since lower seeding densities did not promote 
tubulogenesis under any blocking condition. Again, this redundancy was consistent with our 
in vivo data, where the VEGFR-3-independent organization of new lymphatic capillaries 
occurred only if sufficient time was allowed for LECs to proliferate and migrate into the 
region of regeneration. Likewise, failures in organization, specifically in the proximal half of 
the regenerating region, are thus likely the result of a sparse LEC population at the start of 
receptor blocking. Thus, the strong corroboration between our in vivo and in vitro data 
indicate that the effects seen in vivo are most likely due to receptor activation on LECs and 
not on other cells that might express VEGFR-3, such as macrophages (27-29). 
It has been previously reported that heterodimerization with VEGFR-2 may be 
required for VEGFR-3 phosphorylation in aortic endothelial cells (16), but LECs are known 
to express higher levels of VEGFR-3 than blood endothelial cells (12, 24), particulary those 
from large vessels, and it has also been shown that both VEGFR-3 homodimers and VEGFR-
3/-2 heterodimers can form in human LECs (17). Our data support the concept that both 
homodimer and heterodimer forms play different functional roles, and indeed, we see that 
both forms are phosphorylated with VEGF-C (Fig. 3A). However, we were not able to 
conclusively determine which dimer pairs (or combinations thereof) are required for the 
different stages of LEC proliferation, migration, and capillary organization.  
Our findings have important implications for VEGF-C therapies designed to induce 
lymphangiogenesis and help corroborate seemingly conflicting reports on its effects. If 
VEGFR-3 activation is largely redundant for lymphatic organization, but necessary for LEC 
migration and proliferation, as our data show, then VEGF-C therapy would only be 
potentially useful in augmenting lymphangiogenesis in areas where lymphatics are not present 
or are present in sub-optimal densities. It may also have the effect of making normally 
regenerating lymphatics more hyperplastic rather than creating a denser lymphatic capillary 
network, since VEGF-C overexpression has been reported to lead to increased lymphatic 
diameter (hyperplasia) without increased lymphatic density (20, 30, 31). Furthermore, reports 
that VEGF-C delivery results in increased lymphangiogenesis and/or improved lymphatic 
function come largely from models where lymphatic function was disrupted by wounding 
(32-34); in this case, VEGF-C could act by restoring lymphatic proliferation and migration 
into and across the wound, where lymph or interstitial flow would then help drive lymphatic 
organization. Finally, VEGF-C delivery in tissues that are normally devoid of lymphatics such 
as the cornea would certainly be required to initiate lymphatic endothelial cell migration and 
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proliferation (27, 35, 36) without necessarily being required for lymphatic organization. 
Taken together, these data suggest that VEGF-C therapy may be successful in cases where 
lymphangiogenesis needs to be initiated (as in the case of congenital lymphedema) but not in 
cases where lymphatic capillaries are intact but poorly functional (e.g., if the tissue matrix is 
badly damaged, such as following radiation therapy) or blocked downstream (e.g., following 
lymph node resection).  
In summary, our results demonstrate that VEGFR-3 cooperates with VEGFR-2 in 
early stages of lymphangiogenesis by inducing LEC migration and proliferation, but serves 
redundant functions in later stages of lymphatic capillary organization. Importantly, we show 
that VEGFR-3 signaling is required neither for the organization of lymphatic capillaries nor 
for establishing or maintaining lymphatic function, which may rely instead on the activation 
of other lymphatic receptors such as Tie2 (36, 37) and neuropillin-2 (38) as well as on 
functional cues such as interstitial fluid flow (18, 19). These results also have important 
implications for anti-lymphangiogenesis therapy and corroborate recent evidence (10) 
demonstrating that combined inhibition of VEGFR-2 and VEGFR-3 may more effectively 
reduce tumor lymphangiogenesis and consequent lymphatic metastasis than the inhibition of 
either receptor alone. 
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FIGURE LEGENDS 
 
Fig. 1. Effects of VEGFR-3 neutralization in a model of lymphatic regeneration. A) Left: In 
vivo model of adult lymphangiogenesis. A circumferential band of skin is removed, covered 
with a silastic sleeve, and filled with type I collagen that serves as a fluid bridge between the 
distal and proximal lymphatics and provides a support for tissue regeneration; box indicates 
area of inset, right. Inset: Approximate location of images in B-E. The black square indicates 
the distal region shown in the immunostained thick sections in B and D, while the white box 
indicates the region shown in the microlymphangiography analyses of functional regeneration 
in C and E. B) Immunostaining for BECs (CD31, red) and LECs (LYVE-1, green) at various 
timepoints shows progression of normal (untreated) regeneration lymphangiogenesis. At day 
10, the region is primarily LEC-free. At day 17, many LECs are present, and they appear in 
unconnected clusters. At day 60, fully connected lymphatic structures are present throughout 
the regenerating region. C) Microlymphangiography reveals the lack of functional lymphatic 
vessels at days 10 and 17, and functional and architecturally restored lymphatic network at 
day 60. D) Neutralizing VEGFR-3 from the onset of lymphangiogenesis (day 0 or 10) through 
day 60 completely inhibits any lymphatic growth in the regenerating region. However, 
blocking from day 17 to 60 does not inhibit the organization of LECs that had migrated into 
the regenerating region. Bar=150μm. E) Analysis for blocking schedules in D confirms the 
functionality of lymphatics that form in the absence of VEGFR-3 between days 17 and 60, 
where functional lymphatic transport is visible within the distal portion of the regenerating 
region. Bar=300μm. F) Quantification of LEC numbers in the regenerating region under 
various blocking schedules. In normal regeneration, LEC numbers are low at day 10, medium 
at day 17, and high at day 60. When VEGFR-3 is blocked, cell numbers are similar to those at 
the onset of blocking (i.e., those at days 10 and 17 in control mice), indicating that VEGFR-3 
blocking prevents cell proliferation but does not affect cell survival. *P<0.05 compared with 
day 10 control, # P<0.05 compared with day 17 control. G) Distribution of LECs in the 
regenerating region indicates the direction of LEC migration. In normal regeneration, the few 
LECs present at day 10 are present only in the distal edge; at day 17, LECs are present 
throughout but still more numerous in the distal half; by 60 days, LEC distribution is even 
throughout the region. When VEGFR-3 is blocked during days 10-60 and 17-60, LEC 
distributions are statistically similar to those at the onset of blocking, indicating that LEC 
migration was arrested when VEGFR-3 blocking began. *P<0.05 between distal and proximal 
fraction. 
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Fig. 2. Effects of VEGFR-2 blocking and combined VEGFR-3 and VEGFR-2 blocking on 
lymphatic regeneration. A) VEGFR-2 blocking alone (top panel) prevented lymphatic 
regeneration when the mAb was administered during days 0-60. Minimal regeneration was 
observed when VEGFR-2 was blocked from days 10-60. Organization of LECs into 
lymphatic capillaries was seen when VEGFR-2 was blocked from days 17-60. Combined 
blockade of both receptors between days 17-60 (lower panel) drastically inhibited lymphatic 
organization, with very few vessels present. Bar=150μm. B) The number of LECs in the 
regenerating region at day 60 was somewhat diminished when VEGFR-2 was blocked during 
days 17-60 and diminished greatly when both receptors were blocked during this time period 
indicating that VEGFR-2 signaling may affect LEC survival, particularly that of unorganized 
LECs. *P<0.05 compared with day 10 control, # P<0.05 compared with day 17 control. C) 
The distribution of LECs in the regenerating region. The effects of individually blocking 
either VEGFR-2 or VEGFR-3 on LEC distribution resulted in a cell distribution similar to 
that seen on day 17 of controls, suggesting inhibition of migration and proliferation. 
Combined blocking of both receptors, however, resulted in LEC distribution similar to that of 
day 10 controls. *P<0.05 between distal and proximal fraction.  
 
Figure 3. Signaling by both VEGFR-2 and VEGFR-3 is important for LEC proliferation and 
migration in vitro. A) Wild-type VEGF-C stimulated receptor activation via tyrosine 
phosphorylation of both VEGFR-2 and VEGFR-3 in cultured human microvascular LECs, 
and neutralizing antibodies specifically inhibited phosphorylation of their respective 
receptors, whilst allowing signaling of the other. The top two panels show immunoblots 
(performed in parallel) from VEGFR-2 immunoprecipitated samples; top blot shows PY-20 
and reveals phosphorylated protein of both a 200 kDa and 110 kDa, while second blot shows 
VEGFR-2 appearing only as a 200 kDa protein, verifying equal protein loading and 
demonstrating the presence of co-immunopreciptated VEGFR-3. The bottom two panels show 
immunoblots (performed in parallel) from VEGFR-3 immunoprecipitated samples; third blot 
shows PY-20 and again reveals phosphorylation of both approximately 200 kDa and 110 kDa 
bands, which can be inhibited when VEGFR-3 is neutralized. The second blot shows total 
VEGFR-3. IC indicates where isotype-matched control IgG was used in place of blocking 
antibodies in the medium. B) After 72 hours of treatment, blockade of either VEGFR-2 or 
VEGFR-3 reduced VEGF-C-induced LEC proliferation. This was further inhibited when both 
receptors were blocked simultaneously. C) Blocking either VEGFR-2 or VEGFR-3 
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substantially decreased VEGF-C-induced LEC migration, while combined blockade 
completely abolished this migratory response. *P<0.05, **P<0.01 vs untreated; # P<0.05, ## 
P<0.01 vs other conditions as indicated. 
 
Figure 4. VEGFR-3 is redundant with VEGFR-2 for LEC tubulogenesis in vitro. 
A) VEGF-C stimulated formation of multicellular structures leading to an extensive tubular 
network. Inhibition of VEGFR-2 permitted LEC organization, although the extent of 
tubulogenesis was hindered compared with untreated LECs. VEGFR-3 inhibition did not 
affect LEC tubulogenesis, whilst combined blockade of both receptors completely prevented 
tubulogenesis. Bar=100μm. B) Quantification of organization expressed as total tube length 
per mm2 confirmed these observations and demonstrated that VEGFR-3 blocking has no 
effect on tubulogenesis. #P<0.05, ##P<0.01 as indicated. 
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Table 1 
 Normal Regeneration R3 Block R2 Block R3 + R2 
Block 
Day 0 Cell free          
Day 10 LECs proliferate and 
migrate only at the distal 
edge 
         
Day 17 LECs migrating throughout 
region; primitive and 
disconnected structures 
begin to form 
         
Day 25 Organization continues 
and some functionality is 
established but incomplete 
         
Day 60 Functional, mature 
lymphatic network 
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Supplemental Figure 1 
 
 
 
Supplemental Figure 1: Cells identified as lymphatic endothelial cells (LECs) do not express 
macrophage markers. On 10 μm-thick cryosections, LYVE-1 (green, top panel) labeled 
unorganized LECs in a normal regenerating region at 25 days. F4/80 (red, top panel. BD 
Pharmingen; 1:50) labeled the dense macrophage population in the region. Highlighting the 
LYVE-1 positive cells, there is no overlap (bottom panel). As both markers are found on the 
cell surface, lack of colocalization demonstrates that the mechanism of lymphatic 
regeneration in the mouse tail does not intimately involve LYVE-1 expressing macrophages. 
Bar=100 μm. 
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ABSTRACT 
 
Disturbances in the microcirculation can lead to secondary lymphedema, a common 
pathological condition that, despite its frequency, still lacks a cure. Lymphedema is well-
described clinically, but while the genetic underpinnings that cause lymphatic malformations 
and primary lymphedema are being discovered, the pathophysiology and pathobiology of 
secondary lymphedema remains poorly understood, partly due to the lack of well-described 
experimental models. Here, we provide a detailed characterization of secondary lymphedema 
in the mouse tail and correlate the evolution of tissue swelling to changes in tissue 
architecture, infiltration of immune cells, deposition of lipids, and proliferation and 
morphology of the lymphatic vessels. We show that sustained swelling leads to lymphatic 
hyperplasia and upregulation of vascular endothelial growth factor (VEGF)-C, which may 
exacerbate the edema since the hyperplastic vessels leak lymph back into the interstitium. The 
onset of lymphatic hyperplasia occurred prior to the onset of lipid accumulation and peak 
VEGF-C expression. Langerhans dendritic cells were seen in the dermis migrating from the 
epidermis to the lymphatic capillaries in edematous tissue. Furthermore, these results were 
consistent between two different normal mouse strains, but swelling was significantly greater 
in a matrix metalloproteinase (MMP)-9 null strain. Thus, by characterizing this highly 
reproducible model of secondary lymphedema, we conclude that VEGF-C upregulation and 
lymphatic hyperplasia resulting from dermal lymphatic ligation and lymphedema leads to 
decreased drainage function and that MMP-9 may be important in counteracting tissue 
swelling.   
 
 
 
 
 
 
 
 
 
 
Key Words: lymphatic function, extracellular matrix, lipid deposition, MMP-9, VEGF-C 
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INTRODUCTION 
 
 Lymphedema is a common pathology of tissue fluid balance often due to defects in 
lymphatic uptake and/or transport. Primary lymphedema results from defects of the lymphatic 
system leading to insufficiencies in transport, while the more common secondary 
lymphedema arises as a consequence to surgical, malignant, inflammatory, or traumatic 
disruption of the lymphatics (1, 2). As a chronic disease, lymphedema leads to the remodeling 
of skin and subcutaneous tissues (3), accumulation of lipids (4), macrophage recruitment (5), 
and failures in Langerhans dendritic cell migration (6) in the affected tissue. Unfortunately, 
this potentially debilitating condition lacks a cure and current treatment for chronic 
lymphedema, which include regular massage treatments and pressure applications or surgical 
removal of edematous tissue, can only slow its progression but not reverse the condition (2, 7, 
8).  
Recent studies have identified key regulators of lymphatic development and the 
genetic underpinnings of primary lymphedema caused by lymphatic malformation in 
development. However, the pathophysiology of secondary lymphedema – including the 
interplay between inflammatory events, matrix remodeling, and local lymphatic response – is 
less understood, and because of this, it is still not clear to what extent therapies aimed at 
lymphatic regrowth can be used to treat various types of secondary lymphedema. For 
example, if lymphedema is caused by downstream blockage (e.g., surgical removal of lymph 
nodes), do the previously healthy lymphatic capillaries respond to the tissue swelling by 
growing, or by regressing? Do they still facilitate immune cell trafficking? Without an 
understanding of the tissue-lymphatic pathophysiology of secondary lymphedema, rational 
treatment options will continue to be elusive. 
Key molecular players in lymphatic development have been demonstrated primarily 
by transgenic models; mutations in these regulators commonly lead to either embryonic 
mortality or lymphatic irregularities and symptoms of primary edema (9). Prox1, for example, 
governs the commitment of endothelial cells to a lymphatic lineage in development and Prox1 
null embryonic mice die before birth (10) while surviving Prox1 heterozygotes possess 
discontinuous lymphatic endothelium and exhibit abnormal fluid and lipid accumulation in 
the interstitium (11). Mice lacking angiopoietin-2, thought to play a role in vascular 
remodeling and lymphatic patterning, have disorganized, irregular lymphatic vessels and 
exhibit dermal edema and chylous ascites (12). Mutations in Foxc2, a transcription factor 
expressed on developing lymphatics, have been identified as the cause of lymphedema-
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distichiasis in humans that, unlike other types of congenital lymphedema, is characterized by 
hyperplastic lymphatic vessels (13, 14). Foxc2-null and -heterozygous mice posses 
hyperplastic lymphatic vessels and malfunctioning lymphatic valves that result in lymphatic 
backflow and abnormal lymphatic drainage (15, 16). A mutant allele for vascular endothelial 
growth factor (VEGF) receptor-3 (VEGFR-3) is responsible for Milroy’s disease in humans, a 
congenital disorder characterized by primary lymphedema in the extremities, as well as the 
Chy mouse phenotype that exhibits lymphatic defects similar to the human condition (17). 
VEGFR-3 and its ligand VEGF-C are also critical for both embryonic (18) and adult 
lymphangiogenesis (19, 20). These findings suggest that targeting lymphatic molecular 
mechanisms for improving lymphatic function may lead to a successful treatment of 
lymphedema and, as a result, research has focused on the most well-studied lymphatic 
molecular pathway to potentially treat conditions of both primary and secondary 
lymphedema: VEGFR-3 and VEGF-C (17, 21, 22). However, VEGF-C overexpressing mice 
display hyperplastic lymphatics (23) and we recently showed that excess VEGF-C delivered 
to otherwise normally regenerating skin led to hyperplastic lymphatic vessels without any 
increase in function (24). The proper resolution of lymphedema is likely dependent on the 
initial cause of the pathology, and effective treatments for primary and secondary 
lymphedema are therefore likely to differ. While the causes of primary lymphedema are 
increasingly appreciated, there remain gaps in our understanding of the pathophysiology and 
pathobiology of secondary lymphedema. These gaps are largely due to the absence of well-
characterized models of secondary lymphedema. 
Existing models of secondary lymphedema in the dog hindlimb (25, 26), rat hindlimb 
(27, 28), or rabbit ear (21) disrupt lymphatic transport through the excision of a 
circumferential band of skin and subcutaneous tissue. These models can sustain significant 
lymphedema for 3-4 weeks and result in a chronic increase in limb or ear volume. We earlier 
described a model of secondary lymphedema in the mouse tail skin (29, 30). Here, we 
characterize this model of secondary lymphedema to not only determine the reproducibility 
across several strains of mice, but moreover, to also describe the relative timing of the 
appearance of chronic symptoms, such as changes in extracellular matrix structure, 
accumulation of lipids, and recruitment of macrophages with the overall degree of swelling of 
the tail skin. We then correlate the timing of the lymphatic response and expression of VEGF-
C to these pathological outcomes and show that sustained tissue swelling leads to hyperplasia 
and subsequent decrease in function of the lymphatic capillaries, closely followed by a drastic 
increase in local VEGF-C expression. Additionally, to ascertain the importance of matrix 
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metalloprotenases (MMP)s in the inevitable matrix changes during tail swelling, mice lacking 
MMP-9, a key MMP in tissue remodeling (31), were also examined and found to experience a 
much higher increase in tail volume during secondary lymphedema. Thus, this 
characterization of the mouse tail model and correlation of molecular, cellular, and 
physiological changes over time lends new insight into the pathophysiology of secondary 
lymphedema, including the observation that lymphatic hyperplasia and VEGF-C 
overexpression may be key responses to chronic swelling.  
 
MATERIALS AND METHODS 
 
Mouse tail model of lymphedema 
 
These studies used 6-8 week old female mice, 10 per group, of the following strains: 
BALB/c (Charles River Laboratories, Wilmington, MA), FVB/NJ (Charles River 
Laboratories, France) and MMP-9 null on an FVB background (FVB.Cg-Mmp9tm1Tvu/J; The 
Jackson Laboratory, Bar Harbor, ME). Mice were anesthetized with a subcutaneous injection 
of ketamine (65 mg/kg), xylazine (13 mg/kg), and acepromazine (2mg/kg). An analgesic, 
butorphanol (0.05 mg/kg), was administered subcutaneously twice daily for three days 
following the procedure. All protocols were approved by the ACUC of Northwestern 
University and the Veterinary Authorities of the Canton Vaud according to Swiss law. 
 To create lymphedema, a circumferential incision was made through the dermis close 
to the tail base to sever the dermal lymphatic vessels. The edges of this incision were then 
pushed apart with a cauterizing iron, thereby disturbing the deeper lymphatics, preventing 
superficial bleeding, and creating a 2-3 mm gap to delay wound closure. Care was taken to 
maintain the integrity of the major underlying blood vessels and tendons so that the tail distal 
to the incision did not become necrotic. An age-matched control group of mice was 
maintained without this procedure to measure the baseline tail volume during the time course 
of the analysis. 
 Daily volume measurements of the tails, from the tip to the distal edge of the wound, 
were made by volume displacement. For untreated mice, a circumferential mark was made on 
the tail 10 mm from the tail base to mimic the incision site for reproducibility in measuring. 
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Sample preparation 
 Mice were sacrificed at various times up to 30 days post-procedure. The tail was 
excised at the site of the edema procedure and the distal tissue was flash frozen in liquid N2. 
Tissue samples were transversely cryosectioned into 12 and 60 μm-thick sections and stored 
at -80˚C until immunostaining. 
 
Microlymphangiography 
  Mice were anesthetized as above and the integrity of the lymphatic vasculature of the 
tail was examined by fluorescence microlymphangiography (30, 32, 33). A fluorescently 
labeled macromolecule (2000 kDa tetramethylrhodamine-conjugated dextran, 2 mg/ml; 
Molecular Probes, Carlsbad, CA) was injected intradermally at a constant pressure of 45 cm 
of water into the tip of the tail. Because of its large size, the tracer was taken up by the 
lymphatics but was excluded from the blood vasculature. As the fluorescent tracer was 
transported by the lymphatic vessels, it was clearly visible within dermal lymphatic 
capillaries, thus providing a clear visualization of lymphatic functionality. The filling of the 
lymphatic vasculature was monitored for 90 minutes with a Zeiss Axiovert 200M 
fluorescence microscope and Zeiss MRm camera set at equal exposure time for each mouse. 
 
Immunohistochemistry and histology 
 To visualize lymphatic vessels, thin (12 μm) and thick (60 μm) sections were co-
stained with a primary antibody to the lymphatic-specific marker LYVE-1 (1:500; rabbit 
polyclonal; Upstate, Charlottesville, VA). Thin sections were also labeled using anti-mouse 
antibodies for the macrophage-specific surface marker F4/80 (1:50; rat monoclonal; Serotec, 
Raleigh, NC) and the Langerhans dendritic cell protein langerin (1:50; goat polyclonal; Santa 
Cruz Biotechnology, Santa Cruz, CA). These antibodies were detected with Alexafluor 488 or 
594-conjugated donkey, rabbit, and goat IgG secondary antibodies (1:200, Molecular Probes), 
counterstained with DAPI (Vector Labs, Burlingame, CA), and observed and imaged as 
above. Thick sections were scanned using a Zeiss LSM 510 Meta confocal microscope. 
PCNA staining was achieved on thin sections with a monoclonal biotinylated mouse anti-
PCNA primary antibody (prediluted; Zymed Laboratories, South San Francisco, CA) and 
detected with Texas Red-conjugated avidin (Vector Labs).  
VEGF-C was labeled immunohistochemically on thin sections. Sections were first fixed in 
4% PFA, blocked against endogenous biotin and avidin activity (Biotin Blocking System, 
Dako, Carpenteria, CA), then labeled with anti-mouse VEGF-C (1:50; goat polyclonal; Santa 
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Cruz) and biotinylated secondary antibody (1:500; AffiniPure rabbit; Jackson 
ImmunoResearch, West Grove, PA). This was then visualized using the ABC-AP kit and 
Vector Black (Vector Labs). Sections were counterstained with Orange G (Merck KGaA, 
Darmstadt, Germany), dehydrated, and mounted with Eukitt (Fluka Chemie AG, Buchs, 
Switzerland). Images were captured with an Olympus AX70 Microscope and DP70 Camera. 
Masson’s trichrome was used to stain collagen and oil red O (Sigma-Aldrich, Buchs, 
Switzerland) to stain lipids on thin sections. Sections were mounted and imaged as above, 
except oil red O stained sections were counterstained with hematoxylin and not dehydrated 
but immediately mounted with Glycergel mounting medium (Dako). 
 
Image Analysis 
Images of each tail section were first assembled into complete montages in Photoshop 
(Adobe Systems, San Jose, CA). To quantify LEC hyperplasia, LECs were defined as cells 
with a blue (DAPI-stained) nucleus surrounded by green LYVE-1 staining, and lymphatic 
structures were defined as continuous groups of LYVE-1 labeled cells. The numbers of LECs 
within each structure were counted in three random 12 μm sections from each animal.  
To quantify VEGF-C expression, Metamorph 6.3 image analysis software (Molecular 
Devices Corp., Sunnyvale, CA) was used. Three labeled sections from each timepoint were 
analyzed. In each, the region between the epidermis and underlying tendon was clearly 
identified with a freehand tool, and the total intensity within this region was integrated.  
 
Statistics 
For quantified data, ANOVA followed by two-tailed Student’s t-tests were performed to 
determine statistical significance between two groups or among different timepoints. Data are 
reported as average ± standard deviations. Tail volumes are presented as a change over 
normal, LEC counts as total cells, and VEGF-C as normalized to the maximum.  
 
RESULTS 
 
Degree and sustainability of swelling 
All three strains of mice tested (BALB/c, FVB/NJ, and MMP-9 null) sustained 
reproducible edema for a period of at least 30 days. In the wild-type strains examined, 
FVB/NJ and BALB/c, tail volume measurements consistently peaked at 15 days following the 
ligation procedure with a volume increase of 55-75% (Fig. 1). Resolution of edema in these 
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mice also consistently occurred to within 20% of control volume by 30 days. Two FVB/NJ 
mice were kept for 60 days and their increased tail volumes were sustained (both 17% larger 
than baseline at day 60) in agreement with past work (29). MMP-9 null mice experienced 
significantly more tissue swelling than wild-type controls both with a higher peak volume 
change at 15 days of 115% (P=0.0287) and higher 30 day volume change of 75%. 
 
Matrix changes and lipid accumulation 
 In normal tail skin, the dermis possesses a much higher density of collagen than the 
underlying hypodermis. One day after of lymphatic disruption, we observed an immediate 
reduction in collagen density throughout the dermis, while the subcutaneous tissue layer of 
the hypodermis was drastically swollen (Fig. 2A). Within the first week, however, the density 
of collagen in the dermis increased, and by day 14 the collagen architecture in the dermis 
appeared similar to that of normal tissue. The change in tail volume was thus mainly due to 
hypodermal swelling. The hypodermis remained swollen with decreased collagen density 
until day 30, when collagen density again appeared normal, although total tissue volume was 
significantly increased.  
In addition to its propensity to accumulate fluid and swell, the hypodermis also 
exhibited a striking increase in lipid deposition (Fig. 2B). Lipid accumulation in the 
hypodermis, visualized through oil red O staining, became visible after 7 days, peaked at 14 
days, and was maintained through 30 days. Macrophages were also present throughout the 
dermis and hypodermis in edematous skin at all time points examined (Fig. 2C). 
 
Lymphatic function in edematous tail skin 
 The lymphatic network of the mouse tail skin consists of a regular, hexagonal network 
of dermal lymphatic capillaries that are easily visualized by fluorescence 
microlymphangiography (20, 32, 33). Furthermore, measures of how much volume is infused 
into the tail at fixed pressure is indicative of hydraulic conductivity and lymphatic function 
(30). Microlymphangiography in normal vs. edematous tails revealed functional 
insufficiencies in the lymphatics and increased hydraulic conductivity (Fig. 3). In normal 
mice, the lymphatic capillaries took up ~8 μl in 90 min of fluorescent dextran infused into the 
tail tip at 45 cm water; while in contrast, day 10 edematous tails took up ~30 μl of dextran in 
90 min at the same pressure. Despite the increase in hydraulic conductivity and dramatic 
increase in injected fluid flow rate for a given injection pressure, the lymphatic capillaries in 
edematous tails remained functional in taking up the injected fluid tracer; however, 
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fluorescent tracer was visible in the interstitial space around the capillary network, suggesting 
that the lymphatics in edematous skin were leaky and prone to backflow. After 60 days, the 
edema was reduced and the lymphatic leakiness was decreased but not entirely resolved. 
 
Lymphatic hyperplasia  
 Lymphatic ligation and subsequent tissue swelling led to marked morphological 
changes in the dermal lymphatics caused by the proliferation of LECs and subsequent 
enlargement of the lymphatic vessels. PCNA-positive LECs were seen in hyperplastic 
lymphatic vessels at day 10 (Fig. 4A). A reduced number of PCNA-positive cells were seen in 
lymphatic vessels at 20 days, and none were visible at 30 days. Confocal microscopy of the 
lymphatic vessels in the tail during edema (Fig. 4B) revealed that the morphology of the 
vessels was clearly altered, with striking hyperplasia during the period when overall swelling 
was the greatest (7 to 21 days). The number of LECs counted in each lymphatic structure was 
significantly higher than in normal vessels, peaking at 7 days (P<0.001). After this, the 
number of LECs per structure decreased, but still remained significantly higher than normal 
throughout the resolution of edema (P<0.001) (Fig. 4C).  
 
Heightened VEGF-C expression  
 VEGF-C expression in normal tail skin was low, consistent with earlier findings (24, 
34). In the first days after lymphatic ligation, tail swelling and lymphatic vessel hyperplasia 
were already significant but VEGF-C expression remained low (Fig. 5). VEGF-C began to 
increase throughout the edematous tissue at day 7 (P=0.037) and peaked at day 14 (P=0.022). 
Expression remained high as the swelling began to resolve at day 21 (P=0.014), and was 
decreased to normal levels at day 30. VEGF-C was mostly concentrated in the hypodermis, 
where the swelling was maximal but few lymphatic vessels were present. Thus, while VEGF-
C was upregulated in edematous tissue, its expression patterns did not necessarily correlate 
with lymphatic hyperplasia. 
 
Dendritic cell migration 
 Langerhans dendritic cells reside in the epidermis and migrate to the lymphatics in 
response to immune challenges (35). In normal tissue, Langerin+ cells were seen both in the 
epidermis and in the dermis near lymphatic vessels (Fig. 6). However, these cells were 
confined to the epidermis after lymphatic ligation until day 14, where they appeared to be 
migrating towards the lymphatics despite the hyperplastic appearance and transport 
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insufficiencies of the lymphatic vessels (Fig. 6). Therefore, at days 14, 21, and 30, correlating 
with the peak and resolution phase of edema, these cells were present in the dermis near the 
hyperplastic lymphatic vessels, suggesting a return to normal function. 
 
Increased fluid uptake and propensity for edema in MMP-9 null mice 
 In untreated (non-edematous) mice, the lymphatic capillary architecture was similar in 
MMP-9 null vs. wildtype control tails as visualized by microlymphangiography (Fig. 7A, B), 
although the lymphatic networks in MMP-9 null mice appeared much brighter than in control 
mice and took up 50% more fluid in 90 min at a fixed infusion pressure of 45 cm water than 
did the controls (12 vs. 8 μl). While there appeared to be minor indications of fluorescent 
tracer outside of the well-defined lymphatic vessels (Fig. 7B), there was little evidence of 
actual lymph leakage from the capillaries into the interstitium, as was clearly seen in 
edematous tails. This minor defects were likely the result of the increased brightness of the 
tail images resulting from increased tracer uptake (images were taken at the same exposure). 
Confocal imaging of the lymphatic vessels revealed no obvious differences in lymphatic 
vessel morphology from normal mice, suggesting that the increased fluid tracer uptake in 
untreated MMP-9 null mice was the result of either more efficient lymphatic transport or a 
higher hydraulic conductivity of extracellular matrix.  
Surprisingly, despite the apparently normal or above normal functionality of the 
lymphatics, MMP-9 null mice with lymphatic ligation exhibited a far greater degree of 
swelling than did wild-type mice, particularly between 7 and 21 days (P< 0.001; Fig. 1), and 
took longer to resolve (P<0.001; Fig. 1). This swelling was so rapid and so extensive that it 
actually led to necrosis of the tail in a two of the seven mice tested. Examination of the 
extracellular matrix of the tail skin revealed that the collagen density of MMP-9 null mice 
was, in fact, less than that of the wild-type controls. This was the case both in untreated tails 
and those after 14 days of edema. Therefore, the increased tracer fluid uptake into the tail seen 
in untreated MMP-9 null mice was probably due to an increase in hydraulic conductivity. This 
difference in the matrix architecture, in conjunction with the inability to maintain tail volume 
during swelling, suggests that MMP-9 plays an important role in the maintenance of 
extracellular tissue fluid.  
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DISCUSSION 
 
 To help elucidate the pathophysiology of secondary lymphedema, we characterized 
and correlated key molecular-, cellular-, and tissue-level changes over time in the mouse tail 
edema model and demonstrated its reproducibility and sustainability. We found that in 
otherwise healthy tissue, sustained swelling induced by lymphatic ligation leads to lymphatic 
hyperplasia and VEGF-C upregulation. Interestingly, LEC proliferation began before VEGF-
C upregulation, suggesting that lymphatic hyperplasia may be supported by VEGF-C only 
later, from day 14 (the peak in tail volume) through day 30. Also, the maximal VEGF-C 
expression was seen within the hypodermis, where most of the tail swelling was maintained 
but where lymphatic vessels were scarcer than in the dermis. This VEGF-C upregulation may 
therefore be a response to the accumulated fluid in the hypodermis. 
Lymphatic vessel hyperplasia in the absence of VEGF-C presents a quandary when 
examining the potential for VEGF-C delivery as a therapy for lymphedema. While VEGF-C 
treatment has been shown to hasten the resolution of edema in the mouse tail model, this 
result was accomplished by hastening lymphangiogenesis across the ligation (22) rather than 
necessarily inducing a change in the local function of lymphatics.  Therefore, delivery may 
only be beneficial in cases where transport insufficiencies are the result of a lack of lymphatic 
vessels in the tissue by inducing the growth of new lymphatic capillaries (17, 21, 22). Excess 
VEGF-C has also been shown to cause hyperplasia of lymphatic vessels when no other 
lymphatic defects were present (24). Therefore, our results, showing that increased VEGF-C 
and lymphatic hyperplasia is a response to tissue swelling, suggest that VEGF-C therapy may 
have limited use for treating secondary lymphedema. 
In examining functional lymphatic uptake during lymphedema, we found that the 
disruption in lymphatic transport led to an increase in fluorescent tracer uptake during 
microlymphangiography in part from the well-established increase in hydraulic conductivity 
of the interstitium resulting from in the breakdown of the tail matrix (30, 36, 37). We also 
found that the dilated, hyperplastic lymphatics were less effective at lymph transport and 
leaked lymph back into the interstitium. It is not known whether or how the decreased 
lymphatic transport function contributed to the increased lipid accumulation in adipocytes.  
In addition to decreased fluid drainage from the interstitium, hyperplastic lymphatics 
may exacerbate the edematous pathology by decreasing immune cell trafficking. When 
stimulated, Langerhans dendritic cells normally migrate from the epidermis into the lymphatic 
capillaries to traffic to lymph nodes for antigen presentation. In edematous skin, Langerhans 
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cells were not migrating through the dermis until day 14, even though other inflammatory 
responses like macrophages and massive matrix proteolysis were present earlier in 
lymphedema. Lack of migration may be due to the absence of migration-directing interstitial 
flow which only returns once edema is resolving, although it has yet to be demonstrated that 
interstitial flow specifically guides dendritic cells towards the lymphatics (35).  This apparent 
lack of DC migration to lymphatics during tissue swelling may lead to decreased immune 
response, which in turn may exacerbate the pathological state of the limb. This notion is 
consistent with previous work showing that the immune response is compromised in 
edematous limbs (6), leaving the tissue more prone to infection and further inflammation.  
MMP-9, a key MMP in matrix remodeling (31), appeared to play an important role in 
edema prevention. First, the collagen density in the dermis of MMP-9 null mice was lower 
than that in wildtype mice, both in normal and edematous states. This reduced matrix density 
may leave the tissue more susceptible to fluid accumulation and tissue swelling. Indeed, 
MMP-9 null mice were unable to sufficiently counteract the swelling through responsive 
remodeling of the matrix; the tail apparently relies on MMP-9 in remodeling the extracellular 
matrix to counteract the change in volume. Since all other studied factors appeared similar in 
response to wild type mice, the role of MMP-9 in this pathological state is that of matrix 
maintenance.  
The reproducibility and sustainability of the mouse tail model of lymphedema was 
demonstrated across two normal strains and for roughly 20-30 days, respectively, although in 
some mice (for unknown reasons) edema can be sustained indefinitely (29). This time frame 
is sufficient to observe key features of chronic edema, including collagen breakdown and 
remodeling, lymphatic hyperplasia, and abnormal lipid accumulation in the skin, consistent 
with pathological features observed in longer studies in other models (21, 26, 27). Responsive 
changes in the dermal matrix during swelling – initial degradation followed by compensatory 
rebuilding – were also temporally correlated to lipid accumulation and macrophage 
infiltration throughout the tissue, both chronic indicators of lymphedema (4, 5).  
 In summary, the mouse tail model of lymphedema is reproducible, reliable, and shows 
many characteristics of chronic lymphedema. We found that sustained tissue swelling due to 
lymphatic blockage led to marked lymphatic hyperplasia and lipid accumulation, followed by 
substantial VEGF-C overexpression in the hypodermis. The hyperplastic lymphatic vessels 
were poorly functional at draining interstitial fluid, and the resulting fluid stagnation may 
have contributed to decreased Langerhans dendritic cell homing to the lymphatics. These 
correlations between factors regulating tissue homeostasis and those regulating lymphatic 
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biology during tissue swelling following lymphatic ligation raise important questions in 
considering treatment strategies aimed at lymphatic growth for alleviating secondary 
lymphedema. 
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FIGURE LEGENDS 
 
Fig. 1. Tail volume changes following lymphatic ligation. Two control strains of mice, 
FVB/NJ (blue diamonds) and BALB/c (red squares), displayed nearly equivalent swelling and 
resolution patterns, and both peaked at 15 days. Transgenic mice lacking MMP-9 (green 
triangles) also displayed maximum volume increase at 15 days, but showed a significantly 
greater extent of swelling compared to the wild type strains as well as a longer resolution 
time. 
 
Fig. 2. Extracellular matrix density, lipid accumulation, and macrophage presence in 
edematous tails. (A) In normal skin, a collagen-dense dermis (gold arrow) and less dense 
hypodermis (white arrow) was seen. One day following lymphatic ligation, the collagen 
network was degraded in both the dermis and hypodermis as fluid accumulated. At day 14 
when tail volume reaches its peak, the collagen density in the dermis returned to normal (gold 
arrow) while the architecture of the hypodermis remains severely compromised. At day 30, 
the collagen architecture throughout the tissue appeared normal. (B) Oil Red O staining 
showed that the hypodermis dramatically filled with lipids (red) at day 7 and that this 
accumulation was maintained through 30 days. (C) Macrophages (red) were also present in 
high numbers at all times during edema. Note the hyperplastic lymphatic (green) vessels at 
days 7 and 14 (marked by white arrows) as compared to normal vessels (gold arrows). Scale 
bars = 200 μm. 
 
Fig. 3. Fluorescence microlymphangiography revealed leaky lymphatic capillaries in 
edematous skin, with higher magnification images shown at right. The normal mouse tail skin 
possessed a well-defined hexagonal network of dermal lymphatics that transport the 
fluorescent tracer proximally (left to right) from infusion into the tip of the tail. At 10 days of 
lymphedema, the tail was swollen and the fluorescent tracer filled both the lymphatic vessels 
and the interstitial space (back flow indicated by arrows). At 60 days, the lymphatic transport 
was mostly returned to normal. All images were taken with the same exposure time. Scale 
bars = 2 mm. 
 
Fig. 4. Lymphatic morphology changes during edema. (A) Normal tissue showed few 
proliferating cells and small superficial lymphatics (gold arrow heads) with the underlying 
collecting lymphatic vessels (white arrow heads). PCNA staining indicates that as the tail 
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volume increased, lymphatic endothelial cells (LECs) proliferated (white arrows). At day 10, 
LECs in the vessels were proliferating and the vessels were hyperplastic. This LEC 
proliferation is reduced at 20 days and absent at 30 days. Edema also induced the proliferation 
of other cells in the tail (gold arrows) (B) Confocal microscopy of the dermal lymphatic 
vessels forming the hexagonal network in the tail demonstrated the drastic hyperplasia and 
morphological changes associated with edema at 7 and 14 days, with an abnormal 
morphology still present at 30 days. Scale bars = 100 μm. (C) The number of LECs per 
lymphatic structure was greatest at day 7 in both wild type and MMP-9 deficient mice (* 
indicates P<0.05 over control).  
 
Fig. 5. VEGF-C expression in edematous tails. (A) VEGF-C expression (black) was normally 
quite low and remains so during the onset of edema (through 7 days); orange indicated 
collagen by orange G staining. At 14 days, however, VEGF-C was greatly increased and 
remained so during resolution at day 21. Bar = 200 μm (B) The peak of VEGF-C expression 
(integrated intensity) lagged behind the peak of LEC proliferation and vessel hyperplasia (* 
indicates P<0.05 vs. control).  
 
Fig. 6. Langerhans dendritic cell (DC) trafficking during edema. In normal skin, some DCs 
were seen between the epidermis and lymphatic vessels (green) in the skin, indicating normal 
migration. After 7 days of edema, no DCs could be found below the epidermis. At 14, 21, and 
30 days, DCs were present in high numbers in the dermis and near the hyperplastic lymphatic 
vessels, indicating migration. Yellow arrows indicate some DCs in the epidermis, and white 
arrows indicate migrating DCs. Bar = 200 μm. 
 
Fig. 7. Differences in lymphatic function and morphology and extracellular matrix 
architecture in MMP-9 null mice vs. wild type controls. (A) In untreated animals, constant-
pressure infusion of fluorescent tracer led to 50% more uptake by MMP-9 null mice vs. 
wildtype controls. The lymphatic vessel networks of the MMP-9 null mice appeared to be 
much brighter (with equal exposure time) than those of the wildtype controls, indicating a 
higher uptake rate. Bar = 2 mm. (B) Higher magnification images of the lymphatic structures 
showed normally functioning vessels with no backflow. Bar = 2 mm. (C) Confocal images of 
the lymphatic vessels in each type of mouse showed little or no morphological differences 
between wildtype and MMP-9 null mice; bar = 100 μm. (D) In untreated animals, the collagen 
matrix (blue) appeared to be less dense in the dermis of the MMP-9 null mice than in that of 
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the FVB/NJ mice. Bar = 200 μm. (E) After 14 days of edema, the dermal collagen density 
appeared normal in the wild-type control mice but remained largely degraded in the MMP-9 
null mice. Bar = 200 μm. 
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ABSTRACT 
 
Flow through the interstitium is an important morphogenetic driving force that is 
present in nearly all tissues. The uptake of interstitial fluid is the primary function of 
lymphatic capillaries. In this capacity, they are the modulators of interstitial flow: fluid 
extravasated from blood capillaries is transported across the interstitium to the lower pressure 
lymphatic capillary. The other chief parameter controlling the ease at which fluid moves 
through the extracellular matrix is the tissue hydraulic conductivity. Coupled together, 
lymphatic capillary uptake and tissue hydraulic conductivity dictate interstitial flow rates and, 
therefore, are important parameters with which to describe the potential morphogenetic 
impact of flow on cells within the interstitium. Here, we present a simple poroelastic model of 
interstitial fluid flow and lymphatic capillary uptake that can be used to quantify physiologic 
in vivo lymphatic function and tissue hydraulic conductivity in the mouse tail. The 
implications of lymphatic dysfunction within tissues are described and the governing 
equations for tissue hydraulic condictvity are subsequently reformulated in a model of 
primary lymphedema, the K14-VEGFR-3-Ig mouse. The model is then applied to a mouse 
model in which we discovered lymphatic hyperplasia, the Apolipoprotein E (ApoE) knockout 
mouse. In this model, our model’s calculations demonstrate a significant reduction in 
capillary function. Additionally, this provides the first direct experimental evidence linking 
dyslipidema and lymphatic capillary function. Thus, the quantitative model is sufficiently 
sensitive to detect changes not only when lymphatics are functional, but also to determine the 
consequential effects of lymphatic molecular responses. This model is therefore ideal to 
examine baseline lymphatic function and tissue hydraulic conductivity in transgenic mouse 
models where these physiologic parameters would be highly influential to the results of 
inflammation, lymphedema, or immune cell responses. 
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INTRODUCTION 
 
Lymphatic capillaries reside in nearly all tissues of the body to drain fluid, 
macromolecules, and cells that have extravasated from the blood circulation (1). In doing so, 
interstitial flow is directed from the blood capillary to the lymphatic circulation by means of 
the hydrostatic pressure difference between the two systems (2). Due to the important 
morphogenetic effects of interstitial flow on cells that reside in and traverse the interstitium 
(2), understanding flow through the interstitium is important when exploring cell behavior in 
in vivo and in 3-D in vitro models.  
Due to their critical role in maintaining tissue fluid balance, understanding the uptake 
and transport of fluid via lymphatic vessels is an important aspect of tissue physiology. Very 
little, to date, is known about the capacity of normal, healthy lymphatic capillaries to uptake 
fluid (3); even less is known about pathological states such as lymphedema, where drainage is 
dramatically reduced or nonexistent (4, 5) or in inflammation, where flows are greatly 
increased (6). Coupling lymphatic uptake of fluid to interstitial transport is thus a goal in 
understanding tissue homeostasis. 
Tissue exists essentially as a saturated sponge, with fluid flow driven not only by 
changes in hydrostatic pressure, but flow also being induced by matrix deformation as, for 
example, in articular cartilage (7); and in turn, flow potentially deforming the matrix. Matrix 
mechanics are thus a critical component in modulating lymphatic function (1, 8). This makes 
for potentially complex mathematics if the real-world scenario is modeled. Fortunately, flow 
through fibrous matrices has been previously modeled to quantify interstitial flow (elegantly 
reviewed in (9, 10)); the use of a poroelastic model to describe fluid movement through the 
extracellular matrix has also been performed (11, 12).  
Here, we attempt to clarify the mathematics associated with these models and simplify 
these to parameters readily obtainable through simple experiments for determining tissue 
hydraulic conductivities and lymphatic uptake in vivo. The mathematical models are then 
applied to transgenic mouse models representing lymphatic dysfunction, lipid metabolic 
disorder, and inhibited pathological lymphangiogenesis. 
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METHODOLOGY 
 
Assumptions 
 These calculations all base themselves in soil mechanics and its subsequent 
mechanical models. Soil mechanics function as an ideal model for the interstitium, if, for 
example, an analogy between this tissue and soil is made based on Terzaghi’s principles for a 
matrix of soil. The assumptions: 
(a) Homogenous, isotropic matrix 
(b) Matrix is 100% saturated 
(c) Both solid and liquid phase are incompressible 
(d) Solid phase behaves as a linear elastic solid  
(e) Strains to the matrix are relatively small  
(f) Darcy’s Law can be applied for hydrostatic gradients 
(g) Permeability and compressibility constants remain constant 
(h) There exists a unique relationship between stress and void ratio, dependent on time 
With these assumptions in place, a simple mechanical model can be applied using 
fundamental governing equations for poroelastic theory.  
 
Developing the governing equations 
 
Equation 1 represents a momentum balance for the interstitium as a whole. Stresses are at 
equilibrium, and inertial effects and body forces are neglected. 
 
(1) 0=•∇ τ  
 
The constitutive equation for a linear elastic solid is given as: 
 
(2) μελτ 2++−= II eP  
 
where e is the dilatation of the solid matrix, λ and μ are the Lamé parameters (material 
constants) and ε is the infinitesimal strain tensor. The other governing equation is Darcy’s 
Law for flow through porous medium, Equation 7. First, however, Equations 1 and 2 are 
combined and simplified by further defining their parameters: 
 
(3) u•∇=e  
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The dilatation of the solid phase is equal to the divergence of u, the solid displacement vector. 
 
(4) )(
2
1 Tuu ∇+∇=ε  
 
Equation 4 represents the strain tensor as defined by displacement in a linear elastic solid. If 
the solid is undergoing purely hydrostatic pressure, there are no shear components and uT=u. 
Similarly, the strain tensor will thus only have diagonal components; in pure hydrostatic 
pressure, the divergence of ε equals the gradient of e: 
 
(5) ε•∇=∇e  
 
These relationships (Eq. 3-5) thereby allow us to combine Eq. 1 and 2 into a more applicable 
relationship: 
 
(6) eP ∇+=∇ )2( μλ  
 
Equation 6 demonstrates the direct relationship as to how changes in pressure affect matrix 
dilation, and vice versa. Returning to Darcy’s Law of flow through a porous medium; this is 
defined to obtain the velocity of the interstitial fluid, v, relative to the solid network. In this 
form, the dilatation of the solid phase is coupled: 
 
(7) PK
t
∇−=⎟⎠
⎞⎜⎝
⎛
∂
∂− uvφ  
 
where Φ is the fluid volume fraction and K is the effective hydraulic conductivity of the 
tissue. Combining the rate of change of the liquid phase and the rate of change of solid phase, 
each represented by the divergence of the respective term, and fluid losses, Equation 8 is 
obtained: 
 
(8) 0=+∂
∂•∇+⎟⎠
⎞⎜⎝
⎛
∂
∂−•∇ vJtt
uuvφ  
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where Jv is the fluid input or output, or flux. This equation was previously developed (12) and 
more elegantly written combined as Equation 9. In this form the flux is written as the resultant 
changes in the fluid or matrix: 
  
(9) vJt
−=⎟⎠
⎞⎜⎝
⎛
∂
∂−+•∇ uv )1( φφ  
 
As a combined continuity equation for flux through the interstitium, the average interstitial 
fluid velocity and solid matrix displacement vector equal interstitial fluid generation from 
blood capillary extravastion (11) or interstitial fluid drainage by lymphatic capillaries (12), or 
a combination of both. Since the governing equation of this model is effectively the 
conservation of mass, it is perhaps useful to rewrite Eq. 9 in terms of tissue strain, where the 
form becomes analogous to Fick’s second law of diffusion with reaction: 
 
(10) 0)2( 2 =+∇+−∂
∂
vJeKt
e λμ  
 
Here, dilatation is analogous to the reactive species. Changes in dilatation result in either 
pseudo-diffusion through the tissue governed by K(2μ+λ) – analogous to the diffusion 
coefficient Dab – and a pseudo-reaction term represented by the flux term. Flux, or the 
hydrostatic pressure-driven uptake into lymphatic capillaries, is defined by: 
 
(11) *)( PPPJ biv ββ =−=   
 
where the newly introduced β is defined as the lymphatic conductance in volume of fluid 
drained by the vessels per volume of tissue with respect to time and pressure (final units of 
reciprocal time and pressure) and P* is defined as the hydrostatic pressure driving force 
between the pressure in the interstitium, Pi, and the baseline physiologic pressure, Pb. 
Coupling Equations 10 and 11, the final governing equation is achieved: 
 
(12) 0*)2( 2 =+∇+−∂
∂ PeK
t
e βλμ  
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Factors influencing lymphatic uptake 
Uptake into lymphatic capillaries is similar to the well-described phenomenon of 
blood capillary extravasation; a fundamental equation can be used to explore how changes in 
Starling’s Law for transcapillary transport affect the interstitium and vice versa. Starling’s 
Law in its complete form, for blood capillary extravasation: 
 
(13) ( ) ( )( )erstitiumcapillaryerstitiumcapillaryv PPLpJ intint ππσ −+−=  
 
where the flux is related to the hydrostatic driving force, as well as the osmotic pressure 
driving force, Δπ. Lymphatic intravasation is represented by the appropriate directional 
changes to the driving forces. Physiologically, flux into lymphatic vessels is predominantly 
intercellular, where lymphatic cell-cell junctions are opened – almost valve-like – to 
accommodate flow (6, 13). It is therefore reasonable to neglect osmotic differences because 
interstitial fluid predominantly flows directly into the lymphatic capillary. The filtration 
coefficient, Lp, is dependent on vessel wall area and wall hydraulic conductivity. In blood 
capillaries, a basement membrane and pericytes affect the wall hydraulic conductivity, but, 
again, physiologically this is irrelevant for the initial lymphatics. Hence, when Lp is redefined 
as β above (Equation 11), it is essentially the ease at which fluid is taken across the lymphatic 
capillary wall. Vessel diameter and vessel density will be the contributing physical parameters 
to lymphatic vessel wall area in any volume of tissue. 
 Lymphatic endothelial cell-cell junctions, which presumably mediate the open 
connections through which interstitial fluid enters the capillary, will molecularly contribute to 
lymphatic flux. Repulsion of cell-cell contacts, for example, by podocalyxin expression, may 
also inversely contribute (14). Changes in the expression of these molecules (e.g., VE-
cadherin) may result in changes in uptake. Indeed, during heightened shear conditions and in 
inflammation, where flows are increased, molecular expression of cell-cell connections is also 
altered (6, 13, 15)(Yong, C., et al. unpublished). Equally important in lymphatic drainage 
during increased flows are cell-matrix interactions. Anchoring filaments that link lymphatic 
endothelial cells to the matrix permit the capillary to open with increase interstitial fluid 
pressure in the matrix (Fig. 1). Heightened shear also alters the expression of these molecules 
in lymphatic endothelial cells (Yong, C., et al. unpublished). While incapable of transporting 
larger molecules, aquaporin expression may also mediate transcellular water flux across the 
capillary wall (16). Resultantly, the changes in LEC molecular expression are coupled into β 
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when calculating lymphatic conductance experimentally. The experimental model should thus 
be able to detect not only anatomical differences in the lymphatic network, but also the active 
response of LECs to changes in interstitial flow, molecular agonists, or genetic mutation. 
 
Factors influencing hydraulic conductivity 
 Hydraulic conductivity is a physical property of the tissue. It will change with changes 
in matrix composition and density, as well as the tissue saturation. Physiologic tissues are 
wholly saturated, but the ratio of fluid to solid will affect the overall porosity, or cross-
sectional area accessible to fluid flow. Tissues with higher lipid content per volume (e.g., 
obese or edematious) would have a lower area accessible to flow due to (a) the 
hydrophobicity of the lipds and (b) the inability of flow to pass directly through cells – in this 
case adipocytes – that have taken up the lipid. Matrix components such a proteoglycans also 
posses dense negative charges that inhibit free flow of fluid through the matrix. Further 
discussion on how the matrix impacts hydraulic conductivities is found in the excellent 
Levick review (9). 
 
EXPERIMENTAL DESIGN 
 
A fluorescent tracer is slowly infused into the tail tip of an anesthetized mouse 
beginning at t=0. Flow is driven by a small application of hydrostatic pressure using a water 
column (Fig. 2) set at 40, 45, 50, and 55 cmH2O. As the applied pressures are higher than 
baseline tail pressure, Pb, flow into and through the tissue is created. Very small, constant 
pressures are essential to maintain the tissue state according to our assumptions (e.g., minimal 
matrix strain at steady state) and to allow the lymphatic capillary uptake of the infused fluid to 
reach steady-state with the infusion.  
 The infusion flowrate, Q, is constantly monitored by tracking a small amount of air 
drawn into the tubing that separates the water (used to supply the pressure head) from the 
infused tracer (2% fluorescently-labeled dextran). The distance, x, that fluorescent tracer has 
traveled through the tail is also monitored by fluorescence microscopy. For each pressure, 
sufficient time is given for the interstitial transport and lymphatic uptake to reach steady state 
before the next pressure is applied [This characteristic time can be estimated to be 1/βP0*, or 
approximately 14 minutes based on past measurements of β and K  (12)]. 
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Because the physical geometry in the mouse tail is assumed to be purely axial flow, in a 
symmetric rod geometry, with lymphatic drainage being the outlet of flow, it is easy to recall 
a symmetric, one-dimensional differential form of the solution in Eq. 6 for the constitutive 
equation: 
 
(14) 
x
e
x
P
∂
∂+=∂
∂ )2(* λμ  
 
Combining Eqs. 12 and 14, strain is directly related to the applied force, pressure, and the 
governing equation can be re-written in terms of hydrostatic pressure: 
 
(15) 0***
)2(
1
2
2
=+∂
∂−∂
∂
+ Px
PK
t
P βλμ  
 
The distribution of pressure is controlled by the “stress diffusivity” K(2μ+λ), or K*, and the 
overall lymphatic conductance β(2μ+λ), or β*. Solving this equation is non-trivial; however, 
the solution is available in mathematics texts. The boundary conditions are set for P* as P*(0, 
t)=P*0, P*(∞, t)=0, and P*(x, 0)=0, where P0 is the applied pressure (P0=Pb) at the tail tip. 
Introducing the term α=√(K/β) allows for a characteristic penetration length that will govern 
the steady-state pressure profile, and also permits the final solution for P*(x,t): 
 
(16) ⎟⎟⎠
⎞
⎜⎜⎝
⎛
⎟⎟⎠
⎞⎜⎜⎝
⎛ ++⎟⎟⎠
⎞⎜⎜⎝
⎛ −= − t
K*t
xt
K*t
xPtxP xx *
2
erfce
2
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2
erfce
2
1*),(* //0 ββ αα  
 
Steady-State Approximation 
 
While the complete solution for P* may appear to be quite complicated, at steady-state 
(t→∞) the equation readily describes the behavior of the pressure profile at to be exponential 
decay, governed by the ratio α, or the resistance to flow of the tissue versus uptake by the 
lymphatic capillaries: 
 
(17) α/0 e**
x
ss PP
−=   
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Using this steady-state relationship, the length, L, which is the penetration depth of the 
infused fluid (Figure 1), can be solved for by applying P*ss to Darcy’s Law for the average 
fluid velocity. 
 
(18) αβ /0 e* LPKPK −=∇−=v  
 
The penetration length can then be solved in terms of the ratio, α: 
 
(19) ( )L
L
L PP
P
P
P
PL *ln*ln
*
*
ln
*
*ln 0
0
0
−==−= ααα  
  
In this simple form, it would be possible to readily obtain α by measuring the penetration 
depth versus the applied pressure P*0. The term P*L need not be defined. The only necessity 
is that the ratio P*L/ P*0 be sufficiently small so that convection due to the applied pressure is 
minimized at L. Also, the measurement of L must be consistently performed at each pressure 
so as to not to permit any diffusion of the infused solute to skew the necessary length (the 
time of each measurement period can likewise be shortened so as to eliminate this potential). 
As the experimental procedure utilizes a fluorescent solute, L can be repeatedly and 
confidently measured by taking the average fluorescent intensity along the tail length and 
calculating the distance of the “moving front”. Because lymphatic uptake is in equilibrium 
with axial fluid movement at steady state, after a short time L remains constant at any applied 
pressure (Fig. 3A). As discussed, at steady-state x becomes the constant L because the 
infusion flow rate, Qss, is equivalent to the lymphatic uptake taken over the length, L. If 
lymphatic uptake were less, continued infusion would result in continued movement of L at he 
same rate, but this is not the case due to equilibrium (Fig. 3A). Thus, the changes in Qss with 
applied pressure can be used to similarly obtain a relationship between lymphatic conductance 
and hydraulic conductivity: 
 
(20) ∫∞ ==
0
0*d* PKAxPAQ ssss ββ  
 
Flow rates into the tail remain constant with homogeneous tissue structure and increase with 
each applied pressure (Fig. 3B). Therefore, by monitoring the relationship between the 
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infused flow rate and the penetration length of infusion for each applied pressure, the slopes 
of these regressions allow for the non-invasive quantification of β and K for any experimental 
condition. 
 
Non-steady-state: dysfunctional lymphatic drainage 
 The steady state approximation works well to calculate tissue hydraulic conductivities 
and lymphatic conductances when lymphatic vessels function and interstitial fluid clearance is 
normal. However, some experimental conditions with extremely dysfunctional lymphatics – 
or the complete lack thereof - present a challenge when applying the same governing 
equations. Primary (hereditary) lymphedema presents just such a case. In two mouse models 
of primary lymphedema, the “Chy” mouse (17) and “K14” (K14-VEGFR-3-IgG) mouse (18), 
there are no dermal lymphatics in the tail skin and thus, no lymphatic uptake. If there is no 
equilibrium state between lymphatic uptake and interstitial fluid movement, then L should 
never become constant at any pressure. A new solution must be formulated. 
 
A rigorous non-steady state calculation for K 
The complete solution for P*(x,t) in the tail is represented in Equation 16. In the Chy 
or K14 model, the lack of dermal lymphatics should result in β→0. [As previously mentioned 
in the model’s development, βP* could technically be taken as the pressure driven flux into 
lymphatic capillaries, blood capillaries, or post-capillary venuoles according to Starling’s 
Law. Significant flux into the blood capillaries may result when P*0 is increased and would be 
detected as the movement of L would “equilibrate” with capillary reabsorption with 
increasing P*0.] Simply, with β→0, Equation 16 simplifies to: 
 
(21) ⎟⎟⎠
⎞⎜⎜⎝
⎛=
K*t
xPtxP
2
erfc*),(* 0 . 
 
Equation 21 can be manipulated to solve directly for K*: 
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Using a mathematics software package, this can be solved provided the proper data is taken. 
The recorded times that are taken which were used in the steady-state model to calculate the 
flowrate into the tail, now enter directly into the calculation as t, and the moving front must be 
continuously monitored for x from t=0, rather than just taking the final L value at 30 minutes.  
 
Problems with this approximation 
 Whereas in our steady-state calculation P*, or P(L,t), was mathematically irrelevant, 
here it is now of critical importance. What is a reasonable approximation of this value? When 
the infusion pressure is changed, there is an initially fast moving front that eventually slows. 
In steady-state tissue – that with lymphatic uptake – this decline is rapid. However, if there is 
no lymphatic uptake, the moving front moves constantly, with no change in rate, through the 
tissue (Fig. 4). A “steady-state” L cannot, therefore, be applied and x becomes linearly time 
dependent. The exactness of this model makes it a potential liability for accurate in vivo 
approximations. However, its sensitivity is ideal for detecting flux loss to the vasculature and 
may thus serve as a guide to at least the correct range of potential hydraulic conductivities. 
 
Other approximate solutions for non-steady state K 
 Some problems presented by the exact solution for non-steady state uptake can be 
circumvented by taking into consideration a simplification of the governing equation for flow 
through porous media, Darcy’s Law. If the tail is considered merely to be porous media, with 
all fluid flowing axially through the tail, Darcy’s Law represents a reasonable approximation 
for calculating the hydraulic conductivity in non-steady state tissues. 
 Instantaneous velocities are a problem in the rigorous, full calculation of K. Thus, if 
we utilize Darcy’s Law with an average moving front velocity over the time of infusion at 
each pressure, in differential and integrated forms: 
 
(23) 
L
KP
t
L 0*
d
d −=  
 
(24) τ02 *2KPL =  
 
where τ represents the time of infusion for each pressure. It should be also be noted that L is 
the absolute distance that the solute front has moved, not just the distance for each pressure. 
Unlike the elegant, full calculation for K, this linear approximation will overestimate K. The 
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deviation from what physically happens can be seen in Table 1 for normal versus edematous 
mice. The ambiguities of measurable parameters are, however, eliminated. Because 
monitoring the infusion flowrate is trivial in the experimental setup, Darcy’s Law can also be 
utilized in a form that relates the infused flowrate to the bulk fluid velocity through the tissue: 
 
(25) 
L
KP
A
Q 0*−==v  
 
(26) 0*AKPQL =  
 
As with any approximation using a simplified Darcy’s Law only, the linear result is an 
overestimation of the true tissue K. However, by coupling two measureable quantities, Q and 
L, this approximation maximizes the benefit of the potential experimental inputs for the non-
steady state approximation. A comparison of this calculation for normal and edematous mice 
is seen in Table 1. 
 
How to judge the quality of non-steady-state approximations? 
 In Table 1, the differences in the three potential approximations of K in mice lacking 
dermal lymphatic capillaries are visualized. The question of which method yields the most 
accurate value of K can only be considered if the tissue exhibits true, non-steady-state 
behavior. Is the approximation of non-steady-state even reasonable? There are three potential 
ways to test this question: 
 
Method 1: The moving front of solute in the tail is continually monitored for long periods of 
time to ensure that the interstitial velocity is constant and does not sufficiently decelerate. 
Deceleration at longer times (i.e., over 20 minutes) indicates flux losses to the vasculature. 
 
Method 2: A comparison of K obtained via the non-steady state method can be made to that 
obtained using the steady-state calculation. Since lymphatic uptake is discounted in the non-
steady-state model, the hydraulic conductivity of normal tissue should decrease, while 
edematous tissue should remain the same or increase in K.  
 
Method 3: The infused volume can be directly compared to the volume of tail occupied by the 
fluorescent tracer at each pressure’s infusion. With no loss of solute, the infused volume 
should be accounted for in the tissue space, as defined by Equation 27: 
 
(27) ( )
40454545 *0
*
0
*
0
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0 ==== −=⋅ PPuminterstitiPP LLAQ τ  
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If these “methods” are used to check the validity of the results obtained in Table 1, the exact 
solution is the best and should be applied. It demonstrates not only the ability to successfully 
calculate the tissue hydraulic conductivity, but also the means to sensitively detect flux losses 
to lymphatic capillaries or blood capillary and post-capillary venuole reabsorption of 
interstitial fluid at higher pressures. Fortunately, the simple steady-state solution works for all 
models with functioning lymphatic capillaries – the most likely scenario. 
 
MODEL APPLICATION: Transgenic mouse strains 
 
One of the essential features of a model for lymphatic uptake is that it is sufficiently 
sensitive to detect changes in lymphatic function when molecular signaling in lymphatic 
endothelial cells is potentially altered. An ideal application of the model is thus to examine 
transgenic mouse strains to verify that lymphatic function is normal, as its normalcy – or lack 
thereof – may dictate the results of other studies of edema, inflammation, or immune cell 
migration. To both verify the sensitivity of the model and explore some experimental 
questions, we tested several transgenic mouse strains. 
 
Apolipoprotein E (ApoE) -/- 
 The apolipoprotein E (ApoE) knockout mouse line has long been used as a model of 
artherosclerosis and hypercholesterolemia. Gene array analysis on LECs stimulated with 
VEGF-C and shear stress exhibited significant changes in apolipoprotein expression (19). The 
potential for lymphatics to be altered in ApoE-/- mice was thus motivated by the potential 
roles of lymphatics in lipid metabolism (the gene array analysis) and work demonstrating 
reduced dendritic cell migration (which enter and traffick via lymphatics) in these mice (20). 
 In ApoE-/- mice aged 16-20 weeks on a high fat diet, dermal edema and increased 
lymphatic capillary diameter were observed (data not shown). When lymphatic function was 
measured using the steady-state model, lymphatic conductance was significantly reduced in 
these mice (Fig. 5A). In young mice that are not yet hypercholesterolemic, no difference in 
lymphatic function was measured (Fig. 5B). The tissue hydraulic conductivity was identical in 
all mice. These findings verify not only the sensitivity of the model, but also demonstrate an 
interplay between lipid metabolism and lymphatic function that has been previously 
unexplored.  
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Neural cell adhesion molecule (NCAM) -/- 
 Neural cell adhesion molecule (NCAM) has been identified as a modulator of tumor 
lymphangiogenesis (21), and gene array analysis revealed a marked increase in expression by 
LECs under shear stress (Yong, et al. unpublished). It was thus hypothesized that a lack of 
NCAM expression in NCAM-/- mice may result in decreased lymphatic capillary function. 
 NCAM normal, heterozygote, and homozygote -/- mice were tested. Lymphatic 
capillaries appeared to be normal in these mice, and no significant differences in lymphatic 
function were detected. Also, no differences were calculated in the tissue hydraulic 
conductivity. These findings indicate that while NCAM may play a role in lymphatic biology 
during pathological events (e.g., tumor progression or inflammation), there is little role for 
LEC NCAM in normal capillary function. 
 
CONCLUSIONS 
 
The results of this work demonstrate an easy to apply, quantitative means to measure 
lymphatic capillary uptake and tissue hydraulic conductivity in vivo. As the two key 
parameters modulating interstitial flow , understanding lymphatic function and tissue physical 
properties are essential for understanding the biophysical environment in which cells exist, as 
well as lending knowledge to proper design of in vitro systems that better recapitulate the in 
vivo environment (22, 23). While the need for such an approach has been addressed in the 
past (12), here we have fully explained the mathematics for a better understanding of the 
steady-state formulation, and, for the first time, thoroughly discuss the implications of 
dysfunctional lymphatic uptake on the calculations. These non-steady state governing 
equations can actually be applied even to steady-state systems as simplified versions that 
result in reasonable approximations of tissue hydraulic conductivity. 
 As there is an increasing appreciation of the lymphatic circulation, understanding 
which molecular signaling pathways affect capillary function is crucial. The sensitivity of our 
quantitative approach permits the use of transgenic mouse models and antibody and small 
molecule therapies to determine the relevancy of various molecules and genes to lymphatic 
capillaries. This is critical to correctly answer questions of dermal physiology, for example, if 
dendritic cell migration is actually tied to interstitial flowrates and lymphatic function, or if it 
is wholly independent (15, 24). 
 By applying the steady-state model to transgenic mouse models, immediately a new 
finding in lymphatic capillary biology was found. The ApoE-/- mouse was selected as a 
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model with potentially reduced lymphatic function as indicated by reduced dendritic cell 
migration to the sentinel lymph node (20). Indeed, we found the lymphatic capillary function 
was reduced in these mice, despite normal hydraulic conductivity. This makes a strong case 
for further study on the effect of hypercholesterolemia on lymphatic capillary function. 
Additionally, as lymphatic capillaries in the intestine play a crucial role in lipid uptake, these 
results suggest a whole new realm of research on lymphatic function, lipid metabolism, and 
cardiovascular health. 
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FIGURE LEGENDS 
 
Figure 1: Lymphatic drainage occurs between lymphatic endothelial cells. Increased 
interstitial fluid pressure (IFP), at right, expands the matrix, and – due to the LEC anchoring 
filaments – opens the vessel further to promote drainage. 
 
Figure 2. Experimental setup for calculating hydraulic conductivity and lymphatic 
conductance in the mouse tail. Small increments of 5cmH2O in hydrostatic pressure are 
applied (right) and a fluorescent tracer is infused into the tail at flowrate Q. The fluorescent 
tracer is visualized in the interstitium as the front moves along length x. With lymphatic 
uptake present, the final value of x, L, is constant at each pressure due to conservation of mass 
at steady-state. Actual images of fluorescence in the mouse tail after 24 minutes at each 
applied pressure are shown. 
 
Figure 3: To calculate β and K the change in penetration depth and infusion flowrate with 
pressure for each pressure step are monitored. A) Plot of the penetration depth of fluorescent 
dextran for various pressures demonstrates the approximate steady-state values of L: where 
the curves become level. Steady-state is only possible with lymphatic uptake of infused fluid. 
B) Increasing, and constant infusion flow rates into the mouse tail are recorded by tracking 
the small air bubble in the infusion line. 
 
Figure 4: In the K14-VEGFR-3-Ig mouse, there are no dermal lymphatic capillaries and no 
lymphatic uptake occurs. Thus, the moving front distance continuously increases, with no 
steady-state L being reached as in wildtype mice. 
 
Figure 5. Lymphatic conductance is reduced with the onset of hypercholesterolemia in aduly 
ApoE-/- mice. A) Older ApoE-/- mice, which exhibit high cholesterol, artherosclerosis, 
edematous skin, and enlarged lymphatic capillaries, have significantly reduced lymphatic 
uptake. B) Young transgenic mice exhibit normal lymphatic function. (from Angeli V, Reddy 
ST, Rutkowski JM, Swartz MA, Randolph GJ. Impaired lymphatic function in dyslipidemic 
mice. Submitted for publication, Microcirculation) mice. 
 
Figure 6. NCAM expression does not significantly affect lymphatic function. In normal 
wildtype, heterozygote, and knockout mice, the quantified lymphatic conductance was equal. 
 162
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 163
Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Table 1 
 
 K (mm2/min/mmHg) 
 Wildtype K14-VEGFR-3-Ig 
Steady-State Approximation 0.0272 0.1185 
Non-SS, Exact Solution (P*0=29.4mmHg)* 0.0050 0.1345 
Non-SS, Exact Solution (P*0=40.8mmHg)* 0.0003 0.0050 
Non-SS, Approximation #1 0.0307 0.5071 
Non-SS, Approximation #2 0.0437 0.3489 
* for the exact solution, a P* of 1mmHg was used. 
Table 1: Calculated hydraulic conductivities for one example mouse using the various calculations described. 
Note the variation in change with each technique, particularly the overestimation of the approximate solutions. 
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ABSTRACT 
 Primary lymphedema is a congenital pathology of dysfunctional lymphatic drainage 
characterized by swelling of the limbs, thickening of the dermis, and fluid and lipid 
accumulation in the underlying tissue. Genetic studies in humans and mice have linked 
mutations in genes of lymphatic endothelial cells to the improper development and function of 
the lymphatic vasculature in these patients. Two mouse models, the Chy mouse and the K14-
VEGFR-3-Ig mouse, target vascular endothelial growth factor receptor (VEGFR) -3 
signaling, and exhibit dermal lymphedema symptomatically similar to the human condition. 
The Chy mouse possesses a genetic mutation in VEGFR-3, while the K14-VEGFR-3-Ig 
mouse expresses soluble VEGFR-3 that has prevented lymphatic capillary growth; both 
models lack dermal lymphatic capillaries, and are phenotypically similar. We sought to 
quantitatively determine both the equivalency of the edematous pathology and the functional 
interstitial transport implications as a result of the pathology in these models. We found that 
despite their similarities in increased skin hydration and elevated interstitial fluid pressure, the 
tissue adaptations to a lack of dermal lymphatics were significantly different. Chy mice skin 
possessed much higher levels of collagen and fat, while K14-VEGFR-3-Ig mice skin was 
relatively normal, as compared to their respective wildtype controls. Functionally, this 
resulted in a normal hydraulic conductivity in Chy mice, and a greatly increased conductivity 
in K14-VEGFR3-Ig mouse skin. Thus, based on the principles of interstitial flow, the tissue in 
Chy mice has likely adapted to limit interstitial transport, while the K14-VEGFR3-Ig has 
adapted to permit interstitial flow over longer distances. These opposing tissue responses to 
primary lymphedema suggest that tissue remodeling is not simply a consequence, but a 
purposeful adaption to control the pathology. Thus, successful lymphedema therapy should 
aim not only restore lymphatic function, but remediate the tissue changes. 
Keywords: VEGF-C, lymphatic, hydraulic conductivity, interstitial fluid pressure
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INTRODUCTION 
 
 Primary or congenital lymphedema is an inherited pathological condition in which 
excess fluid accumulates in the limb due to dysfunctional lymphatic drainage (1). As a 
chronic pathology, lymphedema leads to remodeling of the skin and subcutaneous 
extracellular matrix, accumulation of lipids, and failures in immune response (2-6). These 
morphological adaptations can worsen the condition and prevent successful resolution – 
indeed while compression cuffs, massage, and surgical removal of tissue have demonstrated 
success in minimizing the condition, unfortunately, there is no “cure”. In humans, the causes 
of these conditions have been linked to mutations in genes essential for proper lymphatic 
vessel development; improper development of lymphatic valve structures or insufficient 
organization of dermal lymphatic capillaries leads to failed interstitial fluid and lymph 
clearance (7-9). 
To create the pathology of primary lymphedema in mouse models, lymphatic genes 
have been targeted to disrupt the proper formation of lymphatic vessels during development. 
Unfortunately, in most cases, homozygote mutations fail to survive beyond the womb as the 
systemic lymphatic circulation fails to form, and most heterozygote mutations do not truly 
recapitulate the human condition (7-9). Targeting vascular endothelial growth factor receptor 
(VEGFR) -3, a critical receptor in lymphangiogenesis, has proven to be reasonably successful 
in creating an edematous state in two different animal models: the Chy mouse and the K14-
VEGFR-3-Ig mouse. 
The Chy mutant mouse possesses a heterozygous VEGFR-3 mutation that leads to 
developmental deficiencies in lymphatic vessels and a complete lack of lymphatic capillaries 
in the skin. In pups this results in chylous ascites in the gut (the namesake of the strain) and, 
in the adult, dermal lymphedema. It has been shown that the resulting lymphedema, as well as 
the location of the gene mutation, mirror the human condition of Milroy’s disease (7). The 
K14-VEGFR-3-Ig mouse is a transgenic mouse strain developed such that a soluble form of 
the ligand-binding domain of VEGFR-3 is expressed in the epidermis under the keratin-14 
(K14) promoter (10). This results in systemically-present soluble VEGFR-3 that prevents 
proper lymphatic capillary maturation, a lack of dermal lymphatics, and dermal lymphedema 
much like the Chy mouse model. 
Both mouse models exhibit dermal swelling, particularly in the lower limbs, tail, and 
snout, and tissue histology has revealed a pathological state similar to that of human 
 180
lymphedema (i.e., fibrotic thickening of the dermis and swelling and fluid accumulation in the 
hypodermis). However, despite a lack of dermal lymphatics, in neither case does the extent of 
the edematous pathology approach that of the human condition. We thus hypothesized that the 
tissue composition must have adapted to increase the hydraulic conductivity so as to 
maximize interstitial fluid transport in the absence of dermal lymphatics. Tissue collagen, 
lipid, and water concentrations were therefore measured to determine the compositional tissue 
changes in these mice. Interstitial fluid pressures were measured and applied to a quantitative 
in vivo model of tissue hydraulic conductivity. In this way, transport of extravasted fluid and 
macromolecules within the interstitial space when initial lymphatic capillaries are missing 
may be better understood. Despite the fact that each of these models exhibits lymphedema by 
a loss of dermal lymphatic capillaries, we found that the resultant tissue adaptation was quite 
different between the two strains. 
 
MATERIALS AND METHODS 
 
Animals 
 Male Chy mice on a C3H background were crossed with wildtype C3H females to 
obtain heterozygote Chy offspring (7). The Chy mutation was identified by PCR analysis 
prior to all experiments (11). K14-VEGFR-3-Ig heterozygote mice on a C57Bl6 background 
were crossed with wildtype C57Bl6 mice. Offspring were genotyped by PCR (10). 
Heterozygotes and their respective wildtype littermates were used for all studies. Use of the 
Chy mouse was approved by the Norwegian State Commission for Laboratory Animals while 
use of the K14-VEGFR-3-Ig mouse was approved by the Veterinary Authorities of the Canton 
Vaud according to Swiss law (protocol number #1987). 
 
Interstitial Fluid Pressure Measurements 
 Interstitial fluid pressure (IFP) was measured by micropipettes connected to an 
automatic counterpressure system (12) inserted into the tail skin of anesthesized mice as 
previously described in detail (13). After zeroing, measurements were qualified when: (a) the 
measurement was unaltered with increased feedback gain, (b) suction to the pipette resulted in 
a resistance change verifying an open capillary, and (c) the zero reference pressure was 
unchanged (13).   
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In vivo quantification of tissue hydraulic conductivity 
 Mice were anesthetized (an intraperitoneal injection of ketamine (65 mg/kg), xylazine 
(13 mg/kg, followed by subcutaneous additions when necessary) and the functional uptake of 
the lymphatic vascualture was determined by adapting the technique of fluorescence 
microlymphangiography (14). Briefly, a 30-gauge needle catheter containing 0.9% NaCl with 
2% FITC-conjugated 70kDa dextran (Molecular Probes, Carlsbad, CA) was placed 
intradermally into the tail tip. The catheter was attached to a low-pressure reservoir that 
permitted stepwise changes of 5-cm H2O, from 40-cm H2O, up to 100-cm H2O. The low 
infusion pressure allowed physiologic uptake into the lymphatic capillaries (if present) and 
minimized the gross swelling or tissue damage that might have resulted from higher pressure 
injections. The fluorescent dextran, once in the tail, either traveled through the interstitial 
space (linearly with pressure change) or was taken up and transported by the lymphatic 
capillaries. The infusion flow rate was continually monitored (via the tracking of a small air 
bubble introduced into the infusion line); pressures were changed and flow rates monitored 
for 30 minutes per pressure setting. In K14-VEGFR-3-Ig mice, 40-60 cmH2O was used; in 
Chy mice, 40-100 cmH2O was used in 10 cmH2O steps. By also monitoring the convective 
front of fluorescence at each infusion pressure, using a fluorescence-equipped Leica MZ16 
FA stereomicroscope, the hydraulic conductivity of the matrix was calculated (14). Measured 
IFPs were applied to the calculations, as well as the quantified cross-sectional areas. Cross-
sectional areas were also corrected for lipid content, which, as non-aqueous regions, were 
considered to be flow impermeable. 
 
Tissue Water and Collagen Composition 
Tail skin was excised and the wet weight recorded. The sample was then freeze dried 
and weighed again. The difference was recorded as the total tissue water. The freeze dried 
sample was then homogenized for collagen determination. 
Tissue collagen was quantified according to the spectrophotometric method described 
by Woessner (15) based on determination of hydroxyproline content as described in a 
previous publication (16). The absorbance was read at 557 nm on a Spectramax pluss 384 
spectrophotometer (Molecular Devices, Sunnyvale, CA). Hydroxyproline concentration was 
quantified by comparison to a standard curve of L-4-hydroxyproline (Fluka Chemie GmbH, 
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Buchs, France) in 1mM HCl. Collagen content was calculated based on a 6.94 to 1 collagen to 
hydroxyproline ratio (17). 
 
Tissue Lipid Extraction 
 Lipid content of the tail skin was determined by assessing dry weights before and after 
fat extraction. Lipid was extracted placing homogenized tail skin samples overnight in 4 mL 
mixture of chloroform and methanol (2:1). The solvent fraction, containing the lipids, was 
removed and evaporated before weighing. This was repeated thrice; the total lipid isolated is 
reported. 
 
Immunofluorescence and Histology 
 Tail specimens were cut into 10 μm-thick longitudinal cryosections and immunostained. 
To detect LECs, a rabbit polyclonal antibody against the lymphatic-specific hyaluronan 
receptor LYVE-1 (Upstate, Charlottesville, VA) was used along with an Alexa Fluor 488 
conjugated goat anti-rabbit secondary antibody (Molecular Probes). To detect blood 
endothelial cells, a rat polyclonal CD31 antibody (BD Pharmingen) was used along with an 
Alexa Fluor 594 conjugated goat anti-rat secondary antibody (Molecular Probes). Cell nuclei 
were labeled with DAPI (Vector Labs, Burlingame, CA). Sections were fluorescently imaged 
with a Zeiss Axiovert 200M fluorescence microscope and Zeiss MRm camera. 
 For histology, sections were first fixed in 4% PFA. To visualize the matrix, Giemsa 
staining was used on both tail cross-section and axial sections, which were then dehydrated 
and mounted with Eukitt (Fluka Chemie AG, Buchs, Switzerland). Oil red O (Sigma-Aldrich, 
Buchs, Switzerland) was used to stain lipids, with a hematoxylin counterstain, and slides were 
mounted in Glycergel mounting medium (Dako). Color histological samples were imaged 
with a Zeiss MRc camera. 
 
Image Analysis 
To quantify tissue lipid content from mounted skin sections, Metamorph 6.3 image 
analysis software (Molecular Devices Corp., Sunnyvale, CA) was used. Five images were 
captured from each side of the tail of each of five samples. In each, the region between the 
epidermis and underlying tendon was clearly identified with a freehand tool, and the total oil 
red O staining of lipids within this region calculated per area analyzed. Interstitial area was 
similarly quantified on tail cross-sections (taken @ 5mm from the tail tip) with hair follicles, 
bone, tendon, muscle, etc. excluded from the defined area. 
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Statistical methods 
For all quantifications representing tissue extractions or animal measurements, n is 
equal to or greater than 6. For quantifications from histochemistry, 5 samples from each of 3 
animals were analyzed. Data is presented as mean ± one standard deviation. All P values were 
calculated using a two-sided Student’s t-test.  
 
RESULTS 
 
Chy and K14-VEGFR-3-Ig mice lack dermal lymphatic capillaries, but possess deeper 
collecting vessels 
 Immunohistochemical analysis of lymphatic and blood capillaries confirmed the 
absence of lymphatic capillaries in the tail skin with normal blood capillaries in the model 
strains (Fig. 1A). In the mouse tail, from the perspective of fluid transport, a lack of dermal 
lymphatic capillaries implies that interstitial fluid must either drain the entire length of the 
tail, transport the entire depth of the dermis to be taken up by the deeper collecting lymphatic 
vessel, or be reabsorbed into post-capillary venuoles. Histologically, it appeared that 
collecting lymphatic vessels were present in both Chy and K14-VEGFR-3-Ig strains, 
indicating that this route is anatomically possible (Fig. 1A). Functionally, however, direct 
interstitial fluid uptake by collecting lymphatic vessels has not been previously reported. 
When fluorescent tracer was infused into the tail of K14-VEGFR-3-Ig mice, no functioning 
collecting vessels were found (Fig. 1B); tracer moved readily below the dermis.  
 
Chy and K14-VEGFR-3-Ig mice demonstrate significantly increased interstitial fluid 
pressures, but only K14-VEGFR-3-Ig mice show increased hydraulic conductivity 
Interstitial fluid pressure (IFP) is a key parameter of Starling’s Law in its complete 
form, for blood capillary extravasation: 
 
( ) ( )( )erstitiumcapillaryerstitiumcapillaryv PPLpJ intint ππσ −+−=  
 
where the flux is related to the hydrostatic driving force, as well as the osmotic pressure 
driving force, Δπ. Lymphatic intravasation is represented by the appropriate directional 
changes to the driving forces. The filtration coefficient, Lp, is dependent on vessel wall area 
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and wall hydraulic conductivity. During lymphedema, the interstitial fluid pressure is 
increased (18), which would reduce extravasation from the blood capillaries while increasing 
the driving force to lymphatic vessels and potentially permitting increased uptake by post-
capillary venuoles. Osmotically, there are changes in both the molecular concentrations as 
well as in σ, the capillary reflection coefficient (19, 20).  
Average IFP in the tail skin of Chy mice was measured to be significantly higher than 
in wildtype (Fig. 2A). Similarly, in K14-VEGFR-3-Ig, the IFP was significantly higher than 
their wildtype cagemates (both P<0.01). The marked increase in IFP exhibited by these mice 
is another hallmark of their edematous condition. Also, as lymphatic drainage normally 
provides a low-pressure route for fluid transport, the increased IFP in these mice is likely a 
consequence of the lack of lymphatic capillaries.  
While IFP drives fluid movement through the tissue, the tissue’s hydraulic 
conductivity determines its resistance to flow. Factors influencing tissue hydraulic 
conductivity include tissue hydration (21) and matrix composition (22). Hydraulic 
conductivity is also coupled to IFP, as increased IFP leads to swelling of the matrix, which 
opens “pores” and increases the conduction of fluid (23). We utilized a quantitative in vivo 
model of interstitial transport in the mouse tail to quantify the changes in hydraulic 
conductivity induced by lymphedema in these mouse strains (Appendix A).  
In Chy mice, a higher starting infusion pressure of 50 cmH2O (typically beginning at 
40 cmH2O) was necessary to visibly induce significant flow through the interstitium. Once 
flow was established, however, the resultant movement of fluorescent dextran through the 
matrix was similar to wildtype mice at the same infusion pressure. The calculated hydraulic 
conductivity of the Chy mice was the same as the wildtype mice examined (Fig. 2B). No 
uptake and transport by lymphatic vessels was observed ahead of the convective front (Fig. 
2C).  
K14-VEGFR-3-Ig tissue responded differently in that our standard initial infusion 
pressure of 40 cmH2O was sufficient to induce interstitial flow, despite the higher IFP 
recorded in these mice. Again factoring in the larger flow area and IFP, the hydraulic 
conductivity of K14-VEGFR-3-Ig was dramatically increased over matching wildtype 
controls by nearly threefold (Fig. 2D)(P=0.069). Like in the Chy mouse, no lymphatic uptake 
was visualized (Fig. 2E). 
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Chy mice exhibit a greater change in tissue composition than K14-VEGFR-3-Ig mice 
 Despite the phenotypic appearance of lymphedema, we sought to determine if the 
underlying tissue structure and composition in Chy and VEGFR-3-Ig mice could suggest 
adaptations that (a) explain the differences in the measured hydraulic conductivities and (b) 
could offer clues as to why the extent of the human lymphedema condition is avoided.  
Histological analysis of tail skin demonstrated dermal swelling in these strains 
primarily in the hypodermis (Fig. 3A) and a denser tissue structure in the dermis. The 
swelling was further demonstrated quantitatively by calculating the cross-sectional area of the 
interstitium (Fig. 3C). Lipid accumulation, marked by oil red O staining, occurred in the 
edematous tissue as well (Fig. 3B). Quantification of lipid accumulation by image analysis 
revealed, however, that while Chy mice exhibit significantly more lipid accumulation (Fig. 
3D) than their wildtype littermates (P=0.039), K14-VEGFR-3-Ig actually exhibited less, 
though not significantly (P=0.25). These results were applied to the hydraulic conductivity 
model to ensure maximum accuracy in the calculations. 
 To complement the histological analyses, we analyzed the skin for total tissue water, 
collagen, and total lipid concentrations. Total tissue water was significantly higher in both 
Chy and K14-VEGFR-3-Ig mice (P<0.01 for both), indicative of the edematous condition 
(Fig. 4A). Collagen concentration, on a dry tissue weight basis, was significantly higher in 
Chy mice as compared to their wildtype controls (P=0.022) (Fig. 4B).  Conversely, K14-
VEGFR-3-Ig mice had a collagen content equivalent to that of their controls (P=0.87). Lipid 
extraction from tail skin confirmed the validity of our histochemical analysis: Chy mice had a 
significant and marked increase in tissue lipid content, over 25% more (P=0.013), while K14-
VEGFR-3-Ig mice actually had 10% less lipid content (P=0.012) than respective controls 
(Fig. 4C). 
 It is quite interesting that the two mouse strains, both without dermal lymphatics, had 
adapted a very different tissue composition. The Chy mouse adapted a more collagenous 
dermis, with an increased presence of lipids, while the K14-VEGFR-3-Ig mouse was 
compositionally quite similar to its wildtype littermates.  
 
DISCUSSION 
 
 Though both Chy and K14-VEGFR-3-Ig exhibit lymphedema in the skin resulting 
from improper VEGFR-3 signaling and the resultant lack of dermal lymphatic capillaries, in 
neither animal is the extent of lymphedema as severe as the human condition. Despite these 
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similarities, the lack of lymphatics resulted in different tissue adaptations in the two strains 
that consequently impacted the hydraulic conductivities of the skin. These differences 
demonstrate what are, essentially, the ways that tissue might adapt when uptake by the initial 
lymphatic capillaries is absent. 
 Blood capillaries are not impermeable to transmural flow and thus form the starting 
point interstitial flow as fluid and macromolecules extravaste into the interstitium (24). This 
flux from the blood capillaries is governed by Starling forces. In lymphedema, as exhibited by 
both Chy and K14-VEGFR-3-Ig mice, the interstitial fluid pressure is increased (18) and 
interstitial molecule concentrations are altered (11, 19), thus altering the Starling forces not 
only for blood capillary filtration (20), but likely for lymphatic uptake as well. Increased IFP 
may also permit reabsoption of interstitial fluid by post-capillary venuoles. One compensatory 
mechanism by which the tissue may adapt is to reduce flux out of the blood circulation or 
through the interstitium. Indeed, the Chy mouse tissue may have adapted in this manner. 
Another study in the Chy mouse demonstrated that skin colloid osmotic pressure was 
heightened in these mice and that the tissue response to volume loading was exaggerated 
compared to wildtype mice (11). 
 Another adaptive mechanism may be for the tissue to remodel such that the hydraulic 
conductivity is increased. A higher hydraulic conductivity permits flow to pass more easily 
through the interstitium. As a result, for the same hydrostatic pressure driving force across the 
interstitium, fluid can travel further. In K14-VEGFR-3-Ig mice, we quantified a significantly 
higher hydraulic conductivity. Extravasted fluid may, therefore, be more readily transported 
across the interstitium and taken up by lymphatic vessels outside the dermis. 
 These results illustrate that while lymphedema may be a sufficient blanket term to 
describe the pathology resulting from insufficient lymphatic transport, the actual resulting 
tissue effects may be quite different. The differential response in tissue adaptation 
demonstrated in the Chy and K14-VEGFR-3-Ig mouse strains exhibit a range of potential 
adaptations that are possible to not only define qualitatively via pathological methods, but 
also quantitatively and functionally. The tissue adaptations present in these mice may also 
explain why mouse models of congenital lymphedema have, thus far, failed to successfully 
recapitulate the human condition: the tissue adapts too readily to a lack of lymphatic capillary 
uptake. This suggests that therapies for lymphedema must consider not only the growth of 
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new lymphatic vessels to restore lymphatic transport in affected tissues, but should also, 
perhaps more importantly, investigate tissue transformation in any proposed comprehensive 
curative regimen. 
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APPENDIX A 
 
Model of Interstitial Transport 
 
 For all mice, the tissue hydraulic conductivity was calculated using the model 
presented by Swartz, et al. (14). As this model includes a term for flux into lymphatic 
capillaries, and neither the Chy nor the K14-VEGFR-3-Ig mouse has dermal lymphatic 
capillaries, there was some concern as to the applicability of the steady-state formulation 
presented. The model can also be applied when no flux is present; thereby changing the final 
governing equations to solve for K, and a comparison between the two solutions reveals the 
extent of flux losses. Flux in mice without lymphatics would indicate post-capillary venuole 
reabsorption. The dramatic change in K for wildtype mice (Table A.1) illustrates the 
unaccounted for flux to lymphatic capillaries, but as there is little difference in K for the K14-
VEGFR-3-Ig mouse, there is little unaccounted for fluid loss at 29.4mmHg applied infusion 
pressure. At higher applied pressures, however, some capillary reabsorption may occur.  
 
 K (mm2/min/mmHg) 
 Wildtype K14-VEGFR-3-Ig 
Steady-State Approximation 0.0272 0.1185 
Non-SS, Exact Solution (P*0=29.4mmHg) 0.0050 0.1345 
Non-SS, Exact Solution (P*0=40.8mmHg) 0.0003 0.0050 
* for the exact solution, a P* of 1mmHg were used.  
Table A.1. Calculated hydraulic conductivities for one example mouse using the various calculations described. 
The unsteady state solution fails for mice with lymphatic uptake. Higher infusion pressures potentially force 
capillary reabsorption, as a flux loss of tracer appears in the unsteady state calculation. 
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FIGURE LEGENDS 
 
Figure 1: Chy and K14-VEGFR-3-Ig mice lack dermal lymphatic capillaries. As compared to 
their respective wildtype controls, both Chy mice (left) and K14-VEGFR-3-Ig (right) mice 
lack dermal lymphatics (arrows)(green, LYVE-1). Subdermal lymphatic vessels (arrowheads) 
are visible with immunohistochemistry in all mice. The blood vasculature (red, CD31) was 
normal in the dermis of all strains. Bar=200um. B) Following an infusion of FITC-conjugated 
dextran, no deeper lymphatic vessels were visible in K14-VEGFR-3-Ig mice. The collecting 
vessel is visible along the tail vein of wildtype mice. Bar=1mm. 
 
Figure 2: Quantification of interstitial fluid pressure and dermal hydraulic conductivities 
revealed marked differences in the tissue adaptation to lymphedema. A) In both mouse 
strains, the measured IFP was significantly higher than their respective wildtype controls 
(P<0.01). B) In Chy mice, the calculated hydraulic conductivity is the same as in wildtype 
controls, despite the different tissue composition. C) No lymphatic capillary uptake (arrow) 
was seen downstream of the convective front in Chy mice. D) K14-VEGFR-3-Ig mice exhibit 
the expected behavior in lymphedema with a significantly increased hydraulic conductivity in 
the skin. E) Lymphatic capillary uptake (arrow) was not seen in the K14-VEGFR-3-Ig 
transgenic mouse. 
 
Figure 3: Histologic staining of tail tissue demonstrates that characteristics of lymphedema in 
Chy and K14-VEGFR-3-Ig mice. A) Giemsa matrix staining reveals the swelling of the 
hypdermis (arrows) in Chy (left) and K14-VEGFR-3-Ig (right) mice as compared to their 
respective wildtype controls. Dense thickening of the dermis is also present in each 
edematous strain (arrowheads). Bar=500um. B) Oil red O staining reveals the lipid 
accumulation, as compared to normal, in the hypodermis of Chy mice (left). K14-VEGFR-3-
Ig mice (right) did not appear to have significant lipid accumulation. Bar=200um. C) The 
interstitial cross-sectional area is significantly larger in Chy and K14-VEGFR-3-Ig mice at the 
same distance from the tail tip. D) Quantification of % lipid in the dermis confirmed that Chy 
mice accumulate significant amounts of lipid, while K14-VEGFR-3-Ig mice may actually 
have a less fatty hypodermis than normal mice. 
  
Figure 4: Quantifications of tissue water weight, collagen composition, and lipid content 
reveal marked differences between the skin of Chy and K14-VEGFR-3-Ig mice. A) Total 
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tissue water, a common symptom in lymphedema, was significantly elevated in each model 
strain. B) Collagen composition (%, dry weight basis) was significantly increased in Chy 
mouse skin, but normal in K14-VEGFR-3-Ig mice. C) Lipids extracted (% mass) were 
significantly increased in Chy skin, but actually decreased in the skin of K14-VEGFR-3-Ig 
mice. * indicates P<0.05. 
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ABSTRACT 
 
Lymphatic vessels surround developing follicles within the ovary, but their roles in 
follicle maturation and pregnancy, as well as the necessity of lymphangiogenesis in these 
processes, are undefined. Here we demonstrate a critical role for ovarian lymphatics in 
murine reproduction by blocking lymphangiogenesis using systemic delivery of mF4-
31C1, a specific antagonist antibody to vascular endothelial growth factor receptor 
(VEGFR)-3. VEGFR-3 neutralization for two weeks prior to mating and pregnancy 
blocked ovarian lymphangiogenesis in all stages of follicle maturation without limiting 
blood angiogenesis. While the number of oocytes ovulated and fertilized and embryonic 
implantations in the uterus were all normal, all pregnancies were unsuccessful due to fetal 
defects and miscarriage. Preantral follicles isolated directly from treated ovaries, were 
able to grow and mature normally in vitro. When embryos from mF4-31C1 treated mice 
were isolated and transferred to untreated surrogate mothers, pregnancies were normal 
and came to term. Conversely, implantation of normal embryos into treated surrogate 
mothers led to the same fetal deficiencies as observed with pregnancies from mothers 
treated in situ. This suggests the importance of lymphatic capillaries in maintaining an 
ovarian hormonal environment necessary for fetal development and pregnancy 
maintenance. Indeed, pregnant mice with limited follicular lymphangiogenesis also 
exhibited significantly reduced serum progesterone and estradiol, hormones that are 
sourced from the ovarian corpora lutea during pregnancy. In total, these results 
demonstrate that lymphangiogenesis is a necessary process for ovarian lymphatic 
capillaries that transport hormones and thereby critical for successful reproduction. 
 
 
 
 
 
 
 
 
 
Keywords: corpus luteum, folliculogenesis, lymphatic, VEGF-C, VEGFR-3, blastocyst
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INTRODUCTION 
 
Lymphatic vessels are present within the ovary and surround follicles during 
maturation (1, 2), but the importance of the lymphatic vasculature and lymphangiogenesis in 
the ovary is unclear. Consequently, the potential roles of lymphatic vessels in follicle 
maturation and pregnancy, and the extent or even necessity of lymphangiogenesis in 
reproduction, are undefined. This contrasts with ovarian blood angiogenesis, whose critical 
roles in follicular nourishment and maturation as well as the formation and maintenance of the 
corpus luteum is well appreciated; indeed, oocyte fertilization, embryonic implantation, and 
pregnancy all require blood angiogenesis (3-5). Lymphangiogenesis, which is often 
concurrent with blood angiogenesis (6), may play an equally important role in these 
processes.  
Adult blood angiogenesis requires signaling via vascular endothelial growth factor 
(VEGF) receptor -2 (VEGFR-2), most potently by VEGF ligation (7, 8). In murine ovaries, 
VEGF expression increases during angiogenic growth phases (9), and blockade of VEGFR-2 
signaling effectively prevents angiogenesis, resulting in a marked decrease in ovarian weight, 
blood vessel density, number of corpora lutea, and infertility (10-12). Since gonadatropin 
treatment apparently does not correct these deficiencies (13), it is likely that follicle 
maturation and successful pregnancy are highly dependent on VEGFR-2-mediated 
neovascularization (3, 14). 
 VEGFR-3 is expressed primarily on lymphatic endothelial cells (LECs) in adult tissue 
(15, 16), and its signaling, via ligation by VEGF-C or VEGF-D, is necessary for 
lymphangiogenesis by inducing LEC proliferation and migration (16-19). Blockade of 
VEGFR-3 signaling, using a function blocking antibody such as mF4-31C1 (ImClone 
Systems), completely blocks the initiation of new lymphatic vessels in adult mice without 
affecting pre-existing lymphatic morphology or function and without apparently affecting 
blood angiogenesis (17, 18). Here we investigate the roles of lymphatic vessels and 
lymphangiogenesis in reproductive functions of the ovary. Specifically, we hypothesize that 
lymphangiogenesis within the ovary parallels blood angiogenesis during reproductive cycles 
(20-22) and that these new lymphatic capillaries may serve to balance hormones produced 
within the ovary, transport hormones from the ovary and corpus luteum, and aid in hormonal 
communication between the uterus and ovaries during pregnancy (23-25). Using combined in 
vivo, ex vivo, and in vitro methods, we examined which aspects of fertility are influenced by 
inhibited lymphangiogenesis, including oocyte and follicular development and maturation, 
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embryonic implantation in the uterus, and embryonic development. We show that blocking 
ovarian lymphangiogenesis prevents viable, full-term pregnancies due to decreased systemic 
hormone levels, thereby demonstrating a critical role for the ovarian lymphatic vasculature in 
reproduction. 
 
MATERIALS AND METHODS 
 
Animal procedures 
All protocols were approved by the Veterinary Authorities of the Canton Vaud 
according to Swiss law (protocols 1687, 1988, and 1988.1). The function-blocking antibody 
against murine VEGFR-3, mF4-31C1, was kindly provided by ImClone Systems (18). For 
two weeks prior to mating, 0.25 mL of 2.5 mg/mL mF4-31C1 was injected intraperitoneally 
every two days. 0.25 mL saline was similarly injected for some control groups with no 
adverse effects on reproductive potential. 
For studies without fertilization, 3 week old female F1 hybrid mice 
(C57Bl/6JxCBA/caj, Charles River Laboratories, France) were treated for two weeks and then 
sacrificed. Follicles and ovaries were collected for subsequent in vitro culture and histological 
examination, respectively. 
In studies requiring fertilization, 4-6 week old female F1 hybrid (C57Bl/6JxCBA/caj) 
mice were treated for two weeks before mating (to ensure spanning two full menstrual 
cycles). At approximately 6-8 weeks of age, mice in estrus were mated and coitus was 
evaluated by the presence of a vaginal plug 16 hours post-mating. For embryo retrieval, ex 
vivo culture, and transplantation, mice were sacrificed 42 hours post-mating and two-cell 
embryos collected by oviduct flushing with M2 medium (Sigma-Aldrich, St. Louis, MO). 
Embryos were implanted into pseudo-pregnant recipient NMRI mice (Charles River) 
following standard implantation protocols. Embryos from mF4-31C1 treated and untreated F1 
hybrid donors were implanted into treated and untreated recipients. Recipient mice were 
anesthetized using an intraperitoneal injection of ketamine (100mg/kg) and xylazine 
(10mg/kg). A small midsagittal incision, over each oviduct, was made and the donor embryos 
were deposited into each oviduct by mouth pipetting under a stereomicroscope. The incision 
was then sutured and pregnancies were permitted to continue through day 17. Implantation 
success was consistently >90%.  
For examination of fetal development and uterine implantation, mice were sacrificed 
at pregnancy day 17 or after birth. Implantation spots were counted in the uterus and fetuses 
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were graded as either (a) normal, (b) grade i – normal sized but abnormal coloration, (c) grade 
ii –under-developed fetus (in size or limb development), and (d) grade iii – implanted cell 
mass or necrotic fetus (refer to Figure 2B for examples). 
 
In vitro follicle culture and maturation 
To determine the direct effects of in vivo mF4-31C1 treatment on normal follicle 
maturation potential, ovaries were isolated from 5-week-old mice following two weeks of 
antibody treatment. In vitro maturation of preantral follicles was performed as previously 
described (26, 27). Briefly, whole ovaries were placed in 3 mL of L-15 Leibovitz-glutamax 
medium (Gibco, Carlsbad, CA) with 10% FBS (HyClone Laboratories, Logan, UT) and 1% 
penicillin-streptomycin (Gibco) solution. Preantral follicles with diameters of 100-130 μm 
were mechanically separated from the ovaries, washed, transferred to individual 10 µL 
droplets of MEM-alpha-glutamax medium containing 5% FBS, 1% ITS (5 µg/mL, insulin, 5 
µg/mL, transferrin, and 5 µg/mL selenium mixture solution; all Gibco), 1% penicillin-
streptomycin, and 100 MIU/mL recombinant human follicle stimulating hormone (hFSH) 
(Organon, Switzerland).  
On day 12 of in vitro culture, follicle maturation was induced by exposing to medium 
lacking hFSH, but supplemented with 2.5 IU/mL hCG-Pregnyl (Organon) and 5 ng/mL 
murine epidermal growth factor (Sigma). After 16 hours, oocytes were retrieved by removing 
the follicular cumulus cells using 200 IU/mL of hyaluronidase (Sigma). Oocytes were 
classified by the following maturation states: germinal vesicle (GV), germinal vesicle 
breakdown (GVBD) and metaphase II (MII).  
In groups were VEGFR-3 was neutralized directly on normal follicles, follicles were 
cultured using the above reagents in a method modified from West, et al. (28). 10 µg/mL 
mF4-31C1 was added to the culture medium of the test group. 
 
Ex vivo development of 2-cell embryos 
To determine the direct effects of VEGFR-3 inhibition on preimplantation embryonic 
development, two-cell embryos were retrieved from the oviducts and cultured in 4-well dishes 
containing 400 uL of M16 medium (Sigma). The number of embryos that developed into the 
8-cell, morula, and blastocyst stages were quantified and imaged under a Nikon SMZ1000 
stereomicroscope with a Nikon DS-5M monochrome camera at 66, 90 and 114 hours after 
mating, respectively. 
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Immunofluorescence, immunohistochemistry, and histology 
To visualize lymphatic vessels, 6-μm-thick ovary and uterus cryosections were labeled 
with a primary antibody to the lymphatic-specific marker LYVE-1 (1:500; 07-538; Upstate, 
Charlottesville, VA). For blood vessels, ovaries were labeled with a FITC-conjugated primary 
antibody to CD31/PECAM-1 (1:200; 550274; BD Pharmingen, San Jose, CA). Vessels were 
also co-labeled for VEGFR-3 (1:100; AF743; R&D Systems, Minneapolis, MN). Sections 
were also labeled for the macrophage-specific surface marker F4/80 (1:50; MCA497; AbD 
Serotec, Oxford, UK) and collagen IV (1:1000, 10760; MP Biomedicals, Irvine, CA). These 
antibodies were detected with Alexafluor 488 or 594-conjugated donkey, rabbit, or goat IgG 
secondary antibodies (1:200, Molecular Probes) and nuclei were labeled with DAPI mounting 
medium (Vector Labs, Burlingame, CA). Fluorescent labeling was observed and imaged 
using a Zeiss Axiovert 200M microscope with a Zeiss MRm camera. Slides were then rinsed 
and counterstained with hematoxylin and eosin, dehydrated, mounted with Eukitt (Fluka 
Chemie, AG, Buchs, Switzerland), and imaged again using a color Zeiss MRc camera. The 
corresponding fluorescence and chromogenic images were then compared for identification, 
and subsequent quantification, of follicular development.  
To label apoptotic cells, a fluorescence TUNEL kit was used according to 
manufacturer’s instructions (Roche Diagnositics, Rotkreuz, Switzerland). Oil red O (Sigma-
Aldrich, Buchs, Switzerland) was used to stain lipids in ovarian frozen sections. Sections 
were counterstained with hematoxylin and immediately mounted with Möwiol-based 
mounting medium for imaging. 
 
Serum Analysis 
 Serum was collected from all mice when sacrificed and analyzed using ELISA kits for 
estradiol (Calbiotech, Spring Valley, CA) and progesterone (BioSource, Carlsbad, CA) levels 
according to manufacturer’s instructions. Absorbance was measured using a Tecan Safire2 
plate reader (Tecan, Männedorf, Swtizerland). 
 
Image analysis and quantification 
To quantify macrophages, Oil red O, and TUNEL labeled slides, images of entire 
ovaries were assembled, the ovary body was outlined, and the percentage of positive area 
measured using Metamorph 6.3 (Molecular Devices Corp., Sunnyvale, CA). For lymphatic 
and blood vessel quantification, we considered each follicular maturation state. Each follicle 
was outlined using a Wacom CintiQ freehand graphic monitor (Wacom Co., Ltd., Saitama, 
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Japan) for accuracy. Vessel labeling was defined by fluorescence threshold and the number of 
positive pixels for each follicle was measured. The average vessel area for each maturation 
state is reported. Follicle maturation states were scored as follows: (i) preantral follicle 
(secondary follicle), (ii) antral follicle (small follicle with formed atrium), (iii) Graffian 
follicle (large follicle with significant atrium), and (iv) corpora lutea (Supplemental Figure 1). 
These divisions were consistently identified across multiple examiners. 
 
Statistical Methods 
For determining statistical significance between treatments in follicle vascularization 
over the stages of maturation, follicle survival and maturation, and embryo development, 
ANOVA followed by DUNCAN was used. Students’t-tests were used to compare other 
factors in treated vs. untreated plasma or in ovaries as a whole.  
 
RESULTS 
 
VEGFR-3 neutralization prevents successful murine pregnancy 
Female mice were mated at 6-8 weeks of age following 2 weeks of treatment with 
either (i) anti-VEGFR-3 neutralizing antibody (mF4-31C1), (ii) saline, or (iii) no injection 
(normal). All treatments were ceased before mating. Mice receiving saline or no injection 
were equally successful in giving birth to normal and healthy pups. Mice treated with mF4-
31C1, however, failed to produce a single live birth in the animals tested. This unexpected 
response to VEGFR-3 blockade prior to mating led to the hypothesis that lymphangiogenesis 
within the ovary helps mediate reproductive ability. 
 
Ovarian lymphangiogenesis but not blood angiogenesis is inhibited by VEGFR-3 blockade 
First, we examined blood and lymphatic vessels in the ovaries of saline-treated mice 
using CD31 and LYVE-1 co-labeling, and examined their relative expression of VEGFR-3. 
While all lymphatic (LYVE-1+) vessels expressed VEGFR-3 (Fig. 1A), limited VEGFR-3 
expression was found on follicular blood vessels (Fig. 1B). Lymphatic vessels were observed 
surrounding nearly every follicle at all maturation states and did not penetrate into the 
follicular body or thecal layers (Fig. 1A, C). The extent of lymphatic vascularization was 
dependent on the maturation stage of the follicles, with preantral follicles displaying only a 
few sparse lymphatics and corpora lutea displaying a significantly higher degree of peripheral 
lymphatic vessels. In ovaries from mice treated with mF4-31C1, the extent of lymphatic 
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vascularization was greatly reduced at all stages of follicular maturation, as measured by 
vessel density (Fig. 1D). There was not, however, a complete lack of lymphatic vessels. This 
was consistent with our previous studies where VEGFR-3 neutralization prevented 
lymphangiogenesis but had no morphological effects on pre-existing lymphatic vessels (17, 
18).  
While mature blood vessels do not express VEGFR-3, angiogenic blood vessels have 
been observed to express VEGFR-3 during normal development as well as in tumors and 
healing wounds (29-31), and there is evidence that VEGFR-3 inhibition may limit tumor 
angiogenesis (32, 33). Since blood angiogenesis in the ovary is necessary for pregnancy (3-5, 
13, 34), we examined the blood vessels to assess whether mF4-31C1 had any effects on 
ovarian blood angiogenesis. We found VEGFR-3 expression primarily limited to lymphatic 
vessels, with the exception of the blood vasculature within the corpora lutea (Fig. 1B). More 
importantly, the extent of blood vascularization, as quantified by vessel density, was not 
significantly affected by VEGFR-3 blockade (Fig. 1E). Therefore, ovarian blood angiogenesis 
appeared to be unaffected by VEGFR-3 neutralization, consistent with our findings in dermal 
wound healing and regeneration (17, 18).  
 
VEGFR-3 neutralization pre-fertilization leads to retarded embryonic development 
 Since pregnancies were not successful in VEGFR-3 neutralized mice, we sought to 
determine at what stage post-fertilization observable differences could be seen in embryonic 
and fetal development. Mice were treated for two weeks and then mated, and the uteri 
examined at pregnancy day 17. We observed no differences in the number of implantation 
sites in the uteri of treated vs. control mice, but fewer fetuses remained in mF4-31C1-treated 
mice at pregnancy day 17 (Fig. 2A). More strikingly, those fetuses remaining were 
dramatically smaller and underdeveloped (Figs. 2A,B), threatening future miscarriage. 
Combined, these results indicate that multiple abortions had already occurred by day 17, and 
that the remaining fetuses were likely not viable. 
To determine whether the numbers of ovulated oocytes were normal and to examine 
blastocyst development from VEGFR-3-blocked mice, mice were sacrificed 42 hr after 
mating and 2-cell embryos were flushed from the oviduct. The numbers of harvested 2-cell 
embryos per mouse were the same in normal vs treated mice, with an average of 7.1±2.5 and 
8.3±1.5 taken from normal and treated mice, respectively. Additionally, all 2-cell embryos 
were cultured in vitro to blastocysts with 100% success, regardless of treatment (Fig. 2C). 
Thus, although VEGFR-3 neutralization pre-maing dramatically affected embryonic 
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development, it did not appear to reduce ovulation quantity or fertilization potential of 
ovulated oocytes.  
 
VEGFR-3 neutralization decreases number of healthy follicles but has no direct effect on their 
quality 
To explore the possible effects of VEGFR-3 signaling and lack of lymphatic 
vasculature on follicular maturation potential in virgin mice, preantral follicles (100-130 μm 
in size) were retrieved after 2 weeks of treatment. The numbers of healthy preantral follicles 
successfully retrieved was lower (P<0.01) from mF4-31C1-treated mice than from saline-
treated mice (Fig. 3A). This was due to a noted fragile contact between the oocyte and 
granulosa cells in mF4-31C1 treated mice (noting that preantral follicles require interactions 
between surrounding granulosa and theca cell layers and the oocyte (26)). These contacts 
were apparently not, however, due to any loss of integrity of the basal lamina as examined by 
collagen IV staining (Fig. 3B), since no differences were observed in the granulosa-thecal 
boundary. While these discrepancies may impact the local hormonal environment in vivo, 
once separated and cultured in vitro, both groups of preantral follicles exhibited similar 
survival rates (P=0.763, Fig. 3C). Surviving follicles were able to mature normally, as defined 
by the method (27), through the GVBD and MII phase with equal success (Fig. 3C).  
Finally, to determine whether VEGFR-3 blocking had any direct effects on 
folliculogenesis, we isolated preantral follicles from untreated mice and cultured them in the 
presence of 10 μg/mL mF4-31C1 in vitro. All follicles survived (Fig. 3D) and grew to similar 
sizes (P=0.299, Fig. 3E). Thus, VEGFR-3 blocking had no direct effect on in vitro growth and 
maturation of secondary follicles. 
 
Loss of lymphatic capillaries does not alter macrophage recruitment, lipid accumulation, or 
apoptosis within the ovary 
Our combined in vivo and in vitro results suggest that failed pregnancies derive from 
alterations in the follicular environment due to the lack of lymphatic vessels. Since immune 
function may be important in mediating the balance between hormone accumulation (35) and 
follicle maturation and ovulation within the ovary (36, 37), and since lymphatic capillaries 
may be important in ovarian immune cell trafficking (20, 21), we examined macrophage 
populations in the ovaries (Fig. 4A). We found no significant differences in macrophage 
numbers within the ovaries (P=0.362; Fig. 4B). Therefore, the lack of lymphatic capillaries 
did not visibly alter overall macrophage recruitment in the ovary.  
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Furthermore, lymphatic insufficiencies have been linked to excessive tissue lipid 
accumulation in skin (38, 39). Since lipids are necessary for hormone synthesis by granulosa 
and luteal cells in the ovary (40, 41), we examined gross lipid content in the ovaries via oil 
red O staining (Fig. 4C), but no differences were observed between mF4-31C1-treated and 
control animals (P=0.532; Fig. 4D). 
Finally, we sought to determine whether blocking VEGFR-3 would affect cellular 
apoptosis, which normally occurs within certain bodies of the ovary throughout the menstrual 
cycle (42). Analysis of apoptotic cells revealed a similar distribution and number of TUNEL-
positive cells within the ovary (Fig. 4F) in both groups. Consistent with earlier findings (42, 
43), apoptotic cells were confined primarily to the interior layer granulosum of regressing 
antral follicles, regressing corpora lutea, and post-ovulatory cells at the ovarian wall in both 
groups (Fig. 4E). Thus, neither the direct blockade of VEGFR-3 nor the resultant lack of a 
significant lymphatic vasculature led to abnormal cell apoptosis in the ovary. 
 
Loss of ovarian lymphatics results in significantly reduced hormone levels during pregnancy 
With few other differences between ovaries from treated and untreated mice noted, we 
sought to determine whether the lack of ovarian lymphatics altered hormone levels during 
pregnancy. Serum collected from systemic circulation 42 hours after mating revealed no 
change in progesterone levels (Fig. 5A), but a significant decrease in estradiol levels (Fig. 
5B). As estradiol is sourced from the granulosa/luteal cells in the corpus luteum during 
pregnancy, and since mF4-31C1 treatment had the greatest effect on decreasing follicle-
associated lymphatic capillaries around the corpora lutea (Fig. 1D), these data suggest that 
ovarian lymphangiogenesis is critical for hormone transport and that decreased follicular 
lymphatics lead to decreased progesterone and estrogen transport, critical for maintaining 
pregnancy, from the ovary. These findings also support the hypothesis that intraovarian 
lymphatic capillaries are the entry point of ovarian sourced hormones to the systemic 
circulation (25). 
As hormone secretion by the murine corpora lutea has also been linked to proper 
blood angiogenesis, we verified the blood vasculature of pregnant mouse ovaries at day 17. In 
both untreated and treated mice, the blood vasculature of the corpora lutea appeared normal 
(Fig. 5C) while the lymphatic vasculature surrounding these bodies in mF4-31C1 treated 
ovaries was notably deficient. 
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Reduced ovarian hormone production by recipient mothers results in poor fetal development 
and miscarriage of transplanted normal embryos 
Finally, to demonstrate an ovarian, and not uterine, cause to pregnancy failures, we 
isolated two-cell embryos from normal and treated mothers and implanted them into normal 
and treated pseudo-pregnant recipient mothers. Regardless of the treatment of the donor 
mother, transplantation of embryos into normal mothers resulted in normal implantation and 
fetal development with only normal, viable fetuses found in the uterus at day 17 (Fig. 6A). 
Conversely, the deficient ovarian hormone signaling demonstrated in treated recipient 
mothers led to retarded fetal development of implanted embryos (Fig. 6A). In fact, the 
developmental deficiencies observed (Fig. 6B) were nearly identical to those found during in 
situ pregnancies (Fig. 2A,B). This supports the hypothesis of early ovarian 
lymphangiogenesis being necessary for subsequent pregnancy success. 
Further verification of an ovarian source to failed pregnancies was found upon 
examination of the uterine blood and lymphatic vasculature from normal and treated mothers. 
No changes in the blood or lymphatic vessel network of the ovarian wall were noted in early 
pregnancy (Fig. 6D). This lack of differences in the uterine vasculature supported the findings 
of normal implantation rates, and reinforced that ovarian lymphangiogenesis is the likely 
process affecting hormone maintenance. 
 
DISCUSSION 
 
 Taken in total, these results demonstrate that ovarian lymphatics, particularly those 
that develop during folliculogenesis, are necessary for maintaining pregnancy by providing a 
conduit for hormone transport. We saw that blockade of VEGFR-3 effectively halted 
lymphangiogenesis of maturing follicles within the ovary while not visibly affecting blood 
angiogenesis, macrophage recruitment, lipid accumulation, or overall cell apoptosis. In the 
absence of lymphangiogenesis, there were fewer patent secondary follicles, but those that 
were patent could mature normally, were ovulated, and could be fertilized. Embryonic masses 
naturally implanted in the uterus and partially developed, but all eventually miscarried; there 
were no successful births despite a normal number of uterine implantation spots. The absence 
of new lymphatics in the ovary appears mainly to disturb progesterone and estradiol levels 
during pregnancy. As these hormones are sourced from the copora lutea, it is likely the 
follicular lymphatic capillaries are necessary in regulating a hormonal environment conducive 
to normal pregnancy maintenance.  
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The ovarian microvasculature is critical in regulating hormonal transport during 
pregnancy. Normally, as follicles mature, the theca layers become vascularized by blood 
vessels (44) and support follicles by synthesizing estrogen (45); abnormalities in the theca cell 
layers can result in infertility (46). Post-implantation, proper blood vascularization is 
necessary for successful pregnancy (3) and blocking blood vessel formation in the corpus 
luteum leads to pregnancy failures (5). The developing blood vasculature of the corpus luteum 
permits this pseudo-organ to function properly, supplying increased progesterone and 
estrogen to the uterus to maintain pregnancy (5, 34, 47). New lymphatic capillaries must 
supply a route by which hormones produced within the ovary enter systemic circulation (25). 
Additionally, it has also been suggested that retrograde transfer of prostaglandin E2 – 
involved in many crucial processes of pregnancy, including maintenance of the corpora lutea - 
from the uterus to the ovary may occur via lymphatic transport (24, 34). Indeed, our data 
demonstrates that ovarian lymphatic vessels and lymphangiogenesis are essential for 
reproduction. The poorly connected granulose of isolated follicles and lower levels of 
progesterone and estradiol during pregnancy are likely related (48). The blocked growth of 
lymphatic capillaries during folliculogenesis disturbs the hormonal balance, as evidenced by 
reduced estardiol with VEGFR-3 neutralization. The lymphatic vasculature of these follicles 
is then insufficient to modulate the copora lutea and their hormone secretions during 
pregnancy. As VEGFR-3 signaling, and therefore, lymphangiogenesis, was only blocked prior 
to mating, oocytes are ovulated and fertilized and embryos implant normally in the uterus, we 
have isolated a developmental period in which lymphangiogenesis appears to most critically 
occur.  
Another important role of lymphatic vasculature is to maintain fluid balance and 
interstitial fluid pressure (IFP). Throughout the body, these roles are inherently tied to 
lymphatic function. In the ovary, follicles become increasingly vascularized as they grow and 
a fluid-filled antrum is formed. The IFP in antra of developing follicles is approximately 15 
mmHg regardless of size and drops rapidly to 5mm Hg immediately preceding ovulation (49). 
Post-ovulation, the IFP in the highly vascularized corpus luteum has been reported at a very 
high 50 mmHg (49). Ovarian lymphatics clearly must play a role in modulating fluid 
pressures. Furthermore, concurrent lymphangiogenesis is likely necessary to drain 
extravasated fluid from the newly formed blood capillaries (21) and may help to regulate 
morphogenetic processes and signaling on the luteal cells by controlling interstitial flow, an 
important morphoregulator for many cell types (50). 
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Lack of ovarian lymphatics have also been reported in ADAMTS-1 knockout mice (1) 
and Frizzled4 knockout mice exhibit low levels of ovarian VEGF-C, the primary ligand to 
VEGFR-3 (51). Both of these strains are infertile, despite normal mating behavior; infertility 
in these mice was concluded to be the result of failed hormone transport, intrafollicular 
pressure modulation, or maintenance of the corpus luteum. Mice possessing mutations in 
VEGFR-3 such that their lymphatic capillaries are present but poorly functional can 
reproduce, albeit at a lower success rate than wildtype mice (52, 53).  
 
In conclusion, our data demonstrate that VEGFR-3-mediated lymphangiogenesis in 
the ovary is necessary for pregnancy by modulating levels of progesterone and estrogen from 
the corpora lutea. With anti-lymphangiogenic therapies aimed at preventing tumor metastases 
proposed as a cancer therapy (32, 33, 54) and pro-lymphangiogenic therapies proposed for 
treating lymphedema (52, 55, 56), it is critical to understand the role of lymphangiogenesis in 
the ovary and the role of lymphatics in fertility. Moreover, an increased knowledge of the 
physiologic role of lymphangiogenesis in the ovaries may provide insight into causes of 
infertility (and potential therapeutic strategies) and permit a more careful examination of 
angiogenesis and lymphangiogenesis inherent with ovarian cancers. 
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FIGURE LEGENDS 
 
Fig. 1. Ovarian and follicular lymphangiogenesis, but not blood angiogenesis, was inhibited 
by VEGFR-3 blockade in the ovary, preventing successful pregnancy. A) Ovarian lymphatic 
vessels (green, LYVE-1) are VEGFR-3 (red) positive (arrowheads). Some non-lymphatic 
associated VEGFR-3 is found on the vessels within the copora lutea (arrows) B) Blood 
vessels (green, CD31) are mostly negative for VEGFR-3 (red), with the exception of those 
within the corpora lutea (arrow). As lymphatic vessels also express CD31, the strong VEGFR-
3 colocalization is likely marking lymphatics (yellow arrows). C) The extent of lymphatic 
vasculature (green, LYVE-1) normally developing within the ovary, left, was reduced in 
VEGFR-3 blocked ovaries, right; the blood vasculature and blood angiogenesis (red, CD31) 
were unaffected by the treatment. Bars=200μm. D) Quantification of lymphatic vessel 
coverage in (i) preantral follicles, (ii) small follicles with formed atrium, (iii) large follicles 
with significant atrium and (iv) corpora lutea (Supplemental Figure 1) demonstrated the 
significant reduction in lymphatic vessels at each maturation state with VEGFR-3 blockade. 
E) Blood vessel coverage was not statistically affected by VEGFR-3 blockade, despite some 
vessels expressing VEGFR-3. Notice the normal increase in vascularization of the follicles 
with maturation for both lymphatic and blood vessels. *P<0.05 between treatments.  
 
Fig. 2. Pregnancies occurred after lymphangiogenesis was blocked, but embryonic 
development was severely impaired in the womb. A) In mice treated with mF4-31C1 prior to 
fertilization, few bodies remained within the uterus at pregnancy day 17, and they were scored 
as normal, (i) normal sized but discolored, (ii) deficient size and underdeveloped and (iii) 
identifiable cell masses. B) Fetuses extracted at pregnancy day 17 from treated animals 
displayed a marked deficiency from control animals. Grid=4mm. C) 2-cell embryos were 
extracted from fertilized VEGFR-3 treated mice and culture in vitro. The appearance of both 
2-cell embryos and blastomeres appeared identical to those taken from control animals. Scale 
bar=100μm. 
 
Fig. 3. Secondary follicles, once retrieved from the ovaries of treated mice, matured normally 
in vitro. A) Fewer patent follicles were successfully separated from collected ovaries in 
treated mice. B) Patency was not determined by basal lamina quality, as collagen IV staining 
(green) displayed intact basement membranes in both control and treated follicles (arrows). 
Bar=100μm. C) Follicles and their oocytes separated from ovaries of VEGFR-3 treated mice 
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survive normally in vitro. Surviving germinal vesicle (GV) oocytes from treated and control 
mice mature to germinal vesicle breakdown (GVBD) and metaphase II (MII) stages using the 
in vitro drop culture technique at equal rates. D) Survival of secondary follicles directly 
treated with the VEGFR-3 blocking antibody in vitro was unihibited. E) Maturation potential, 
as determined by follicle size, was also unaffected by direct VEGFR-3 treatment on the 
follicles. 
 
Fig. 4. Macrophage recruitment, lipid accumulation, and cell apoptosis in the ovary appeared 
to be unaffected by VEGFR-3 blockade. A) Macrophages (red, F4/80) present in the ovary 
was limited to follicular peripheries in both control and treated ovaries. Bar=100μm. B) The 
total number quantified within the ovary was unchanged. C) The ovaries contain large amount 
of lipids (red, Oil Red O), particularly in the copora lutea (arrowheads). Bar=300μm. D) Lipid 
accumulation in the ovary was not significantly different without lymphatics. E) Apoptotic 
cells (green, TUNEL) were limited to interior granulosa cells (arrows) of regressing follicles 
and regular apoptosis of regressing corpora lutea and corpus hemorrhagicum (arrowheads) in 
both treatments. Bar=100μm. F) No difference was measured in the number of apoptotic cells 
within the ovary with mF4-31C1 treatment. 
 
Fig. 5. Blockade of lymphangiogenesis led to reduced systemic estradiol levels in mice 
following fertilization and decreases in both eastradiol and progesterone during pregnancy. A) 
Serum progesterone levels in control and mF4-31C1 treated mice were normal at pregnancy 
day 2, but significantly reduced at pregnancy day 17. Since treatment was halted before 
mating, and since no difference was seen in serum levels at day 2, the mF4-31C1 treatment 
did not directly affect these hormones. B) Estradiol levels were significantly reduced during 
pregnancy when ovarian lymphangiogenesis was blocked. *P<0.05 between treatments. C) 
The blood vasculature (red, CD31) corpora lutea in the ovaries of pregnant mothers at day 17 
was normal in mice when lymphangiogenesis was blocked prior to mating. In normal 
mothers, lymphatic vessels (arrows) (green, LYVE-1) surround the corpus luteum and other 
follicles. Bar=200μm. 
 
Fig. 6. All embryos – normal and treated – implanted into treated recipient mothers were 
insufficiently developed despite normal uterine vasculature. A) Both normal and treated 
embryos implanted into normal, pseudo-pregnant recipient mothers developed into normal, 
viable fetuses by day 17. In pseudo-pregnant mothers pre-treated with mF4-31C1, no embryos 
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developed into normal fetuses, despite normal implantations. Grid=4mm. B) The distribution 
of fetal quality at day 17 following normal embryo transfer to mF4-31C1 treated recipients 
closely replicated that of in situ fetal development, as reported in Figure 2. C) Blood (red, 
CD31) and lymphatic (green, LYVE-1) capillaries in the uterine wall appeared normal in both 
mF4-31C1 treated and untreated mothers, further supporting an ovarian cause. Bar=200μm. 
 
Supplemental Figure 1. Follicular vasculature was calculated for four stages of follicle 
maturation. A) Follicles exist in various maturation states within the murine follicle with 
increasing vasculature with maturation. Follicles that had reached preantral status were 
identified for quantifying their surrounding vasculature. B) Each follicle was first identified 
and numbered on hematoxylin labeled sections, where follicular structure was easier to 
recognize. C) On the corresponding fluorescence image, each follicle was then outlined in 
Metamorph software (white lines indicate the concept) and the percent area of lymphatic and 
blood vessel coverage within each region of interest was quantified. Bars=200μm. 
 221
Figure 1 
 
 222
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 223
Figure 2 
 
 224
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 225
Figure 3 
 
 226
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 227
Figure 4 
 
 228
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 229
Figure 5 
 
 230
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 231
Figure 6 
 
 232
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 233
Supplemental Figure 1 
 
 234
 
 
 
 
 
 
 
 
 
 
This page is intentionally left blank. 
 
 235
CHAPTER 9: 
CONCLUSIONS & FUTURE DIRECTIONS 
 
 Research in lymphatic biology has been rapidly growing as the importance of the 
lymphatic circulation is increasingly appreciated. Fundamental work in lymphatic 
development, interstitial fluid balance, lymphatic vessel pumping, and tumor 
lymphangiogenesis has laid the critical groundwork, but more research is necessary to 
elucidate the role played by lymphatic capillaries. These vessels act as the entry point of 
interstitial fluid, immune cells, and lipids into the lymphatic system, thus placing lymphatic 
capillary biology at the intersection of many essential physiologic processes and diverse fields 
of study. It is therefore an important step in understanding lymphatic biology to explore the 
interactions between potential molecular and mechanical regulators of lymphatic capillary 
function. The overall aim of this thesis was to do just that, specifically: identifying 
contributing factors to lymphangiogenesis during wound healing, determining the lymphatic 
capillary and tissue response to lymphedema, developing a model to quantify lymphatic 
capillary fluid uptake and tissue hydraulic conductivity, and defining a role for lymphatic 
capillaries in reproduction. In accomplishing these aims, this thesis contributes a significant 
body of original and important knowledge towards furthering our understanding of lymphatic 
capillary biology. 
 By taking an integrative biomedical engineering approach to studying lymphatic 
capillary biology in vivo, novel mechanisms of lymphatic capillary biology were elucidated. 
We believe that this approach has allowed us to place our results in a more physiologically 
relevant context than what would have been possible in vitro; indeed, there is no in vitro 
technique that can recapitulate a functional lymphatic capillary. In lymphangiogenesis, our 
model of skin regeneration in the mouse tail provided a unique platform in which to study not 
only the growth factors and proteases essential for the growth of new lymphatic capillaries, 
but also the importance of interstitial flow as an organizational guiding force. Interstitial flow 
is absolutely essential for LEC organization into functional lymphatic capillaries and the tail 
model, as a virtue of its reproducibility and resultant well-defined stepwise lymphatic 
regeneration was able to elegantly illustrate that VEGF-C signaling only initiates 
lymphangiogenesis. These key findings – the first to demonstrate that a biomechanical force 
guides lymphangiogenesis - have several immediate implications. Firstly, as described in this 
thesis, we now know why, in lymphedema, lymphatic capillaries become hyperplastic and 
highly dysfunctional despite the presence of high concentrations of growth factor: there is no 
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flow to guide proper cellular organization. Hence, VEGF-C to VEGFR-3 signaling initiates an 
exaggerated proliferative response, but without interstitial flow LECs remain in situ and 
generate tortuous hyperplastic vessels. Secondly, we demonstrate that growth factor therapies 
to cure diseases of lymphatic dysfunction (e.g., lymphedema) will have limited success due to 
the lack of flow necessary to organize a functional vasculature. Our additional findings in 
lymphedema – the massive breakdown and remodeling of the ECM – have identified another 
roadblock to successful remediation of edematous tissue: lymphatic dysfunctionality is further 
worsened by connective tissue destruction and the resultant loss of intimate connections 
between LECs and ECM that permit drainage. In primary lymphedema, where lymphatic 
capillaries were never present in the dermis, we found that different animal models exhibit 
different tissue adaptations to modulate capillary extravasation and interstitial transport. The 
combined findings in our integrative models of lymphangiogenesis and lymphedema demand 
that any future approach to therapies for lymphatic pathologies must seek to (a) restore 
interstitial flow and (b) remediate the matrix morphology; growth factor therapy alone will be 
insufficient. One potential means to grow new lymphatics, restore flow, and remodel the 
matrix might be to purposefully target antigen-presenting cells (APCs) in the tissue (i.e., 
dendritic cells and macrophages) to stimulate migration by alternative activation (anti-
inflammatory activation) and the secretion of pro-lymphangiogenic factors. Therefore, 
utilizing immunobiomaterials to target APCs in the tissue that normally migrate via the 
lymphatics might simultaneously provide sufficient proteolytic remodeling of the matrix and 
lymphatic capillary growth. 
 Our model of dermal interstitial transport and lymphatic capillary uptake provides a 
starting point for future studies that question which molecules play a role in LEC biology and 
lymphatic function. Studies utilizing either transgenic mouse models or the delivery of 
agonistic or antagonistic molecules can now readily determine not only a yes-or-no as to 
which molecules are important to lymphatic capillary function, but also the quantitative extent 
to their functional modulation. In the ApoE-/- mouse, for example, we found the dyslipidemia 
or hypercholesterolemia resulted in significantly decreased uptake by lymphatic capillaries. 
Not only did this verify the applicability and functionality of the model, but also opened a 
whole new realm of research in lymphatic-lipid interplay. If dyslipidemia alters lymphatic 
vessel function, the opposite might also be true: lymphatic dysfunction leads to lipid 
metabolic disorders. Currently, we are beginning to explore more deeply this interplay. One 
approach is to quantify if correction of the lipid metabolic disorder (e.g., via delivery of 
cholesterol medication) improves lymphatic function. Another is to determine if lymphatic 
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dysfunction, as in the Chy or K14-VEGFR-3-Ig mouse, leads to dyslipidemia. The exciting 
potential of these interactions has significant implications ranging from lymphatic therapies to 
obesity.   
Finally, we have identified a new role for the lymphatic circulation: modulation of 
hormone levels during pregnancy. With this work, we are only just beginning to scratch the 
surface of lymphatics in reproduction. We have successfully demonstrated that 
lymphangiogenesis occurs within the ovary during folliculogenesis, that this is essential for 
pregnancy, and that this is likely the cause of a systemic decrease in estrogen; just how the 
lymphatic circulation modulates this is still unknown. Also, as lymphatic vessels are critical in 
inflammation and fluid balance, there is even more potential for reproductive lymphatic 
circulation to control the complex processes of folliculogenesis, ovulation, and pregnancy. 
Some researchers describe ovulation as a massive inflammatory event: the modulation of 
pressures within the antrum of developing follicles, the massive secretion of hormones, and 
the eventual rupture of the ovarian capsule should present an almost insustainable 
inflammatory environment. Clearly, lymphatic vessels have the potential to modulate these 
factors as would occur in other tissues. Further examination of intrafollicular pressures, 
granulose cell molecular expression and hormone secretion, and hormonal rescue therapy may 
elucidate the roles of ovarian lymphatic capillaries more sufficiently. 
 In summary, this thesis has produced a series of significant and unique contributions to 
our understanding of the dynamism of lymphatic capillary biology and the complex 
biochemical and biomechanical environments in which they reside.  Specifically, we 
demonstrated, for the first time, that:  
• Lymphangiogenesis requires interstitial flow as an organizational guiding force 
• VEGFR-3 signaling is only required for LEC proliferation and migration in the initial 
stages of lymphangiogenesis 
• Lymphedema therapy requires an integrative approach targeting both the restoration of 
interstitial flow and matrix remediation for success 
• Matrix remodeling, lymphedema, and dyslipidemia reduce lymphatic capillary 
function 
• Lymphangiogenesis within the ovary is an essential process in reproduction 
Within various realms of biological research, the lymphatic circulation has become 
increasingly appreciated. As the initial component of the lymphatic circulation and a critical 
mediator of the interstitial environment, the functional behavior of lymphatic capillaries 
demands further attention, and has implications not only to the lymphatic research 
 238
community, but also to those interested in inflammation, immunology, lipid metabolism, and 
reproduction.  
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